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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1
Introduction 
Diabetes mellitus is a heterogeneous disorder characterized by chronic hyperglycaemia, 
resulting from various pathophysiological processes. It is classified into two main types: 
type 1 and type 2 diabetes. Type 1 diabetes usually starts in childhood or early adulthood, 
although it may present at any age. It is predominantly characterized by pancreatic beta-cell 
failure due to an auto-immune process, and rapidly evolves to absolute insulin deficiency 
necessitating intensive insulin therapy. Type 2 diabetes usually presents at an older age 
and is strongly associated with obesity and a sedentary life style. Its pathophysiology is 
complex in which decreased insulin sensitivity and (relative) insulin deficiency are key 
elements. Importantly, pancreatic beta-cell function progressively declines in type 2 
diabetes, but some endogenous insulin secretion is maintained even in late stages [1]. 
The global incidence and prevalence of both types of diabetes are rising, but this increase 
is particularly pronounced for type 2 diabetes in developing countries, in conjunction 
with increased obesity rates and a more westernized lifestyle. The International Diabetes 
Federation (IDF) global estimates for 2015 suggest that 60 million adults have diabetes 
in Europe and 415 million worldwide, and these numbers are anticipated to increase by 
the year 2040 to almost 71 and 642 million, respectively [2]. This translates not only into 
significant human suffering, but also into massive costs related to treatment and diabetes 
complications, with a total annual diabetes-related health expenditure in Europe increasing 
from 140 billion Euros in 2015 to 156 billion in 2040 [2].
. 
Chronic hyperglycaemia is an independent risk factor for micro- and macrovascular 
complications, such as retinopathy, nephropathy, neuropathy and cardiovascular disease, 
causing considerable morbidity and mortality [3]. More than 60 percent of patients with 
type 2 diabetes will develop cardiovascular disease [2,3]. Mortality rates due to diabetes 
have been estimated to amount more than half a million in Europe in 2015, with 26.3% 
of those deaths in people under the age of 60 [2]. In addition, quality of life is often low 
in patients with diabetes, especially when glycaemic control is poor [4]. Taken altogether, 
diabetes is a highly prevalent, serious and costly disorder, hence effective treatment 
strategies, aiming for adequate glycaemic control are of obvious importance. 
Treatment of diabetes
Type 1 diabetes generally requires intensive insulin treatment, near physiological insulin 
substitution based on actual glucose levels and carbohydrate intake. Interventions aiming to 
cure diabetes, including islet or whole-pancreas transplantation and immune-modulating 
treatments that postpone insulin therapy or reduce insulin requirements are so far not 
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diabetes-related complications, while treatment with metformin decreased also cardio- 
vascular mortality [9-11]. Metformin is a biguanide that suppresses hepatic glucose production, 
improves insulin sensitivity, is weight neutral and does not increase the risk for hypo-
glycaemia. It is widely recommended as first choice for the treatment of type 2 diabetes 
[5,6]. Sulphonylureas stimulate insulin release by the pancreatic beta-cell, are often used 
in conjunction with metformin, but increase body weight and the risk of hypoglycaemia 
[5,6]. Other oral glucose-lowering agents include glinides, amylin agonists or acarbose, 
but for varying reasons these drugs have never been widely adopted in clinical practice in 
Europe or the USA [6]. Thiazolidinediones were briefly popular because they were thought 
to act on the pathophysiological disturbances of type 2 diabetes by increasing insulin 
sensitivity and reducing hepatic fat. However, the associated higher risks of heart failure 
(due to fluid retention) and bone fracture (particularly in women) have decimated their 
use to a subgroup of patients with hepatic steatosis [6,12]. 
More recently introduced drugs that have been developed in the past 10-15 years include 
the dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose co-transporter 2 
(SGLT-2) inhibitors. DPP-4 inhibitors lower glucose by blocking the degradation of GLP-1 
(see below), have few side effects and are considered weight neutral [1,13]. SGLT-2 inhibitors 
facilitate glucose excretion through the kidneys and consequently promote weight loss, 
at the cost of an increased number of urogenital infections [14-16]. Normoglycaemic 
diabetic ketoacidosis is a rare, but serious adverse effect of treatment with SGLT-2 inhibitors [17]. 
In the Netherlands, these newer drugs are used sparsely, in part because of reimbursement 
issues. 
GLP-1 receptor agonists
The incretin hormone glucagon-like peptide 1 (GLP-1) is released in response to meal 
ingestion and stimulates insulin secretion, inhibits glucagon secretion and reduces food 
intake by slowing down gastric emptying and increasing satiety (Figure 2) [1,18]. Natural 
GLP-1 is rapidly degraded by DPP-4, hence agonists of GLP-1 have been developed that 
are relatively resistant to such degradation. These injectable GLP-1 receptor agonists act as 
incretin-mimetics, so that they improve glucose control and induce weight loss [19]. 
Various GLP-1 receptor agonists with varying durations of action have been developed for 
the treatment of type 2 diabetes [20]. As these agents stimulate insulin release and 
suppress glucagon secretion in a glucose-dependent manner, they do not increase the 
risk for hypoglycaemia [21]. The use of GLP-1 receptor agonists is associated with gas-
tro-intestinal side effects, such as associated with nausea, diarrhoea, and vomiting [19]. 
Because of their weight-reducing effects, GLP-1 receptor agonists have also been studied 
for weight management in overweight or obese persons without diabetes [22,23]. 
very effective or associated with significant side effects. Discussion of these treatments is 
beyond the scope of this thesis. For the glucose-lowering treatment of type 2 diabetes, 
a step-up approach is widely advocated [5,6]. This approach recommends to start with 
lifestyle adjustments concerning diet and physical activity, followed by pharmacological 
interventions when HbA1c goals are not achieved with such measures alone (Figure 1). 
This pharmacological treatment generally starts with oral glucose-lowering agents. 
On the long term, however, insulin therapy is frequently required to maintain glycaemic 
control [6]. Most guidelines, including the Dutch General Practitioner guidelines, then 
recommend to add (basal) insulin [5,6], although starting with premixed or prandial insulin 
is equally effective [7,8]. The characteristics of the various glucose-lowering drugs are 
discussed below in greater detail.
Oral glucose-lowering agents
Currently, there is a wide range of oral glucose-lowering drugs for the treatment of type 2 
diabetes available. Of these, metformin and sulphonylurea derivatives are the oldest 
available and the cheapest options. Both agents have been shown to reduce the risk of 
Figure 1  The step-up approach in type 2 diabetes treatment
The first treatment step consists of lifestyle measures, next steps can be taken if HbA1c goals are not 
met within 3 months after a prior treatment step. Strategies that are recommended by the Dutch 
General Practitioner guidelines are indicated in bold; strategies that are reimbursed for use in the 
Netherlands are indicated in italic. TZD, thiazolidinedione; DPP-4i, DPP-4 inhibitor; SGLT-2i, SGLT-2 
inhibitor; GLP-1ra, GLP-1 receptor agonist. Figure adapted from [6].
Lifestyle measures: Healthy eating, weight control, increased physical activity 
(monotherapy) Metformin
(dual therapy) Add Sulphonylurea 
          (or TZD, DPP-4i, SGLT-2i, GLP-1ra, insulin)
(triple therapy)
GLP-1ra
(only 
reimbursed 
if BMI≥35 
kg/m2)
DPP-4iInsulin SGLT-2i TZD
Metformin + Sulphonylurea +
• TZD + (SGLT-2i or DPP-
  4i or GLP-1ra or insulin)
• DPP-4i + (SGLT-2i
  or insulin)
• SGLT-2i + (DPP-4i
  or insulin)
•  GLP-1ra + insulin       
Metformin +
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Epidemiologic analyses of 10-year data of the UKPDS, conducted in patients with type 2 
diabetes, have indicated that for every 1% (11 mmol/mol) reduction in HbA1c with 
intensive treatment (insulin, sulphonylurea or metformin), myocardial infarction, diabetes- 
related death, and microvascular disease were reduced by 14%, 21%, and 37%, respectively [3]. 
Apart from its ability to improve glycaemic control, insulin therapy is generally affordable, 
and has an excellent long-term safety profile [3,24,25]. 
Limitations of insulin therapy 
Although insulin is considered the most effective glucose-lowering therapy for patients 
with diabetes, there are important limitations and side effects that need to be discussed. 
Weight gain
Insulin therapy often induces weight gain, particularly in people with type 2 diabetes 
[8,26]. Most of this insulin-induced weight gain occurs within the first 9-12 months of 
insulin therapy and has been estimated at 2-3 kg for every 1% (11 mmol/mol) fall in HbA1c, 
but with large inter-individual differences [8,26,27]. Indeed, although some patients show 
no or only minimal weight gain, weight gain is pronounced in a considerable number of 
patients, often exceeding 5% of their initial body weight [26]. This weight gain is obviously 
undesirable especially when a patient is already overweight, and may lead to aversion 
against the therapy. In addition, it may worsen insulin resistance, leading to higher insulin 
dose requirements, ongoing weight gain, reversal of the beneficial effects of insulin, and 
a more unfavourable cardiometabolic risk profile [28]. The determinants of pronounced 
insulin-induced weight gain are not completely understood, but several putative mechanisms 
have been proposed: the anabolic effects of insulin increasing fat storage; improvement of 
glycaemic control decreasing glucosuria; a decrease in metabolic rate and a fall in energy 
expenditure; and defensive eating habits because of (fear of) hypoglycaemia [26,27,29]. 
Hypoglycaemia
Insulin treatment creates a considerable risk for hypoglycaemia [25,30]. Patients with type 
1 diabetes are estimated to experience mild hypoglycaemic events at a weekly basis and 
those with type 2 diabetes on a monthly to two-monthly basis, depending on the choice 
of glucose-lowering strategy [31,32]. Population-based data indicate that 30-40% of 
people with type 1 diabetes experience an average of one to three episodes of severe 
hypoglycaemia (requiring third-party assistance) each year, whereas up to 10% of patients 
with insulin-treated type 2 diabetes experience about one-third that number [31,32]. 
Risk factors for the occurrence of hypoglycaemia in insulin-treated diabetes include 
endogenous insulin deficiency and long diabetes duration in combination with absolute 
or relative excess of therapeutic insulin, such as excessive, ill-timed or wrong type insulin 
Insulin 
Since almost a century, therapeutic insulin is a safe and highly efficacious product for 
glycaemic management in patients with diabetes that has been shown to reduce micro- 
and macrovascular complications [3,9,24,25]. Insulin is a lifesaving therapy in type 1 diabetes, 
and an important cornerstone for the treatment of type 2 diabetes. For those with type 2 
diabetes, most national and international guidelines recommend insulin as first-line 
treatment when HbA1c is very high [5,6]. Several landmark studies have conclusively 
shown the significant benefits of improving glycaemic control with insulin. The DCCT 
(Diabetes Control and Complications Trial) and the UKPDS (United Kingdom Prospective 
Diabetes Study) have shown that intensive insulin therapy to maintain near-normoglycaemia 
reduced the incidence and severity of microvascular complications by 50-70% in patients 
with type 1 diabetes [25] and by 25% in those with type 2 diabetes [9], respectively. 
Figure 2  The multiple physiological actions of GLP-1
The gut hormone GLP-1 is secreted from the intestine in response to meal ingestion. It functions primarily 
in the pancreatic islets by increasing insulin secretion and suppressing glucagon secretion, leading to 
a fall in plasma glucose concentration. Inhibition of gastric emptying also contributes to the 
reduction in postprandial glucose concentrations. In addition, appetite and food intake are reduced. 
Figure adapted from [1]
 Gastric Emptying
GLP-1
 Insulin secretion
 Glucagon secretion
 Hepatic glucose output
 Postprandial hyperglycaemia
 Plasma glucose
 Appetite  
 Body Weight
Food intake 
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Insulin combination therapy
Insulin in combination with oral glucose-lowering agents
Until about 20 years ago, all oral agents were usually discontinued in people with type 2 
diabetes when they started insulin therapy. However, in theory, all available glucose- 
lowering agents can be combined with insulin (Figure 1). Currently, it is widely recommended 
to continue metformin in whatever combination with insulin therapy in type 2 diabetes [5,6]. 
It is common practice to continue sulphonylureas in combination with basal insulin, despite 
the associated weight gain, but sulphonylureas should be discontinued when prandial 
insulin or premixed insulin is started because of enhanced risk of hypoglycaemia. Although 
guidelines differ widely, DPP4-inhibitors can be safely used in combination with insulin 
[6,41,42], as they lead to a (modest) improvement in HbA1c, and are weight neutral [43,44]. 
The addition of an SGLT-2 inhibitor to insulin has also been shown to improve glycaemic 
control and may additionally induce weight loss [14,15,45]. 
Insulin – GLP-1 receptor agonist combination therapy
Addition of a GLP-1 receptor agonist to existing (basal) insulin therapy has many potential 
benefits for patients with type 2 diabetes. As stated, these agents particularly attenuate 
postprandial glucose excursions by stimulation of endogenous insulin secretion, reduction 
of appetite, and slowing of gastric emptying [21]. Such a combination may thus lower the 
need for exogenous insulin in general but in particular that of prandial insulin, whereas a 
reduction in caloric intake may be expected to reverse or prevent insulin-induced weight 
gain [21,46]. At the start of this PhD thesis in 2012, only a few randomized controlled trials 
on insulin - GLP-1 receptor agonist combination therapy had been published [47,48], and 
the efficacy of the combination was mainly described in observational studies [49-56]. 
These studies reported improved glycaemic control and suggested weight loss and an 
insulin-sparing effect in patients with often poorly controlled type 2 diabetes [47-56]. 
Placebo effects and responses in diabetes treatment
Every medical treatment harbours a placebo effect [57]. Many factors impact on placebo 
effects, including patients’ expectations and received information regarding (side) effects 
of a treatment [58-60]. A potential placebo effect might thus be especially relevant for 
injectable GLP-1 receptor agonists, as they are associated with gastro-intestinal side effects and 
weight loss. Placebo effects are generally larger on subjective than objective endpoints 
[58-61]. Appetite and satiety and the willingness to adhere to lifestyle recommendations 
may be considered subjective. Also, it has been suggested that eating behaviour impacts 
on the level of weight loss induced by GLP-1 receptor agonists [62]. Therefore, even 
‘objective’ endpoints such as body weight and (indirectly) HbA1c may benefit from 
placebo effects. Importantly, the ‘true’ placebo effect must be distinguished from the 
placebo response, which represents the change within the placebo group of a randomized 
clinical trial from pre-treatment to posttreatment (Figure 3). Placebo responses may be 
dosing [31]. While most people recover uneventfully from hypoglycaemia, particularly 
severe events carry a considerable risk for harm (e.g. in traffic). In the ACCORD (Action to 
Control Cardiovascular Risk in Diabetes) and the ADVANCE (Action in Diabetes and Vascular 
Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation) studies, both 
examining the effect of strict glycaemic control in type 2 diabetes, the occurrence of 
severe hypoglycaemia was associated with excess mortality from both cardiovascular and 
non-cardiovascular causes [33,34]. In the DCCT, the same applied for patients with type 1 
diabetes [35]. Apart from physiological consequences, hypoglycaemia also has a significant 
impact on quality of life [36]. Moreover, hypoglycaemia prevents optimal glycaemic 
control, as it is a major barrier to the implementation of intensive treatment and might 
result in rebound hyperglycaemia [32].
Fluctuations in blood glucose levels
Profound fluctuations in blood glucose levels frequently occur in patients with insulin- 
treated diabetes, which is in part due to the relatively slow pharmacological profile of 
insulin products to prevent or treat meal-related hyperglycaemia [37,38]. For example, 
the time until the maximal glucose-lowering effect of rapid-acting insulin analogues has 
been shown to amount more than 90 minutes, and the duration of significant hyper-
insulinemia often exceeds 3 hours [37,38]. As a consequence, patients with type 1 diabetes 
or insulin- requiring type 2 diabetes who are treated with rapid-acting insulin analogues 
are at relatively high risk of immediate postprandial hyperglycaemia and of late post - 
prandial hypoglycaemia. Hyperglycaemia significantly affects overall glycaemic control, 
even when elevated glucose levels exist only for a short period of time [39]. Furthermore, 
it may be difficult to correct hyperglycaemia, especially when marked, because hyper-
glycaemia-induced glucose toxicity may temporarily induce insulin resistance, so that a 
higher insulin dose is required [40]. Conversely, aggressive correction of hyperglycaemia 
may lead to rebound hypoglycaemia.
Alternatives to standard insulin therapy
As stated above, oral agents are recommended as first-line treatment for the management 
of type 2 diabetes. However, as type 2 diabetes progresses, these agents usually fail to 
maintain normoglycaemia in the long run. When following the advocated step-up 
approach, introducing insulin therapy usually achieves at least reasonable glycaemic 
control in patients with type 2 diabetes who fail to do so with lifestyle measures and oral 
antidiabetic agents alone. Some patients, however, suffer from pronounced weight gain, 
recurrent or severe hypoglycaemia and/or highly fluctuating blood glucose levels, 
resulting in reluctance to insulin therapy. To overcome these problems, several alternative 
treatment strategies or approaches might be considered.
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Insulin administration by jet-injection 
Rapid correction of (particularly) marked hyperglycaemia is important to limit its negative 
impact on overall glycaemic control and to prevent repeat insulin administration with 
the risk of hypoglycaemia and glucose fluctuations. In daily practice, however, even 
rapid-acting insulin analogues appear to act too slow to achieve such a rapid correction. 
Insulin administration by jet injection is a needle-free alternative to conventional insulin 
injections, which delivers insulin at a high velocity (typically >100m/s) across the skin, 
dispensing it over a larger subcutaneous area than insulin injected with a needle, either by 
syringe or insulin pen (Figure 4) [66]. This method of insulin administration, first developed 
in the 1950s, significantly accelerates insulin absorption from the subcutaneous tissue into 
the systemic circulation [67]. Insulin injected by jet stream results in a more direct onset 
due to a placebo effect, but other factors may contribute, including the natural course of 
the disease or trial effects [58,61]. Other factors contributing to the placebo effect are the 
attitude of the physician, the type and price of the treatment and the appearance of the 
drug [59,63,64]. Also, the route of drug administration is an important driver of the placebo 
effect, with injections having a stronger effect than pills [58], which has particular relevance 
for treatment with GLP-1 receptor agonists or insulin. It might thus be reasoned that 
injectable glucose-lowering treatments harbour stronger placebo effects than oral drugs, 
such as DPP-4 inhibitors or SGLT-2 inhibitors. Placebo effects or responses have never 
been studied in diabetes treatment. If the weight- (and HbA1c-) reducing effect of a drug 
would partly consist of a placebo effect, this may be exploited therapeutically as even 
a simple explanation of expected effects in itself would add to its therapeutic efficacy. 
Such an approach may lead to a more effective treatment [65]. 
Figure 3   Contributors to the placebo effect and the placebo response
Placebo responses may be due to a placebo effect, but other factors contribute. These factors include the 
natural course of the disease, regression to the mean, or trial effects, such as (alterations in) the use 
of background medication and lifestyle measures, and the effect of trial- participation itself, also 
known as the Hawthorne effect [58,61].
Figure 4   The diffusion of insulin after injection with a needle, and a contemporary  
jet injector (InsujetTM)
Attitude of caregiver 
Attitude of patient 
Information (from caregiver,
friends/relatives, social media) 
Type of treatment
Appaerance of drug/
Route of drugadministration
Price of drug   PLACEBO RESPONSE
Natural course of disease
Hawthorne effect
Background medication 
Lifestyle measures
Regression to the mean
PLACEBO EFFECT
A
The diffusion of insulin after injection with a needle (left) and the Insujet (right). 
InsujetTM. Courtesy of the European Pharma Group.
B
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adding liraglutide to insulin with continuation only when meeting predefined targets. 
We evaluated different thresholds for weight loss, HbA1c and reduction in insulin dose at 
early timepoints as predictors of long-term response. Our goal was to find the best 
cost-controlling treatment strategy: keeping the trial period as short as possible yielding 
the highest number of effectively treated patients. 
We gradually wondered whether the fact that (expensive) GLP-1 receptor agonists are 
administered as an injection, could lead to anticipated placebo effects and nocebo effects. 
To test this hypothesis, we explored the placebo response associated with new glucose- 
lowering agents for the treatment of type 2 diabetes. As stated, the placebo effect in 
type 2 diabetes has never been studied or systematically reviewed, and may be an 
important contributor to the overall effect of type 2 diabetes treatment. Furthermore, 
the role of the drug administration route is completely unknown. To answer this question, 
we performed a meta-analysis in which we compared the response to injectable placebo 
from placebo-controlled studies on GLP-1 receptor agonists with the response to oral 
placebo tablets from studies on DPP-4 inhibitors and SGLT-2 inhibitors. We investigated 
placebo responses on body weight, glycaemic control and adverse events. The results of 
this meta-analysis are presented in Chapter 5.
Patients with diabetes on insulin are not only confronted with chronic hyperglycaemia, 
but also face acute episodes of hyperglycaemia for which corrections with insulin are 
needed. In this context, we investigated the therapeutic potential of insulin administered 
by jet injection, a method of insulin administration that leads to a more rapid insulin 
absorption. Chapter 6 presents the results of a randomized, controlled cross-over trial 
investigating the effect of the rapid-acting insulin analogue aspart, administered by jet 
injection as compared with conventional insulin injection for the correction of marked 
hyperglycaemia. This study included adult patients with type 1 or type 2 diabetes treated 
with intensive insulin treatment, who were either overweight or obese. As standard sliding 
scale regimens, which are still widely applied for the correction of marked hyperglycaemia, 
tend to underestimate the required correctional insulin dose, we used a new algorithm 
based on the individual insulin-sensitivity factor in this trial to calculate correctional insulin 
doses. In Chapter 7 we present the performance of this novel algorithm. 
The results of the presented studies are summarised and put into perspective in Chapter 8. 
and shorter duration of insulin action as compared with insulin injected with a needle 
[66-69]. Another advantage of insulin administration by jet injection is that the rate of 
insulin absorption is much less affected by higher insulin doses and body weight than 
insulin injected conventionally [70,71]. By improving insulin’s pharmacological profile, 
jet injection technology might decrease fluctuations in blood glucose levels and be especially 
useful for enhancing the correction of acute, marked hyperglycaemia with rapid-acting 
insulin analogues. 
Outline of the thesis
Many patients with diabetes require insulin therapy. Although insulin effectively lowers 
blood glucose levels, hyper- and hypoglycaemic events and fluctuations in daily glucose 
profiles are particularly common and insulin-induced weight gain often occurs. The objective 
of this thesis is to explore novel strategies to optimize insulin treatment in patients with 
diabetes. 
Our starting point was to focus on patients who showed pronounced weight gain after 
the initiation of insulin therapy. We aimed to investigate the efficacy of adding a GLP-1 
receptor agonist to insulin treatment in patients with type 2 diabetes who showed 
pronounced insulin-associated weight gain. Evidence suggests a beneficial role for GLP-1 
receptor agonists in reducing body weight. However, all previous studies on insulin - 
GLP-1 receptor agonist combination therapy were designed to improve glycaemic control 
in patients who were poorly controlled with insulin. We designed the ‘Effect of Liraglutide 
on insulin-associated wEight GAiN in patients with Type 2 diabetes’ (ELEGANT) trial to test 
the hypothesis that pronounced insulin-associated weight gain could be reversed by 
addition of the GLP-1 receptor agonist liraglutide, while maintaining glycaemic control, 
in patients with at least fair glycaemic control at baseline. In Chapter 2, the 26-week 
results of this trial are presented. The trial had a predefined extension period, during which 
patients initially randomized to the control arm received additional liraglutide treatment, 
while those initially randomized to liraglutide continued this treatment for another 
26 weeks. Chapter 3 describes the results of this second phase of the study. In this part of 
the study, we investigated whether the effects observed with liraglutide during the first 
26 weeks were sustained up to 52 weeks, and if liraglutide would still be effective when 
added to insulin therapy six months later. 
As a GLP-1 receptor agonist is considered expensive, it is very important to control 
treatment- related costs. Based on the findings in chapters 2 and 3, we calculated 
(incremental) costs of additional liraglutide treatment, the results of which are described 
in Chapter 4. In this analysis, we investigated the costs of a short-term trial period of 
22 23
CHAPTER 1 GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 
2 diabetes. N Engl J Med 2008; 359: 1577-89.
25. The effect of intensive treatment of diabetes on the development and progression of long-term complications 
in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl 
J Med 1993; 329: 977-86.
26. Jansen HJ, Vervoort GM, de Haan AF, et al. Diabetes-related distress, insulin dose, and age contribute to insu-
lin-associated weight gain in patients with type 2 diabetes: results of a prospective study. Diabetes Care 2014; 
37: 2710-7.
27. Jansen HJ, Hendriks JC, de Galan BE, et al. Contribution of change in glycosylated haemoglobin to insulin- 
associated weight gain: results of a longitudinal study in type 2 diabetic patients. Endocrine 2011; 39: 190-7.
28. Jansen HJ, Vervoort G, van der Graaf M, Tack CJ. Pronounced weight gain in insulin-treated patients with type 2 
diabetes mellitus is associated with an unfavourable cardiometabolic risk profile. Neth J Med 2010; 68: 359-66.
29. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without 
metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-12.
30. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al. Effects of intensive 
glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
31. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 
2014; 10: 711-22.
32. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-12.
33. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and 
mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: 
b4909.
34. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 
2010; 363: 1410-8.
35. Writing Group for the DERG, Orchard TJ, Nathan DM, et al. Association between 7 years of intensive treatment 
of type 1 diabetes and long-term mortality. JAMA 2015; 313: 45-53.
36. Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-re-
ported outcomes in Type 2 diabetes: a narrative review. Diabet Med 2012; 29: 293-302.
37. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed 
analogue of human insulin. Diabetes 1994; 43: 396-402.
38. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: 
absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. 
Diabetes Care 1999; 22: 1501-6.
39. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the 
overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes 
Care 2003; 26: 881-5.
40. Solomon TP, Knudsen SH, Karstoft K, et al. Examining the effects of hyperglycemia on pancreatic endocrine 
function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab 2012; 97: 4682-91.
41. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 
diabetes mellitus. N Engl J Med 2013; 369: 1317-26.
42. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 
diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 
2015; 385: 2067-76.
43. Rosenstock J, Rendell MS, Gross JL, et al. Alogliptin added to insulin therapy in patients with type 2 diabetes 
reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab 2009; 11: 
1145-52.
44. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in 
patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 167-77.
45. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 
Diabetes. N Engl J Med 2015; 373: 2117-28.
46. van der Klauw MM, Wolffenbuttel BH. The combination of insulin and GLP-1 analogues in the treatment of 
type 2 diabetes. Neth J Med 2012; 70: 436-43.
References 
1. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and 
diabetes. Trends Mol Med 2008; 14: 161-8.
2. International Diabetes Federation, IDF Diabetes Atlas. Seventh Edition, 2015. www.diabetesatlas.org Accessed 
August 28, 2016.
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular 
complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
4. Lustman PJ, Anderson RJ, Freedland KE, et al. Depression and poor glycemic control: a meta-analytic review of 
the literature. Diabetes Care 2000; 23: 934-42.
5. Rutten GEHM, De Grauw WJC, Nijpels G, Houweling ST, Van de Laar FA, Bilo HJ, Holleman F, Burgers JS, Wiersma 
TJ, Janssen PGH. NHG-Standaard Diabetes mellitus type 2 (derde herziening). Huisarts Wet 2013; 56: 512-25.
6. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient- 
centered approach. Position statement of the American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96.
7. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. 
N Engl J Med 2009; 361: 1736-47.
8. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 
diabetes. N Engl J Med 2007; 357: 1716-30.
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and 
risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) 
Group. Lancet 1998; 352: 837-53.
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 
2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
11. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic 
review. Arch Intern Med 2008; 168: 2070-80.
12. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. 
Cell Metab 2014; 20: 573-91.
13. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of 
type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369.
14. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose 
cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 
2015; 38: 403-11.
15. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and 
no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese 
inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815-23.
16. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: 
a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-74.
17. Peters AL, Buschur EO, Buse JB, et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment 
With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 2015; 38: 1687-93.
18. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced 
deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-5.
19. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on 
weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771.
20. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 
2012; 8: 728-42.
21. Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. 
Diabetes Obes Metab 2013; 15: 3-14.
22. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 
Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015; 314: 687-99.
23. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight 
Management. N Engl J Med 2015; 373: 11-22.
24 25
CHAPTER 1 GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
1
47. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 
2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-12.
48. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of 
exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept 
study. Diabetes Care 2010; 33: 1509-15.
49. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes 
and high insulin requirements. Diabetes Technol Ther 2011; 13: 592-5.
50. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes 
and obesity. QJM 2010; 103: 687-94.
51. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients 
with type 2 diabetes mellitus. Endocr Pract 2008; 14: 285-92.
52. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the 
Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes Obes Metab 2011; 13: 703-10.
53. Viswanathan P, Chaudhuri A, Bhatia R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus 
treated with insulin. Endocr Pract 2007; 13: 444-50.
54. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of 
clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009; 31: 1511-23.
55. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces 
HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes 2012; 6: 41-6.
56. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with 
insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract 2012; 18: 17-25.
57. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with 
no treatment. N Engl J Med 2001; 344: 1594-602.
58. Meissner K, Fassler M, Rucker G, et al. Differential effectiveness of placebo treatments: a systematic review of 
migraine prophylaxis. JAMA Intern Med 2013; 173: 1941-51.
59. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in 
patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003.
60. Hauser W, Bartram-Wunn E, Bartram C, Reinecke H, Tolle T. Systematic review: Placebo response in drug trials 
of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related 
predictors. Pain 2011; 152: 1709-17.
61. Breidert M, Hofbauer K. Placebo: misunderstandings and prejudices. Dtsch Arztebl Int 2009; 106: 751-5.
62. de Boer SA, Lefrandt JD, Petersen JF, et al. The effects of GLP-1 analogues in obese, insulin-using type 2 
diabetes in relation to eating behaviour. Int J Clin Pharm 2016; 38: 144-51.
63. de Craen AJ, Roos PJ, Leonard de Vries A, Kleijnen J. Effect of colour of drugs: systematic review of perceived 
effect of drugs and of their effectiveness. BMJ 1996; 313: 1624-6.
64. Espay AJ, Norris MM, Eliassen JC, et al. Placebo effect of medication cost in Parkinson disease: a randomized 
double-blind study. Neurology 2015; 84: 794-802.
65. van Vliet LM, van Dulmen S, Mistiaen P, Bensing JM. [The placebo effects of good communication]. Ned 
Tijdschr Geneeskd 2016; 160: D251.
66. Malone JI, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet stream and disposable 
insulin syringe. Diabetes Care 1986; 9: 637-40.
67. Weller C, Linder M. Jet injection of insulin vs the syringe-and-needle method. JAMA 1966; 195: 844-7.
68. Halle JP, Lambert J, Lindmayer I, et al. Twice-daily mixed regular and NPH insulin injections with new jet 
injector versus conventional syringes: pharmacokinetics of insulin absorption. Diabetes Care 1986; 9: 279-82.
69. Lucas A, Ribas L, Salinas I, et al. Insulin levels after injection by jet stream and disposable syringe. Diabetes Care 
1988; 11: 298-9.
70. de Galan BE, Engwerda EE, Abbink EJ, Tack CJ. Body mass index and the efficacy of needle-free jet injection for 
the administration of rapid-acting insulin analogs, a post hoc analysis. Diabetes Obes Metab 2013; 15: 84-6.
71. Engwerda EE, Tack CJ, de Galan BE. Needle-free jet injection of rapid-acting insulin improves early postprandial 
glucose control in patients with diabetes. Diabetes Care 2013; 36: 3436-41.
Liraglutide reverses pronounced 
 insulin-associated weight gain,  
improves glycaemic control and  
decreases insulin dose in patients  
with type 2 diabetes: a 26 week, 
randomised clinical trial (ELEGANT)
2
Helena M. de Wit, Gerald M.M. Vervoort, Henry J. Jansen, Wim J.C. de Grauw, 
Bastiaan E. de Galan, Cees J. Tack
Diabetologia 2014 Sep;57(9):1812-9
28 29
CHAPTER 2 LIRAGLUTIDE FOR INSULIN-ASSOCIATED WEIGHT GAIN (ELEGANT TRIAL 26 WEEKS)
2
Abstract
Aim: The best treatment strategy for a patient with type 2 diabetes who shows pronounced 
weight gain after the introduction of insulin treatment is unclear. We determined whether 
addition of a glucagon-like peptide-1 (GLP-1) analogue could reverse pronounced insulin- 
associated weight gain while maintaining glycaemic control, and compared this with the 
most practised strategy, continuation and intensification of standard insulin therapy.
Methods: In a 26-week, randomised controlled trial (ELEGANT), conducted in the outpatient 
departments of one academic and one large non-academic teaching hospital in the 
Netherlands, adult patients with type 2 diabetes with ≥4% weight gain during short-term 
(≤16 months) insulin therapy received either open-label addition of liraglutide 1.8 mg/day 
(n=26) or continued standard therapy (n=24). A computer-generated random number list 
was used to allocate treatments. Participants were evaluated every 4-6 weeks for weight, 
glycaemic control and adverse events. The primary endpoint was between-group weight 
difference after 26 weeks of treatment (intention to treat).
Results: Of 50 randomised patients (mean age 58 years, BMI 33 kg/m2, HbA1c 7.4% [57 
mmol/mol]), 47 (94%) completed the study; all patients were analysed. Body weight 
decreased by 4.5 kg with liraglutide and increased by 0.9 kg with standard therapy (mean 
difference −5.2 kg [95% CI −6.7, −3.6 kg]; P<0.001). The respective changes in HbA1c were 
−0.77% (−8.4 mmol/mol) and +0.01% (+0.1 mmol/mol) (difference −0.74% [−8.1 mmol/
mol] ([95% CI −1.08%, −0.41%] [−11.8, −4.5 mmol/mol]; P<0.001); respective changes in 
insulin dose were −29 U/day and +5 U/day (difference −33 U/day [95% CI −41, −25 U/day]; 
P<0.001). In five patients (19%), insulin could be completely discontinued. Liraglutide was 
well tolerated; no severe adverse events or severe hypoglycaemia occurred.
Conclusions: In patients with pronounced insulin-associated weight gain, addition of 
liraglutide to their treatment regimen reverses weight, decreases insulin dose and 
improves glycaemic control, and hence seems a valuable therapeutic option compared 
with continuation of standard insulin treatment. 
Trial registration: ClinicalTrials.gov NCT01392898
Introduction
The introduction of insulin therapy is common practice when oral glucose-lowering 
agents fail to maintain glucose control in patients with type 2 diabetes [1,2]. Insulin is safe 
and efficacious in improving glycaemic control, thereby reducing micro- and possibly 
macro-vascular complications [3,4], but it may induce weight gain. This weight gain shows 
large interindividual differences, with some patients showing no or only minor weight 
gain and others even losing weight [5]. In a substantial group of patients, however, weight 
gain is more pronounced (≥4-5%). This is obviously undesirable in an already overweight 
population, and it may lead to aversion against the therapy and a further increase in 
insulin dose, and offset the beneficial effects of insulin [6]. Most insulin-induced weight 
gain, on average 2–6 kg, occurs within the first 9-12 months of insulin therapy [5,7,8]. 
Hence, a therapy that ameliorates pronounced weight gain when encountered within this 
time frame would be extremely desirable, but the best treatment strategy for this clinical 
problem is unclear.
Glucagon-like peptide-1 (GLP-1) analogues stimulate insulin secretion, suppress glucagon 
release, and reduce food intake, resulting in improved glycaemic control and weight loss 
in type 2 diabetes [9-15]. Addition of GLP-1 analogues to insulin therapy may thus be 
beneficial in reversing pronounced insulin-induced weight gain. However, GLP-1 
analogues are expensive, have gastrointestinal side effects, and lack long-term safety and 
efficacy data, which renders it important to select those patients that are most likely to 
benefit from this therapy. Previous studies on the combination of GLP-1 analogues and 
insulin all focused on glycaemic benefit, with some reporting additional weight loss and 
others stable body weight [16-31]. Furthermore, most studies are either placebo controlled 
or observational and do not compare clinically relevant treatment strategies. We hypothesised 
that addition of a GLP-1 analogue to insulin therapy may reverse pronounced insulin- 
induced weight gain while maintaining glycaemic control, in comparison with the 
standard approach, i.e. continuation and intensification of insulin. This hypothesis was 
tested by the Effect of Liraglutide on Insulin-associated Weight Gain in Patients with Type 2 
Diabetes (ELEGANT) trial.
Methods
Study design and participants 
This 26-week open-label, randomised, controlled clinical trial was conducted in the 
Radboud University Medical Centre and one affiliated large non-academic teaching 
hospital (Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands) between February 
2012 and October 2013. The trial was approved by the institutional review board (IRB) of 
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the Radboud University Medical Centre and conducted according to Good Clinical 
Practices and the Declaration of Helsinki. All participants provided written informed 
consent and received reimbursement of travel costs.
Potentially eligible individuals with type 2 diabetes were selected from the outpatient 
departments of the two participating hospitals, recruited by advertisement, or enrolled by 
their diabetes nurse or general practitioner. They were men or women aged 18-75 years, 
with a BMI of ≥25 kg/m2 and HbA1c of ≥6.5 and ≤8.5% (≥48 and ≤69 mmol/mol), who had 
recently started insulin therapy (≥3 and ≤16 months), with concomitant documented 
weight gain of ≥4% body weight since initiation of insulin treatment. All types and 
regimens of insulin were allowed. Exclusion criteria were recurrent hypoglycaemia, 
diabetic gastroparesis, use of oral glucose-lowering agents or drugs known to interfere 
with blood glucose levels other than sulfonylurea or metformin, recent start of diuretics, 
heart failure (left ventricular ejection fraction of <30%), inflammatory bowel disease, 
a recent history of pancreatitis, uncontrolled thyroid disease, liver enzymes ≥3.0 times 
upper normal limit, plasma creatinine >130 μmol/l, and pregnancy.
The initial protocol was amended twice: the duration of insulin treatment was changed 
from ≤12 to ≤16 months because it turned out that weight change was notified later than 
expected resulting in delayed inclusion in the trial, and the number of participants was 
decreased as the weight-reducing effect of liraglutide was greater than anticipated. Both 
amendments were submitted to and approved by the IRB. 
Randomisation and study procedures 
Participants who met the screening criteria were randomised (1:1), using a computer- 
generated random number list, to open-label treatment with liraglutide (Novo Nordisk, 
Bagsvaerd, Denmark) 1.8 mg once daily or standard therapy (continuation and intensification 
of insulin therapy without liraglutide). Participants were randomised in blocks of four 
according to body weight (≤100 kg or >100 kg). 
After enrolment, all participants continued their usual diet and exercise regimens as well 
as insulin therapy and oral glucose-lowering agents (sulfonylurea and metformin). None 
of the patients received a dietary consultation; also, no additional nutritional recommen-
dations were made. In patients randomised to liraglutide, total insulin dose was decreased 
by 20% to avoid hypoglycaemia. Liraglutide was injected subcutaneously into the thigh or 
abdomen and administered at any (consistent) time of day. It was initiated in 0.6 mg/day 
weekly increments to a final 1.8 mg/day dose. When adverse events occurred, participants 
were allowed to return to the 1.2 mg dose. For safety reasons, participants were instructed 
to perform daily self-measured capillary blood glucose profiles during the first 3 weeks 
after the start of liraglutide, and insulin dose was adjusted weekly by telephone consultation. 
For both treatment groups, follow-up visits were scheduled at 4, 8, 12, 16, 20 and 26 weeks. 
During every visit, participants were asked to report adverse events, body weight was 
measured on a calibrated scale (with the participant in light underwear), blood pressure was 
measured, and insulin dose was adjusted using a specific algorithm (adapted from the 
Wolverhampton protocol) [24]. According to this protocol, insulin dose was adjusted with 
−2 to +6 U per injection, aiming at fasting glucose levels of 4.0-6.5 mmol/l, and premeal 
(or postprandial) values of ≤8.0 mmol/l. HbA1c was determined every 8 weeks using an 
HPLC method. At baseline and end of follow-up, blood was drawn for determination of 
fasting blood glucose, HbA1c, full blood cell count, thyroid function, liver enzymes and 
serum creatinine. 
Measurements of all variables were performed in the national accredited clinical laboratory 
units of the two participating hospitals, according to standard procedures. Also, at baseline 
and at 26 weeks, quality-of-life questionnaires on diabetes-related distress (Problem Areas 
in Diabetes Scale [PAID]) [32] and depression (Beckman Depression Inventory II [BDI-II]) 
[33] were administered, and waist and hip circumference were measured. Physical activity 
including energy expenditure and average metabolic equivalent (METS; 1 MET equals 
consumption of 4 kJ [1 kcal]/kg of body weight per hour) was measured quantitatively at 
baseline and at 26 weeks via a portable armband (HealthWear Bodymedia, Pittsburgh, 
Pennsylvania, USA) [34] for four consecutive days. The armband was worn around the 
upper right arm and was removed only for showering and bathing purposes. It had to be 
worn at least 90% of time to be included for analysis. 
Outcome measures 
The primary efficacy endpoint was the change in body weight between the two treatment 
groups from baseline to week 26. Secondary endpoints included change in HbA1c, insulin 
dose, physical activity and quality of life, and number of patients discontinuing insulin. 
Safety assessments included adverse events and number and severity of hypoglycaemic 
episodes. Hypoglycaemia (<3.9 mmol/l) was graded asymptomatic or mild (grade 1), 
moderate (requiring additional oral carbohydrate; grade 2) and severe (requiring third- 
party assistance, irrespective of glucose levels; grade 3).
Statistical analysis and power calculation 
All statistical analyses were performed according to intention-to-treat, using IBM SPSS version 
20.0 (Chicago, Illinois, USA). p<0.05 was considered significant. Descriptive  characteristics 
are expressed as mean ± SD; results are expressed as mean ± SEM, unless otherwise indicated. 
With 50 randomised participants and a dropout rate of <20%, 21 participants per treatment 
arm would provide an 80% power to detect a clinically relevant treatment difference of 4% 
(4.0 kg) in the absolute change in body weight from baseline to week 26. This assumed an 
SD of 4.6 kg with a two-sided 5% significance level.
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A linear mixed model for repeated measures was used to estimate the effect of treatment 
on weight, HbA1c and insulin dose at multiple time points with fixed effects for treatment, 
visit, treatment-by-visit interaction, baseline weight stratum, baseline of the variable analysed 
and centre. Treatment differences are summarised by maximum likelihood means and 
95% CIs from the mixed model. Missing values were not imputed. Independent two-tailed 
t tests (or Mann–Whitney U tests for non-parametric data) were performed to assess 
between-group differences in all other secondary endpoints, baseline continuous variables 
and hypoglycaemia rates. The Fisher exact test or χ2 test was used as appropriate for analysis of 
between-group differences in categorical variables. Multiple linear regression analysis was 
used to assess factors at baseline and at follow-up associated with weight loss after 26 weeks 
of liraglutide treatment. Variables included in linear regression analysis were selected using 
the backward stepwise method. A variable stayed in the model if it had a p value of <0.05. 
Results
A total of 64 potentially eligible participants underwent screening. Fifty were randomised 
and assigned to liraglutide or standard therapy (Fig. 1). Three participants (6%) dropped 
out prematurely: two in the standard therapy group withdrew consent after 1 and 10 weeks 
of follow-up, respectively; one patient randomised to liraglutide stopped after 4 weeks 
of treatment because of exaggeration of acne, which could not be objectified by the 
research staff and was judged to be unrelated to study medication. Baseline characteristics 
of the two groups were similar and are presented in Table 1. Participants in this trial were 
generally middle-aged and overweight (mean BMI of 33 kg/m2), with fair glucose 
regulation (mean HbA1c 7.4% [57 mmol/mol]), and had gained on average 7.1 kg while on 
insulin treatment. Most were white, except for one who was of Asian origin. 
Change in body weight and anthropometric variables 
Body weight had decreased by 4.5 ± 0.5 kg after 26 weeks of treatment with liraglutide 
and increased by 0.9 ± 0.6 kg with standard therapy (maximum likelihood mean difference 
−5.2 kg [95% CI −6.7, −3.6 kg]; p<0.001) (Fig. 2), corresponding to −4.8 ± 0.5 vs +1.0 ± 0.5 
percentage change in body weight, and between-group difference in BMI of −1.7 ± 0.3 
kg/m2. Patients in the liraglutide group lost on average 81.3% of insulin-associated weight 
gain; 10 participants (38.5%) even showed complete reversal of weight gain, compared 
with none of the patients in the standard therapy group. Baseline factors associated with 
weight loss were being female, high insulin dose and lower BMI, while, during follow-up, 
the decrease in HbA1c was closely related to weight loss (data not shown). After 26 weeks, 
waist and hip circumference decreased by 2.1 and 1.5 cm, respectively, in the liraglutide 
group and increased by 2.7 and 3.0 cm, respectively, in the standard therapy group (p<0.05 
for both comparisons) (Table 2). 
Secondary efficacy measures 
Glycaemic control, reflected by the change in HbA1c, decreased by 0.77 ± 0.11% (8.4 ± 1.2 
mmol/mol) with liraglutide and increased by 0.01 ± 0.12% (0.1 ± 1.3 mmol/mol) with 
standard therapy (maximum likelihood mean difference −0.74% [−8.1 mmol/mol] ([95% CI 
−1.08%, −0.41%] [−11.8, −4.5 mmol/mol]); p<0.001) (Fig. 2). Nineteen (73%) participants in 
the liraglutide group and seven (29%) in the standard therapy group reached an HbA1c 
value of 7.0% (53 mmol/mol) or less (P=0.004). The insulin dose was reduced by 29 ± 3 U/
day (−55.7 ± 4.1%) with liraglutide and increased by 5 ± 3 U/day (+11.8 ± 4.4%) with insulin 
(maximum likelihood mean difference −33 U/day [95% CI −41, −25 U/day]; p<0.001) (Fig. 2), 
corresponding to −0.29 ± 0.03 U/kg and +0.04 ± 0.03 U/kg, respectively. Five participants 
(19%) in the liraglutide group were able to discontinue insulin therapy. This subgroup had 
a baseline BMI of 29 ± 5 kg/m2, weight reduction after 26 weeks of −3.8 ± 0.8 kg, an HbA1c 
reduction of −0.4 ± 0.3% (−4.4 ± 3.3 mmol/mol), and a relatively low insulin dose at 
baseline (four of them were treated with 20-24 U/day, one was treated with 84 U/day). 
No statistically significant changes in blood pressure and heart rate occurred in either 
group (Table 2).
Figure 1   Enrolment and outcomes
64 Patients were screened  
 14 Were excluded  
13 Did not meet inclusion criteria  
 7 Had HbA 1c >8.5%  
2 Had HbA1c <6.5%  
2 Had no weight gain  
2 Had other reasons  
1 Declined to participate  
25 Completed 26 weeks  
26 Were analyzed  
1 Discontinued because  
of adverse event  
24 Assigned to standard treatment  
22 Completed 26 weeks  
24 Were analyzed   
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Table 1  Baseline characteristics
Characteristic Liraglutide 
(n=26)
Standard therapy 
(n=24)
Age, years 57±10 59±8
Sex, male : female 16 : 10 15 : 9
Diabetes duration, years 8.3±5.9 7.6±6.2
Insulin treatment duration, months 11±4 10±4
Body weight, kg 102.3±20.1 97.7±18.5
BMI, kg/m2 34±7 32±5
Insulin-associated weight gain 
kg 6.7±3.8 7.5±4.2
% 6.8±2.8 8.2±3.8
HbA1c
% 7.2±0.6 7.5±0.7
mmol/mol 56±7 59±7
Waist circumference, cm 110±13 107±15
Hip circumference, cm 106±11 104±12
Oral glucose-lowering medication, n (%)
None 3 (11.5) 3 (12.5)
Metformin only 13 (50) 12 (50)
Sulfonylurea only 2 (7.7) 2 (8.3)
Sulfonylurea and metformin 8 (30.8) 7 (29.2)
Insulin dose
U/day 54±34 50±33
U kg−1 day−1 0.51±0.30 0.50±0.29
Insulin regimen, n (%)
Basal insulin (only) 14 (53.8) 13 (54.2)
Basal bolus 8 (30.8) 8 (33.3)
Biphasic insulin 4 (15.4) 2 (8.3)
Pump therapy 0 1 (4.2)
Concomitant medication, n (%)
Antihypertensive 17 (65.4) 14 (58.3)
Cholesterol-lowering 21 (80.8) 19 (79.2)
Current smoker, n (%) 1 (3.8) 4 (16.7)
Alcohol consumption ≥1 U/day, n (%) 5 (19.2) 7 (29.2)
Data are expressed as mean ± SD unless otherwise indicated 
p>0.05 for all between-group differences
Figure 2   Maximum likelihood mean ± SEM changes in (A) weight, (B) HbA1c and (C) 
insulin dose, from baseline to week 26 for the liraglutide-added group  
(black circles) compared with the group continuing standard insulin therapy 
(white squares)
*p<0.05, **p<0.001 compared with standard therapy at the same time point. To convert values for 
HbA1c in DCCT % into mmol/mol, subtract 2.15 and multiply by 10.929
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Safety 
Liraglutide-treated patients often reported adverse gastrointestinal events, mostly 
decreased appetite (92.3%), dyspepsia (76.9%), constipation (53.8%) and nausea (42.3%) 
(Table 3). Although common, adverse events were mostly mild-to-moderate in severity 
and typically resolved after the first 4-8 weeks; at 26 weeks, only nine (35%) liraglutide- 
treated patients reported any gastrointestinal complaints, the majority of mild severity. 
In two participants, diarrhoea resolved after metformin was discontinued. No serious 
adverse events were reported. No change in liver or renal function occurred. Of the 
26 participants treated with liraglutide, three (11.5%) were on a dose of 1.2 mg. The overall 
rate of hypoglycaemia was similar across treatment groups (Table 3). Minor (grade 1, 2) 
hypoglycaemia rates were 3.85 and 2.70 events per participant per year for the liraglutide 
and standard therapy group, respectively. No major (grade 3) hypoglycaemic events 
occurred.
Table 2  Changes from baseline in secondary outcome variables 
Variable Liraglutide 
(n=26)
Standard therapy 
(n=24)
p value
Cardiovascular
Systolic blood pressure, mmHg
Baseline 137±16 141±15
Change from baseline to week 26 −7±2 −3±3 0.25
Diastolic blood pressure, mmHg
Baseline 81±6 82±8
Change from baseline to week 26 −2±1 −3±2 0.80
Heart rate, beats/min
Baseline 74±10 72±9
Change from baseline to week 26 −3±2 −2±3 0.79
Anthropometric 
Change in BMI, kg/m2 −1.4±0.3 0.3±0.2 <0.001
Change in waist circumference, cm −2.1±1.3 2.7±1.2 0.01
Change in hip circumference, cm −1.5±1.4 3.0±1.4 0.03
Quality of life scoresa
PAID
Baseline 14±11 16±13
Change from baseline to week 26 −5±2 −4±2 0.67
BDI-II
Baseline 10±8 9±8
Change from baseline to week 26 −1±2 0±1 0.46
Physical activity
TEE, kJ/day
Baseline 8.6±2.0 8.8±1.4
Change from baseline to week 26 0.01±0.34 0.03±0.20 0.54
Steps per day
Baseline 6346±2914 7219±3103
Change from baseline to week 26 275±621 −141±408 0.74
METS per day, kJ kg−1 h−1 
Baseline 5.5±1.3 5.9±1.1
Change from baseline to week 26 0.23±0.19 −0.09±0.15 0.20
Data are expressed as mean ± SD for baseline (descriptive) characteristics; changes from baseline are expressed 
as mean ± SEM 
a Scores on quality of life, as assessed by the patient, with higher scores indicating a poorer quality of life
METS, metabolic equivalents (1 MET equals consumption of 4 kJ [1 kcal]/kg of body weight per hour); 
TEE, total energy expenditure 
Table 3  Number of patients reporting adverse events
Event Liraglutide 
(n=26)
Standard therapy 
(n=24)
p value
Any severe adverse event 8 (30.8) 2 (8.3) 0.08
Decreased appetite 24 (92.3) 2 (8.3) <0.001
Dyspepsia 20 (76.9) 1 (4.2) <0.001
Constipation 14 (53.8) 2 (8.3) 0.001
Nausea 11 (42.3) 3 (12.5) 0.03
Diarrhoea 10 (38.5) 6 (25) 0.37
Headache 10 (38.5) 6 (25) 0.37
Vertigo 10 (38.5) 4 (16.7) 0.12
Abdominal pain 9 (34.6) 1 (4.2) 0.01
Rhinopharyngitis 8 (30.8) 7 (29.2) >0.99
Vomiting 6 (23.1) 1 (4.2) 0.10
Hypoglycaemia
Grade 1 13 (50) 8 (33.3) 0.27
Episodes patient−1 year−1 3.23±1.09 2.52±1.29 0.21
Grade 2 4 (15.4) 2 (8.3) 0.67
Episodes patient−1 year−1 0.62±0.31 0.17±0.17 0.21
Grade 1,2 15 (57.7) 8 (33.3) 0.10
Episodes patient−1 year−1 3.85±1.17 2.70±1.30 0.10
Counts are displayed as number (%) of patients reporting an adverse event or mean ± SEM 
Only adverse events reported >5% are depicted
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Physical activity levels and quality of life 
There were no changes in average total energy expenditure and physical activity (as 
reflected by steps per day and average METS per day) or quality of life (as reflected by the 
BDI-II and PAID questionnaires), neither among nor between the two groups during 
treatment (Table 2).
Discussion
Our study shows that addition of the GLP-1 analogue, liraglutide, to patients with 
pronounced insulin-induced weight gain results in a substantial reversal of weight, while 
glucose control is maintained or even improved. These findings suggest that adding 
liraglutide to insulin treatment is a valuable treatment strategy for these patients, for 
whom other methods to lose weight are difficult to implement, whereas continuation and 
intensification of insulin therapy leads to further weight gain. 
Some previous studies, mostly observational, have investigated the effect of adding GLP-1 
analogues to existing insulin treatment in patients with type 2 diabetes [16-31]. Our study 
differs from previous randomised controlled trials (RCTs) in that this is the first RCT where 
liraglutide was added to reverse weight gain in fairly well controlled patients, while all 
other trials added GLP-1 analogues to improve glycaemic control, and reported results on 
body weight as secondary outcomes, showing mixed results [16,17,19,23,25-27]. Furthermore, 
we compared two clinically relevant treatment strategies for handling insulin-induced 
weight gain, a therapeutic challenge often faced by clinicians, which no RCT has ever 
addressed. The 5.4 kg weight difference we found between addition of liraglutide and 
continuation of insulin is far greater than reported earlier in RCTs on the combination of 
GLP-1 analogues and insulin, where average weight loss after 26 weeks did not exceed 2.8 kg 
[17,23,25-27]. Only one recently published trial, by Lane and colleagues, found a 5.3 kg 
weight loss after 24 weeks in 21 extremely obese (BMI 39.6 kg/m2) patients with insulin -
resistant type 2 diabetes [19]. The larger weight loss observed in the present study may be 
explained first by the fact that it was not designed with the intention to improve glycaemic 
control, as improvement in glycaemic control is usually associated with weight gain [5,8]. 
Second, liraglutide-induced insulin dose reductions were greater in our study than in 
others [17,19,23,25-27], and the decrease in insulin dose was also a predictor of weight loss. 
Finally, patients in our study were selected for pronounced insulin-associated weight gain. 
Interestingly, the amount of insulin-induced weight gain was not significantly related to 
the amount of liraglutide-induced weight loss. In contrast with the registration trials 
[10-14], weight loss with liraglutide was inversely related to BMI, with the greatest weight 
loss occurring in patients with a lower rather than a higher BMI. 
Although not intended, HbA1c fell by 0.77% (8.4 mmol/mol) after 26 weeks, which is a 
known effect of liraglutide and within the range of reductions observed in most previous 
RCTs on insulin-GLP-1 analogue combinations [19,23,25-27]. The two treatment groups 
showed numerical differences in smoking and drinking habits, which may be relevant, as 
smoking is known to influence insulin resistance. However, these differences were not 
statistically significantly different, and, with linear regression analyses, we found no 
relationship between smoking and drinking habits and HbA1c reduction and weight loss. 
In our study, one in five patients could completely discontinue insulin. As glycaemic 
control in most patients improved beyond target, one may speculate that more aggressive 
down-titration of insulin might have resulted in even more weight loss and a larger 
proportion of patients being able to discontinue insulin treatment. 
As expected, adverse gastrointestinal events associated with liraglutide occurred in the 
first 4-8 weeks of treatment and mostly concerned loss of appetite, dyspepsia and 
constipation rather than vomiting and diarrhoea, as often reported [35]. Neither the 
presence nor the severity of these events was related to the magnitude of weight loss or 
HbA1c reduction. The withdrawal rate due to adverse events was much lower in our study 
than in others [17,24,27], possibly because we monitored patients every 4-6 weeks and 
allowed them to remain on a lower liraglutide dose when needed. This could also have 
prevented a higher rate of hypoglycaemia in the liraglutide-treated group, the absence of 
which has been described previously [17,19,22,23,25]. The use of sulfonylurea was similar in 
the two groups, and sulfonylurea did not explain changes in body weight or occurrence 
of hypoglycaemia in linear regression analysis.
Our study has limitations. First, only patients with pronounced insulin-induced weight 
gain in the first 16 months of insulin therapy were included and therefore we cannot 
vouch for the efficacy of liraglutide in patients with less pronounced weight gain or 
weight gain on long-term insulin treatment. We defined 4% weight gain as pronounced, 
as this reflects the upper 50% of insulin-associated weight gain and a minimal weight 
reduction of 3-5% in obese participants is already associated with a clinically relevant 
reduction in health risk [6,36,37]. Second, as our study duration was 26 weeks, it cannot 
determine whether the effects of addition of liraglutide to insulin are sustained after this 
time period. Our study included only 50 patients, and, although intended, it was not 
placebo controlled, which could be viewed as a limitation. The open study design may 
have caused unintended differences in compliance with dietary advice between the 
treatment groups, although the similar physical activity scores suggest such an effect to 
be minimal at the most. Next, the three additional telephone consultations in the first 
4 study weeks for liraglutide-treated patients may have added to the effect of the 
liraglutide intervention. These consultations were appointed for safety reasons only and 
were not scheduled in the group receiving standard therapy, because they were less likely 
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to experience hypoglycaemia and treatment-related adverse events. Furthermore, as two 
different treatment strategies were compared, these consultations are not part of a regular 
insulin-treatment strategy. Nevertheless, the comparison of two different, clinically 
relevant, treatment strategies is just the strength of the study. Currently, the most practised 
approach for patients with insulin-associated weight gain is continuation and intensification 
of insulin treatment. A further strength of this investigator-initiated study is that it reflects 
real-world clinical practice and permitted various insulin regimens and oral glucose- 
lowering agents. 
In current clinical practice, insulin therapy is still the cornerstone of type 2 diabetes 
therapy. Most patients will reach a good or at least fair HbA1c level with insulin but, in some 
patients, at the expense of significant weight gain. According to clinical practice guidelines, 
addition of a GLP-1 analogue is not indicated in this situation [1]. We show, however, that 
the addition of liraglutide in patients with pronounced weight gain was effective in 
reversing weight gain, allowed one in five patients to discontinue insulin treatment 
completely, and reduced insulin need in most others, while glycaemic control further 
improved. Nevertheless, not all patients responded to the therapy. In fact, the effects of 
the therapy were clear within 12-16 weeks and indicative already after 8 weeks. Hence, 
a 3 month trial period may be a suitable approach to test the weight and HbA1c-reducing 
potential of liraglutide in individual patients with pronounced insulin-associated weight 
gain. In those that show no response within this time frame, the treatment could be 
discontinued. Further studies are needed to assess whether such an approach within the 
modern concept of personalised, patient-centred healthcare is cost-effective. Our trial 
contributes to future debates on these matters. 
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Abstract 
Aim: Pronounced weight gain frequently complicates insulin therapy in patients with type 
2 diabetes (T2DM). We have previously reported that addition of liraglutide for 26 weeks 
can reverse insulin-associated weight gain, decrease insulin dose and improve glycaemic 
control, as compared with continuation of standard insulin treatment. 
Objectives: To investigate whether the beneficial effects of liraglutide are sustained up 
to 52 weeks and whether similar effects could be obtained when liraglutide is added 
6 months later. 
Methods: Adult T2DM patients with ≥4% weight gain within 16 months of insulin therapy 
completing the first 26-week trial period of open-label addition of liraglutide 1.8 mg/day 
(n = 26) versus continuation of standard insulin therapy (n = 24) were all treated with 
liraglutide for another 26 weeks. Results were analysed according to the intention-to-treat 
principle.
Results: Overall, 24 (92%) and 18 (75%) patients originally assigned to liraglutide and 
standard therapy, respectively, completed the study. Addition of liraglutide decreased 
body weight to a similar extend when given in the first 26 weeks (liraglutide group) or 
second 26 weeks (original standard therapy group): -4.4 versus -4.3 kg (difference -0.32 kg, 
95% confidence interval -2.2 to 1.6 kg; P = 0.74). Similar results were also seen in the two 
groups with regard to decrease in haemoglobin A1c (HbA1c) (-0.77 vs. -0.66%; P = 0.23) and 
insulin dose (-28 vs. -26 U/day; P = 0.32).  In both groups, 22% of patients could discontinue 
insulin. Continuation of liraglutide until 52 weeks led to sustained effects on body weight, 
HbA1c and insulin dose requirements.
Conclusions: In T2DM patients with pronounced insulin-associated weight gain, addition 
of liraglutide within 2 years leads to sustained reversal of body weight, improved glycaemic 
control and decrease in insulin dose. Thus liraglutide offers a valuable therapeutic option.
Introduction
Insulin therapy is frequently needed to achieve adequate glycaemic control in patients 
with type 2 diabetes, but often at the expense of weight gain [1-4]. Although large inter- 
individual differences exist, estimated insulin-associated weight gain is 2–6 kg during the 
first year of insulin therapy, or 2–3 kg for every 1% fall in haemoglobin A1c (HbA1c) [1-4]. 
When insulin-associated weight gain is pronounced, it may not only worsen insulin 
resistance, leading to higher insulin dose requirements and ongoing weight gain, but also 
undermine any effort to lose weight in an already overweight population. Such weight 
gain has proved difficult to reverse and may lead to unwillingness to continue the therapy. 
Other than dietary and lifestyle advice, which is often unsuccessful, there is currently no 
effective treatment that ameliorates pronounced weight gain after the initiation of insulin 
therapy.
Recently, we reported the 26-week results of the randomized controlled Effect of 
Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes (ELEGANT) 
trial, which was conducted in patients with type 2 diabetes who had shown pronounced 
insulin-associated weight gain after short-term insulin therapy [5]. The primary outcome 
of the study was weight. Addition of the glucagon-like peptide-1 (GLP-1) analogue 
liraglutide to insulin therapy during 26 weeks effectively reversed weight gain, while 
improving glycaemic control and decreasing insulin-dose requirements, as compared 
with continuation of standard insulin treatment. Here, we report the results of the full 
52-week study, the objective of which was to investigate the sustainability of liraglutide- 
induced weight loss. Because patients initially randomly assigned to standard treatment 
were additionally treated with liraglutide after 26 weeks of follow-up, we also aimed to 
determine whether insulin-induced weight gain would still be reversible when liraglutide 
was added to insulin  6 months later. 
Materials and methods
Study design and participants
The ELEGANT trial was conducted between February 2012 and April 2014 in the outpatient 
departments of two study centres in the Netherlands: Radboud University Medical Center 
and Jeroen Bosch Hospital (a large teaching hospital). The study was approved by the 
institutional review board of the Radboud University Medical Center and conducted 
according to Good Clinical Practice and the Declaration of Helsinki. This trial is registered 
at clinicaltrials.gov (identifier: NCT01392898). All patients provided written informed consent 
to participate.
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The design and results of the first phase of the study (phase 1; 0–26 weeks) have been 
described previously [5]; phase 2 (26–52 weeks) followed the same standard study 
procedures. Briefly, adult patients with type 2 diabetes, with a body mass index (BMI) of 
≥25 kg/m2  and HbA1c between 6.5% and 8.5% (48–69 mmol/mol), who had recently 
started insulin therapy (between 3 and 16 months; all types and regimens allowed) and 
had gained ≥4% of body weight since the start of insulin treatment, were enrolled in the 
study. After enrolment, participants were randomly assigned to one of two treatment 
strategies: open-label addition of liraglutide or continuation of insulin without liraglutide 
(standard therapy). All participants continued their glucose-lowering treatment (only 
metformin and sulphonylurea were allowed as oral glucose-lowering agents), but the 
total insulin dose was reduced by 20% in patients assigned to liraglutide. Liraglutide (Novo 
Nordisk, Bagsvaerd, Denmark) was initiated in 0.6 mg weekly increments to a final dose of 
1.8 mg. When adverse events occurred, subjects were allowed to return to the 1.2 mg 
dose. Participants were evaluated every 4–6 weeks with regard to weight, glycaemic 
control and adverse events. Insulin dose was adjusted using a specific treatment algorithm, 
with a fasting glucose target of 4.0–6.5 mmol/L [5,6]. HbA1c was determined every 8 weeks. 
Every 26 weeks, blood was collected for determination of fasting blood glucose, full blood 
cell count and thyroid, liver and renal function; in addition, quality of life questionnaires 
regarding diabetes-related distress [(Problem Areas in Diabetes (PAID) scale [7]] and 
depression (Beckman Depression Inventory II: BDI-II [8]) were administered, waist and hip 
circumferences were measured and physical activity was quantified by wearing a portable 
armband (HealthWear Bodymedia, Pittsburgh, PA, USA) [9] for four consecutive days. 
After 26 weeks of follow-up (weeks 26–52: phase 2), patients receiving standard care were 
treated with additional liraglutide for 26 weeks (insulin–liraglutide group). The liraglutide- 
treated group continued liraglutide treatment for an additional 26 weeks.
Outcome measures 
The primary efficacy end-points were change in body weight in the liraglutide group after 
52 weeks of treatment and difference in weight change between the two treatment 
groups after the first 26 weeks of liraglutide treatment. Secondary end-points included 
change in HbA1c, insulin dose, physical activity and quality of life, and the number of 
patients discontinuing insulin. Safety assessments included adverse events and number 
and severity of hypoglycaemic episodes. Hypoglycaemia (<3.9 mmol/L) was graded as 
asymptomatic or mild (grade 1), moderate (i.e. requiring additional oral carbohydrate; 
grade 2) and severe (i.e. requiring third-party assistance, irrespective of glucose levels; 
grade 3).
Statistical analysis 
The power calculation for this study was based on weight difference between addition of 
liraglutide and continuation of standard insulin therapy after 26 weeks (end of phase 1), 
as described previously [5]. All statistical analyses were performed using SPSS 20.0 
(Statistical Package for Social Sciences, Chicago, IL, USA), and P < 0.05 was considered 
statistically significant. Descriptive characteristics are expressed as mean ± SD; results are 
expressed as mean ± SE, unless otherwise indicated. 
Three analysis populations were identified: the intention-to-treat (all randomly assigned 
patients), per-protocol (all patients who completed 52-weeks of follow-up) and safety 
(all patients who received at least one dose of liraglutide) populations. 
A linear mixed model for repeated measures was used to estimate the effect of treatment 
on weight, BMI, HbA1c, insulin dose, blood pressure and heart rate, at multiple time points 
with fixed effects for treatment, visit, treatment-by-visit interaction, baseline weight 
stratum, baseline level of the variable analysed and centre. Treatment differences were 
summarized by maximum likelihood (ML) means and 95% confidence intervals (CIs) from 
the mixed model. Independent two-tailed t tests (or Mann–Whitney U tests for non- 
parametric data) were performed to assess between-group differences in all other secondary 
end-points; paired t tests (or Wilcoxon signed-rank tests) were used to assess within-group 
changes. Fisher’s exact or chi-squared tests were used as appropriate for analysis of 
between-group differences in categorical variables. Missing values were not imputed for 
mixed model data; for other data missing values were imputed using the last observation 
carried forward. 
Multiple linear regression analysis was used to assess factors associated with weight loss 
after liraglutide treatment. Variables were selected using the backward stepwise method. 
All variables with a P-value of <0.05 stayed in the model. 
Results
Fifty patients were included in the study; 26 were initially assigned to liraglutide (liraglutide 
group) and 24 to standard insulin therapy (insulin–liraglutide group; Fig. 1). 
The study population comprised middle-aged, overweight individuals with type 2 
diabetes, who had gained on average 7.1 kg (7.5% of body weight) while on insulin 
treatment for a mean of 10 months (54% basal insulin alone, 12% biphasic, 32% basal bolus 
and 2% on pump therapy). Glycaemia was relatively well controlled in all patients: mean 
HbA1c 7.4% (57 mmol/mol). Forty-seven (94%) participants completed the first 26 weeks of 
the study. In study phase 2, five participants (10%) dropped out. In the insulin–liraglutide 
group, one patient declined liraglutide and withdrew consent after phase 1, and three 
patients dropped out at 4, 8 and 9 weeks after initiation of liraglutide treatment because 
of gastrointestinal adverse events; in the liraglutide group, one patient was excluded after 
46 weeks of follow-up due to noncompliance with study medication. 
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Body weight 
Patients in the insulin–liraglutide group, who had shown a further increase in body weight 
with insulin during study phase 1, lost 4.3 ± 0.6 kg (4.7 ± 0.7% of body weight) with 
liraglutide during phase 2. This weight loss was not different from the decrease of 4.4 ± 0.7 kg 
in the liraglutide group during phase 1 (ML mean difference -0.32 kg, 95% CI -2.2 to 1.6 kg; 
P = 0.74; Fig. 2B). The liraglutide group regained some weight during phase 2, with a total 
loss of 3.3 ± 0.7 kg (3.8 ± 0.7% of baseline body weight) after 52 weeks of liraglutide 
treatment (Fig. 2A).
For all included patients, 26 weeks of liraglutide treatment resulted in loss of 67 ± 11% of 
insulin-associated weight gain (79 ± 12% in the per-protocol population), equivalent to a 
1.5 ± 0.2 kg/m2 decrease in BMI (Table 1). 
The weight response to liraglutide treatment was heterogeneous. In total, 16 of 50 
participants (32%; 38% in the per-protocol population) showed complete reversal of insu-
lin-associated weight gain, whereas nine of 47 (19%) liraglutide-treated patients gained 
weight with liraglutide. There was one ‘outlier’ in the liraglutide group with a gain of 3.7 
and 19.8 kg after 26 and 52 weeks of treatment, respectively. The reason for this excessive 
weight gain was unknown; there were no signs of fluid retention and after trial participation, 
the patient opted for bariatric surgery. When this participant was excluded from the 
primary (intention-to-treat) analysis, weight loss after 26 and 52 weeks in the liraglutide 
group was 4.8 ± 0.6 and 4.3 ± 0.6 kg, respectively. 
Secondary outcomes
In the insulin–liraglutide group, after glycaemic control had remained stable during study 
phase 1, HbA1c decreased by 0.66 ± 0.13% (7.2 ± 1.4 mmol/mol) with liraglutide during 
phase 2. This decrease was not statistically different from that of 0.77 ± 0.13% (8.4 ± 
1.4 mmol/mol) in the liraglutide group during phase 1 [ML mean difference -0.22% 
(-2.4 mmol/mol), 95% CI -0.59% to 0.15% (6.4 to 1.6 mmol/mol); P = 0.23; Fig. 2D]. 
After 52 weeks of treatment, HbA1c decreased by 0.60 ± 0.13% (6.6 ± 1.4 mmol/mol) in the 
liraglutide group (Fig. 2C). Thirty of all included participants (60%; 71% in the per-protocol 
population) achieved an HbA1c of 7.0% (53 mmol/mol) or less after 26 weeks of liraglutide 
treatment. In the liraglutide group, this percentage was sustained up to 52 weeks.
The insulin dose decreased by 26 ± 3 U/day (-56.3 ± 5.7%; 0.24 ± 0.03 U/kg) in the insulin–
liraglutide group with liraglutide treatment in study phase 2, after a slight increase in study 
phase 1. Again, this was not different from the decrease of 28 ± 3 U/day in insulin dose 
observed in the liraglutide group during phase 1 (ML mean difference -5 U/day, 95% CI -14 
to 5 U/day; P = 0.32; Fig. 2F). After 52 weeks, the mean decrease in insulin dose remained 
28 ± 3 U/day (-58.0 ± 5.8%; 0.29 ± 0.04 U/kg) in the liraglutide group (Fig. 2E). During the 
trial, 11 subjects (22%; 26% in the per-protocol population) discontinued insulin therapy 
after a median of 12 weeks: seven (27%) in the liraglutide group (two during phase 2) and 
four (17%) in the insulin–liraglutide group. In addition, the insulin regimen was simplified 
from basal bolus to basal insulin alone in three patients. 
Figure 1   Study flow, showing enrolment, baseline characteristics and follow-up
HbA1c, haemoglobin A1c; BMI, body mass index.
25 Completed 26 weeks  
 
1 Discontinued because of 
adverse event  
Age (years)  57 ± 10  
Male: female  16:10  
Weight (kg)   102 · 3 ± 20 · 1 
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Figure 2   Effect of early and late initiation of liraglutide on body weight,  
haemoglobin A1c (HbA1c) and insulin dose 
The time courses of maximum-likelihood mean ± SE changes in body weight (A and B), HbA1c (C and D) 
and insulin dose (E and F) are shown for the liraglutide group (52 weeks of liraglutide treatment, 
starting at baseline; black circles) and the insulin–liraglutide group (standard insulin therapy from 
baseline to 26 weeks, with additional liraglutide treatment in study phase 2 from 26 to 52 weeks; 
white squares). (B, D and F) Direct comparison of the effects of early (phase 1) and late (phase 2) 
initiation of liraglutide treatment over 26 weeks. The results represent the primary (intention-to-treat) 
analysis. *P < 0.05; **P < 0.001, compared with standard therapy at same time point. 
Baseline factors predicting liraglutide-induced weight loss were female gender, no use of sulphonylurea, 
use of basal insulin alone and a high HbA1c at baseline. Together, these factors explained 26% of all 
weight loss. Abdominal pain and decreased appetite reported during follow-up explained an 
additional 12% of liraglutide-induced weight loss (Table S1).
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Table 1  Mean values of secondary outcome variables at different time points
Baseline 26 weeks 52 weeks
Liraglutide Insulin–
liraglutide
Liraglutide Insulin–
liraglutide
Liraglutide Insulin–
liraglutide
Anthropometric
BMI, kg/m2 
Waist circ, cm
Hip circ, cm
33.6 ± 6.4
110 ± 13
106 ± 11
31.6 ± 5.1
107 ± 15
104 ± 12
32.1 ± 0.3*‡
108 ± 3*
104 ± 2
31.9 ± 0.3
109 ± 3*
107 ± 2*
32.6 ± 0.3*
108 ± 3
105 ± 2
30.5 ± 0.3*†
106 ± 3†
104 ± 2†
Cardiovascular
BPsyst, mmHg
BPdiast, mmHg 
Heart rate, bpm
137 ± 16
81 ± 6
74 ± 10
141 ± 15
82 ± 8
72 ± 9
129 ± 2*‡
79 ± 1
70 ± 2
138 ± 2
80 ± 1
71 ± 2
131 ± 2*
81 ± 1
74 ± 2
128 ± 3*†
78 ± 1*
74 ± 2
Quality of lifea 
PAID 
PAID ≥40, n (%)
BDI-II
BDI-II ≥11, n (%)
17 ± 14
3 (12)
10 ± 8
8 (31)
19 ± 17
4 (17)
9±8
5 (22)
11 ± 3*
2 (8)
9 ± 2
9 (35)
14 ± 3*
1 (4)
8 ± 1
7 (30)
15 ± 3
3 (12)
9 ± 2
6 (23)
13 ± 3*
1 (4)
7 ± 2
5 (22)
Physical activity
TEE, kcal/day
Steps per day
METS, kcal/kg/h
2054 ± 483
6346 ± 2914
1.3 ± 0.3
2101 ± 332
7219 ± 3103
1.4 ± 0.3
 
2066 ± 108
6542 ± 575
1.3 ± 0.0
2107 ± 62
7102 ± 676
1.4 ± 0.1
2014 ± 114
6032 ± 613
1.3 ± 0.1
2028 ± 71
6631 ± 655
1.4 ± 0.1
circ, circumference; bpm, beats/min; BPsyst, systolic blood pressure; BPdiast, diastolic blood pressure; PAID, 
Problem Areas in Diabetes; BDI-II, Beckman Depression Inventory II; TEE, total energy expenditure; METS, 
metabolic equivalents (1 MET is equivalent to consuming 1 kcal/kg of body weight per h). 
Liraglutide group received liraglutide from 0–52 weeks; insulin–liraglutide group continued standard insulin 
therapy from 0–26 weeks and received liraglutide from 26–52 weeks. Baseline values are expressed as mean ± SD; 
follow-up parameters as mean ± SE. *P < 0.05 compared with same treatment at baseline; †P < 0.05 compared 
with same treatment at 26 weeks; ‡P < 0.05 compared with insulin–liraglutide group at same time point. 
aScores assessed by the patient, with higher scores indicating a poorer quality of life. A PAID score of ≥40 is 
generally used to indicate seriously elevated diabetes distress [10]. A BDI-II score of ≥11 indicates elevated 
depression symptoms, with at least mild depression [11]. Mean quality of life scores are calculated for 49 
participants as questionnaires were not obtained from one participant who dropped out early.
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Twenty-six weeks of liraglutide treatment significantly reduced systolic blood pressure 
and waist and hip circumferences, and improved quality of life as reflected by the PAID 
questionnaire (Table 1). Liraglutide had no statistically significant impact on average total 
energy expenditure and physical activity after 26 or after 52 weeks. 
Safety
The most commonly reported adverse events among liraglutide-treated patients were 
decreased appetite (95.7%) and dyspepsia (72.3%), typically resolving after the first 4–8 weeks 
of treatment (Table 2). One patient in the insulin–liraglutide group developed an erythematous 
rash on the chest and extremities 2-3 weeks after the start of liraglutide, which improved 
after the dose was decreased to 1.2 mg, and completely resolved 2.5 months after dis-
continuation of liraglutide, at the end of the study. Of the 47 subjects treated with liraglutide, 
four (8.5%) discontinued the drug due to adverse events, and six (12.8%) could not tolerate 
a dose higher than 1.2 mg. One patient had a myocardial infarction (after 18 weeks of 
liraglutide treatment), which was deemed unrelated to the study drug and was treated 
with percutaneous revascularization. Minor (grade 1 and 2) hypoglycaemia rates were 
2.9 and 0.9 events per participant-year, respectively (Table 2). No major hypoglycaemia 
was reported.
Discussion
Our findings show that in patients with pronounced insulin-associated weight gain, 
addition of the GLP-1 analogue liraglutide, both within 16 and within 22 months after the 
start of insulin, results in a substantial and sustained weight loss, with preserved and even 
improved glucose control. Insulin dose can be reduced, and in one out of five patients 
insulin can be completely discontinued. This suggests that liraglutide represents a valuable 
treatment option for pronounced weight gain occurring shortly after the initiation of 
insulin therapy. 
The weight loss of 4.4 kg after 6 months of liraglutide treatment in the present study is 
more than the mean maximum weight loss of 2.8 kg reported in most previous randomized 
controlled trials of the GLP-1 analogue–insulin combination [12-18]. This difference could 
be explained by the specific selection of participants with marked insulin-associated 
weight gain in the present study. Furthermore, our aim was not to improve glycaemic 
control, as most patients were already ‘on target’, although HbA1c still decreased by 
0.66–0.77%. It may be speculated that more aggressive down-titration of insulin dose 
could have resulted in even more weight loss. 
Later addition of liraglutide was statistically as effective as early initiation in promoting 
weight loss and improving glycaemic control, but the decrease in insulin dose tended to 
be more prominent with early initiation. This trend, as well as the observation that the 
effects of liraglutide on glycaemic control tended to diminish over time, could possibly be 
explained by the use of higher insulin doses when liraglutide is started later and progressive 
loss of beta cell function when diabetes progresses [19]. This hypothesis is consistent with 
previous findings which suggested that the successful introduction of liraglutide 
treatment in patients with type 2 diabetes was related to residual beta cell function 
[20-22]. In the present study, however, no significant relationships between diabetes 
duration and decreases in insulin dose, HbA1c or body weight were found by linear 
regression analysis. 
Table 2   Treatment-emergent adverse events (AEs) in patients who received any dose 
of liraglutide to week 52
Any liraglutide dose (n = 47); 34.36 PYs 
n (%) Events (events/PY)
Any AE certainly related to study drug
Any AE at least probably related to study drug
Any AE at least possibly related to study drug
47 (100)
47 (100)
47 (100)
204 (5.9)
342 (10.0)
529 (15.4)
Any severe AE 20 (42.6) 60 (1.8)
Any serious AE 1 (2.1) 2 (0.06)
Decreased appetite 45 (95.8) 127 (3.7)
Dyspepsia 34 (72.3) 81 (2.4)
Rhinopharyngitis 27 (57.5) 58 (1.7)
Constipation 24 (51.1) 61 (1.8)
Diarrhoea 24 (51.1) 65 (1.9)
Nausea 23 (48.9) 60 (1.8)
Headache 21 (44.7) 51 (1.5)
Abdominal pain 21 (44.7) 41 (1.2)
Vertigo 18 (38.3) 47 (1.4)
Vomiting 12 (25.5) 21 (0.6)
Injection-site reaction 3 (6.4) 6 (0.2)
Hypoglycaemia
  grade 1
  grade 2
  grade 1/2
28 (59.6)
13 (27.7)
32 (68.1)
98 (2.9)
31 (0.9)
129 (3.8)
PY, patient year.
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Recently, two other clinical trials of GLP-1 analogue–insulin combination therapy have 
been reported with a long follow-up duration of 52 weeks; both demonstrated a decrease 
in body weight of 0.4 kg after 52 weeks [23,24]. In general, several previous retrospective 
studies reported continuing weight loss beyond 26 weeks, with a mean weight loss after 
52 weeks of 4.3–7.6 kg [25-27]. This greater weight loss is probably due to the fact that 
patients in observational trials with less or no response to the therapy are more likely to 
discontinue treatment and be excluded from the study. By contrast, we found a slight 
regain in body weight towards the end of the study in patients randomly assigned to 
liraglutide, which we postulate may have been related to a decrease in adverse gastroin-
testinal effects. Based on linear regression analysis, abdominal pain and decreased 
appetite were related to liraglutide-induced weight loss, but these adverse events 
generally decrease after 2 months of therapy. In the registration trials, sustained nausea 
was associated with liraglutide-induced weight loss [28,29]. In animal studies, neuronal 
GLP-1 receptors have been shown to play an essential role in both liraglutide-induced 
reduction in body weight and appetite [30,31]. Whether this mechanism is relevant in the 
human situation is unclear and was not investigated in the present study.  
Clinicians face a lack of treatment options for patients with type 2 diabetes who show 
pronounced insulin-associated weight gain. Increasing physical activity and decreasing 
energy intake are obvious potential interventions, but already part of the treatment and 
generally fail. Bariatric surgery is only an option in a minority of cases. Pronounced weight 
gain may offset the benefits of improved glucose control and impair quality of life, and a 
subsequent reversal of weight by 3–5% may lead to significant improvements in 
cardiovascular disease risk markers [32,33]. Although liraglutide may be a valuable 
treatment option, not all patients respond to this expensive therapy. Given the large in-
ter-individual differences in the response, a 3-month trial period for patients with 
pronounced insulin-associated weight gain could result in a more cost-effective treatment. 
This is supported by several findings: 23 of 47 (~50%) liraglutide-treated patients in our 
trial responded to the therapy [defined as at least two of ≥4% weight loss, HbA1c ≤7% (53 
mmol/mol) and discontinuation of insulin therapy]; responders lost a mean of 6.7 kg (7.1% 
of body weight); withdrawal due to adverse effects generally occurred within 6 weeks; 
and patients who were able to completely discontinue insulin did so within a median of 
12 weeks. Moreover, such an approach fits well within the current concept of personalized 
healthcare.
Our study has both strengths and limitations. A strength of this study is that it reflects 
real-world clinical practice, in that virtually all insulin regimens and most commonly used 
oral glucose-lowering agents were permitted. Although the absence of a placebo could 
be considered a limitation, the purpose of this study was to compare two treatment 
strategies: continuation of insulin, and addition of a GLP-1 analogue early or later in the 
course of type 2 diabetes as would be the case in a clinical practice situation. Hence, we 
believe that our findings are generalizable to the overall insulin-treated type 2 diabetes 
population, in whom pronounced weight gain after the start of insulin treatment is often 
observed. However, as this study was conducted in a predominantly Caucasian population, 
we cannot guarantee the similar efficacy of this treatment strategy in other ethnic groups, 
or the efficacy of adding other GLP-1 analogues to insulin. Given the recent suggestion 
that activation of GLP-1 receptors in the central nervous system could play a role in the 
action of GLP-1 analogues [30,31], the molecular size of the GLP-1 analogue may be 
relevant for the effect on weight loss.  
In conclusion, in patients with type 2 diabetes and pronounced insulin-associated weight 
gain, the addition of liraglutide within 2 years after initiation of insulin therapy reverses 
most of the weight gained, improves glycaemic control and decreases insulin dose 
requirements. Thus liraglutide might offer a valuable therapeutic option, but it should be 
discontinued when no response to therapy is encountered within 3 months. 
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Supplement to Chapter 3
Supplemental Table S1   Parameters associated with liraglutide-induced weight loss  
at baseline and follow-up
B SE 95% CI P-value
Baseline (model R2 0.33;  adjusted R2 0.26)
(Constant) -1.20 6.24 -13.83 to 11.44 0.85
Gender 3.77 1.12 1.50 to 6.03 0.002
Sulphonylurea use 2.83 1.33 0.13 to 5.52 0.041
Insulin regimen 1.51 0.64 0.22 to 2.80 0.023
Baseline HbA1c (%) -1.75 0.81 -3.40 to -0.11 0.037
Follow-up (model R2 0.17;  adjusted R2 0.12)
(Constant) -2.96 1.14 -5.27 to -0.65 0.013
Abdominal pain 1.22 0.59 0.03 to 2.40 0.044
Decreased appetite -0.95 0.43 -1.82 to -0.09 0.031
Multiple linear regression analysis with body weight change (kg) after 26 weeks of liraglutide treatment as 
dependent variable. Variables were selected using the backward stepwise regression method; variables with 
a P-value of <0.05 stayed in the model. 
Baseline parameters considered for the model were: gender (female 1; male 2), age, weight stratum (≤100 or 
>100 kg), body weight, insulin-associated weight gain (kg and %), duration of insulin treatment, diabetes 
duration, insulin dose (U/day), use of sulphonylurea (no sulphonylurea use 0; sulphonylurea use 1) , insulin 
regimen (basal insulin alone 1; biphasic 2; basal bolus 3; pump therapy 4), body mass index, haemoglobin A1c 
(HbA1c; %), steps per day, metabolic equivalents (METS) per day, Problem Areas in Diabetes Scale (PAID) and 
Beckman Depression Inventory II (BDI-II) scores, waist and hip circumference, alcohol use, smoking and 
centre.
Follow-up parameters considered for the model were: change in insulin dose (%), change in HbA1c (%), 
reported hypoglycaemia (grade 1 or 2), discontinuation of insulin treatment, magnitude of reported nausea, 
vomiting, abdominal pain, constipation, decreased appetite, dyspepsia, diarrhoea, vertigo or headache, 
amount of steps and METS per day after 26 weeks, PAID and BDI-II scores after 26 weeks and liraglutide dose 
(1.2 mg or 1.8 mg). B, unstandardized coefficients; CI, confidence interval for B.
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Abstract
Aim: addition of the GLP-1 receptor agonist liraglutide to insulin can reverse insulin- 
associated weight gain, improve HbA1c and decrease insulin need, but is expensive. From a 
cost perspective, such treatment should be discontinued as soon as it is clear that 
treatment targets will not be achieved. Our aim was to find the best cost-controlling 
treatment strategy: the shortest possible trial period needed to discriminate successfully 
treated patients from those failing to achieve predefined targets of treatment success.
Methods: we used data from the ’Effect of Liraglutide on insulin-associated wEight GAiN 
in patients with Type 2 diabetes’ (ELEGANT) trial, comparing liraglutide added to insulin 
(n=47) and standard insulin therapy (n=24) during 26 weeks, to calculate (incremental) 
costs associated with different trial periods. Treatment success after 26 weeks was defined 
by having achieved ≥2 of the following goals: ≥4% weight loss, HbA1c ≤7% (53 mmol/
mol), and/or discontinuation of insulin.
Results: The additional direct costs of adding liraglutide for 26 weeks were €699 per patient, 
or €137 per 1 kg weight loss, compared to standard insulin therapy. The best cost-con-
trolling treatment strategy (identifying 21 of 23 responders, treating 4 non-responders) 
was to continue treatment in patients showing either ≥3% weight loss or ≥60% decrease 
in insulin dose at 8 weeks, with a total cost of €246 for this trial period, saving €453 in case 
of early discontinuation. 
Conclusions: an 8-week trial period of adding liraglutide to insulin in patients with 
pronounced insulin-associated weight gain, with discontinuation in patients not showing 
early responses regarding weight loss or insulin reduction is an effective cost-controlling 
treatment strategy.
Introduction
Insulin treatment is frequently needed to maintain glucose control in patients with type 2 
diabetes, but often at the expense of pronounced insulin-associated weight gain [1,2]. 
Average weight gain has been estimated at 2 kg per 1% (13 mmol/mol) drop in HbA1c, but 
can be much higher (up to 5% of body weight or more) in individual cases [1]. Such weight 
gain is obviously undesirable in an already overweight population, leads to a more 
unfavourable cardiometabolic profile, and may offset the beneficial effects of better 
glucose control [3]. 
Glucagon-like peptide-1 (GLP-1) receptor agonists are a relatively new class of glucose- 
lowering agents that also induce weight loss [4]. They can be used as an adjunct to diet, 
in combination with oral drugs and in combination with insulin [5,6]. However, treatment 
with GLP-1 receptor agonists is expensive and many health care systems have limited the 
reimbursement [7-9]. In individual cases, where more commonly used treatments fail 
or lead to significant side effects, GLP-1 receptor agonists may be a suitable treatment 
alternative. In the Effect of Liraglutide on insulin-associated wEight GAiN in patients with 
Type 2 diabetes (ELEGANT) trial, we showed that addition of the GLP-1 receptor agonist 
liraglutide reversed body weight, decreased insulin requirements and improved glycaemic 
control in patients with type 2 diabetes who had pronounced weight gain after the 
initiation of insulin [10,11]. Approximately 40% of patients lost all body weight gained after 
initiating insulin and 20% of patients were able to stop insulin therapy completely.
While addition of GLP-1 receptor agonists increases direct treatment costs, costs associated 
with insulin therapy such as glucose monitoring and hypoglycaemia decrease [6]. Because 
liraglutide also reduces the incidence of cardiovascular disease and death [12], indirect 
costs may decrease as well. As not all patients respond to treatment with GLP-1 receptor 
agonists, extra costs may be further reduced by early selection of patients with a positive 
response, allowing timely discontinuation in non-responders. The aim of the present study 
was to determine the best cost-controlling treatment strategy for additional GLP-1 
receptor agonist treatment in patients with type 2 diabetes and pronounced insulin- 
associated weight gain: the shortest possible trial period while yielding the highest 
number of effectively treated patients.
Methods
A simulation model was developed, using data from the ELEGANT randomized controlled 
trial, which was conducted between February 2012 and April 2014 in the Netherlands 
[10,11]. The methods of this trial have been described previously. Briefly, patients with type 
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2 diabetes who had shown pronounced (≥4% of body weight) weight gain between 3 
and 16 months after the initiation of insulin therapy were randomized either to addition of 
liraglutide (1.2 or 1.8 mg) to insulin therapy or to continuation of standard insulin therapy 
for 26 weeks. The study had a waiting-list design so that patients who initially continued 
insulin therapy from 0-26 weeks, which was uptitrated when necessary to achieve 
treatment targets, were also offered liraglutide treatment from 26-52 weeks. As clinical 
effects of liraglutide treatment were similar for both groups of patients [11], we pooled the 
26-week data on liraglutide-insulin combination therapy from the entire study population 
(n=47). These data were compared with the 26-week data from the group of patients 
initially randomized to continuation and uptitration of standard insulin therapy (n=24), 
and used for the simulation model to calculate 8,12,16 and 26-week health outcomes. 
Study protocol
After inclusion, participants in the ELEGANT trial were evaluated every 4-6 weeks (study 
visits at 0, 4, 8, 12, 16, 20 and 26 weeks) for adverse events, hypoglycaemia, body weight 
and insulin dose, and every 8 weeks for HbA1c (determined at 0, 8, 16 and 26 weeks). 
Liraglutide was initiated at 0.6 mg/day and increased over two weeks to 1.8 mg/day. When 
adverse events occurred, participants were allowed to return to the 1.2 mg dose. When 
liraglutide was started, total insulin dose was decreased by 20% to avoid hypoglycaemia. 
Participants were instructed to perform daily (4-point) capillary blood glucose profiles, 
during the first 3 weeks after the start of liraglutide, and twice weekly thereafter. Patients 
who continued standard insulin treatment were instructed to perform capillary blood 
glucose profiles at their own discretion, but at least once weekly. Every study visit, insulin 
dose was adjusted aiming for a fasting glucose target of 4.0-6.5 mmol/l. The dose of oral 
glucose-lowering agents (metformin and sulphonylurea) remained unchanged unless 
hypoglycaemia persisted after the discontinuation of insulin. 
Simulation model structure
The model was developed as a decision tree that compared health outcomes within a 
treatment period of 26 weeks consisting of: 1) continuation and uptitration of standard 
insulin therapy, or 2) liraglutide 1.2-1.8 mg once daily added to standard insulin therapy 
(Figure 1). The second treatment strategy could result in three different scenarios: a) adverse 
events, prompting the discontinuation of liraglutide; b) ineffectiveness of the therapy 
(not meeting treatment targets) without (severe) adverse events, which should also lead 
to discontinuation of liraglutide; or c) effectiveness of the therapy, justifying the continuation 
of liraglutide from a clinical point of view. Effectiveness was defined as achieving at least 
two of the following treatment targets after 26 weeks of liraglutide treatment: (1) ≥4% 
weight loss, and/or (2) HbA1c ≤7% (53 mmol/mol), and/or (3) discontinuation of insulin 
therapy without (severe) adverse events. Key-events and changes in therapy over the 
26-week treatment period included changes in insulin dose, uptitration of liraglutide to 
the maximum tolerable dose (1.2 or 1.8 mg), treatment discontinuation due to adverse 
events (trial-based: at 4 weeks and within 12 weeks), and (failure to) achieve treatment 
targets regarding weight loss, HbA1c and discontinuation of insulin therapy.
Model inputs
Model-inputs were derived from the ELEGANT trial; medical expenditure inputs were 
derived from pharmacy costs (Zorginstituut Nederland [9]), as explained below. Costs 
were defined from a health care perspective, societal costs were excluded. 
Effectiveness of liraglutide and insulin use 
Effectiveness inputs and patient flow including drop-out rates of the use of liraglutide 
and/or insulin were derived from the ELEGANT trial (Figure 1 and Table 1). Treatment 
efficacy was evaluated based on (change in) body weight, HbA1c, and insulin dose.
Treatment costs
Direct medical expenditure, consisting of medication-related costs (insulin, liraglutide, 
needles, and test strips needed to perform daily self-measured capillary blood glucose 
profiles), was derived from pharmacy costs (Zorginstituut Nederland [9]) and evaluated at 
8, 12, 16 and 26 weeks. 
Nine of 47 (~1/5) patients were on a liraglutide dose of 1.2 mg, so that the average 
liraglutide dose for all patients was 1.7 mg (at ~€2,83 per mg). For insulin, we calculated 
the average costs per unit of insulin, based on the insulin regimens that were used by the 
trial participants: 54% used basal insulin only (~€0,037 per unit); 34% were on basal-bolus 
regimens (~€0,033 per unit); and 12% were on biphasic insulin (~€0,027 per unit). This 
translated into €0,034 per unit of insulin. The change in insulin dose (units per day) for each 
participant and treatment group was derived from the ELEGANT trial and included the 
20% decrease in insulin dose when liraglutide was started. We assumed a 100% adherence 
for both liraglutide and insulin, while on treatment. 
We assumed that injection needle costs increased with one additional needle (~€0,20 per 
needle) per day after the start of liraglutide, and was reduced by two needles per day 
after the discontinuation of insulin. Patients used disposable test strips for performing 
self-measured capillary blood glucose profiles (~€0,50 per strip). Following the study 
protocol, 28 strips per week were used in the first 3 weeks after the start of liraglutide to 
perform daily (4-point) capillary blood glucose profiles, and 8 strips per week thereafter. 
We assumed that patients continuing standard insulin therapy used 4 strips per week 
and that patients who could discontinue insulin therapy no longer performed blood 
glucose profiles.
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We did not model costs related to the use of metformin and sulphonylurea. Also, we did 
not include the costs associated with a visit to the doctor or laboratory in the model, 
as these were the same for patients in both groups.
Treatment discontinuation and adverse effects
In the ELEGANT trial, 4 of 47 (8.5%) patients discontinued liraglutide due to adverse effects. 
We assumed that two patients stopping liraglutide within 4 weeks incurred drug costs for 
28 days, and those stopping later (within 8 and 9 weeks) incurred drug costs for 12 weeks 
of treatment, but not with any additional costs. We also assumed return to baseline levels 
of insulin dose, HbA1c, and body weight in patients who discontinued therapy. Two of 
24 patients (8.3%) who were initially assigned continuation of standard insulin treatment 
withdrew consent after 1 and 10 weeks of follow-up, respectively, both of whom are 
included in the present analysis. 
We did not take into account costs related to adverse effects. Although particularly gastro- 
intestinal adverse effects occurred more frequently with liraglutide than with standard 
insulin therapy (52.8% versus 8.3%), they were mostly mild-to-moderate in severity and 
typically resolved after 4-8 weeks, and did not lead to hospital admission, increased 
medication costs or unscheduled outpatient visits. As hypoglycaemia rates did not differ 
between the two groups [10,11], we also did not incorporate hypoglycaemia into our 
model. 
Model outcomes
The simulation model was used to answer the following questions. First, the total costs of 
adding liraglutide to insulin for 26 weeks were calculated, on the basis of intention to treat. 
Then, we calculated costs associated with a trial period of 8, 12 or 16 weeks of adding 
liraglutide to existing insulin therapy, as compared to continuation and uptitration of standard 
insulin therapy. Second, the incremental costs (ICER= incremental cost- effectiveness ratio) 
per 1 kg weight loss and per 1% decrease in HbA1c were calculated. Third, several 
thresholds regarding weight loss (in %), change in HbA1c, and reduction in insulin dose (in 
%) at 8, 12 and 16 weeks were explored, to predict if a patient would meet the predefined 
treatment targets after 26 weeks of liraglutide treatment. We assumed that patients who 
would not meet these targets, discontinued liraglutide treatment. These calculations were 
performed to find the shortest possible trial period that would yield the highest number 
of successfully treated patients and the lowest number of patients not meeting treatment 
success, translating into the lowest costs per successfully treated patient. 
Statistical analyses
All statistical analyses were performed using SPSS (IBM SPSS Statistics for Windows, Version 
20.0, IBM Corp, Armonk, NY). Missing data were imputed according to last-observation- 
carried-forward. As both groups were comparable at baseline regarding insulin regimen 
(both 2.1 insulin injections per day) and insulin dose (55.6 ± 34.9 units/day for liraglutide 
arm, 50.0 ± 32.9 units/day for standard insulin therapy, P=0.51), we used raw data to 
calculate treatment costs, not using a linear mixed model. Results for subgroups were 
tested for normal distribution and are displayed as mean ± standard error (SE).
Results
Figure 1 represents the simulation model, including the number of participants in the 
ELEGANT trial assigned to a certain treatment, dropping out, and achieving the predefined 
treatment targets of ≥4% weight loss, HbA1c≤7% and discontinuation of insulin after 26 weeks 
of treatment. In total, 23 out of 47 patients achieved at least two of these treatment targets.
The (incremental) costs of additional liraglutide treatment
The additional costs of adding liraglutide to insulin treatment in the ELEGANT trial 
amounted €246 per patient after 8 weeks of treatment, and €699 per patient after the full 
26 weeks of treatment, as compared with continuation and uptitration of standard insulin 
therapy (Table 1). As liraglutide was very effective in reducing body weight (by -4.3 ± 
0.6kg), the incremental cost-effectiveness ratio (ICER) for a 1 kg reduction in body weight 
was €137; the ICER for a 1% decrease in HbA1c was €999 (Table 1). These costs are spend in 
all patients, including non-responders. Clearly, it would be more cost-efficient to treat only 
patients showing a positive treatment response.
Early predictors of treatment success at 26 weeks 
Figure 2 represents changes in body weight, HbA1c or insulin dose at 8, 12 and 16 weeks 
for responders (patients meeting at least two of the predefined treatment targets at 
26-weeks) and non-responders. Early weight loss of 2.5-3% was a strong indicator of 
long-term treatment success, whereas change in HbA1c did not differentiate between 
responders and non-responders, neither at 8 nor at 16 weeks. The best treatment strategy 
for controlling costs, using weight change only, was to discontinue liraglutide after a 
treatment period of 8 weeks in patients showing less than 3 percent weight loss. This 
strategy would erroneously include four non-responders and exclude five responders not 
yet identified as such. At the 8-week time-point, three of these five responders showed 
more than 60 percent reduction in insulin dose. Consequently, a strategy based on a 
mixed criterion of either ≥3 percent weight loss or ≥60 percent decrease in insulin dose at 
8 weeks would be more cost-controlling, correctly identifying 21 of 23 responders, whilst 
4 non-responders would be treated ‘erroneously’ until week 26. Using such an 8-week trial 
period as a go/no-go decision point would correspond to a sensitivity of 91%, specificity 
of 83%, positive predictive value of 84% and negative predictive value of 91%. 
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Table 1   (Incremental) costs and outcomes per patient for a short-term treatment 
period of adding liraglutide versus continuation of standard insulin therapy 
8 weeks 12 weeks 16 weeks (26 weeks)
Insulin (€0.034 per Unit)
Liraglutide + insulin − 1147 ± 144U
− €39.00 ± 4.91
− 1862 ± 239U
− €63.32 ± 8.13
− 2535 ± 332U
− €86.21 ± 11.29
− 4604 ± 605U
− €156.54 ± 20.59
Standard (insulin) treatment 29 ± 29U
€0.98 ± 1.00
102 ± 57U
€3.46 ± 1.93
224 ± 98U
€7.63 ± 3.33
880 ± 316U
€29.93 ± 10.75
Liraglutide (€2.83 per mg)
Liraglutide + insulin 81.6 ± 2.0mg
€231.03 ± 5.78
127.0 ±3.7mg
€359.57 ± 10.52
170.6 ± 5.6mg
€483.06 ± 15.84
279.6 ± 10.7mg
€791.77 ± 30.42
Standard (insulin) treatment - - - -
Needles (€0.20 per needle)
Liraglutide + insulin 51 ± 2
€10.25 ± 0.43
73 ± 4
€14.66 ± 0.88
92 ± 7
€18.35 ± 1.36
131 ± 14
€26.27 ± 2.74
Standard (insulin) treatment - - - -
Test strips (€0.50 per strip)
Liraglutide + insulin 121 ± 1
€60.64 ± 0.61
150 ± 3
€74.94 ± 1.25
176 ± 4
€88.21 ± 1.94
239 ± 8
€119.53 ± 3.91
Standard (insulin) treatment 32 ± 0
€16 ± 0
48 ± 0
€24 ± 0
64 ± 0
€32 ± 0
104 ± 0
€52 ± 0
Total costs
Liraglutide + insulin €262.92 ± 8.00 €385.85 ± 13.07 €503.41 ± 18.66 €781.03 ± 34.13
Standard (insulin) treatment €16.98 ± 1.00 €27.46 ± 1.93 €39.63 ± 3.33 €81.93 ± 10.75
Difference €245.93 ± 7.00 €358.38 ± 11.14 €463.78 ± 15.33 €699.10 ± 23.38
Body weight change 
Liraglutide + insulin − 3.0 ± 0.4kg − 3.4 ± 0.5kg − 3.9 ± 0.5kg − 4.3 ± 0.6kg
Standard (insulin) treatment 0.2 ± 0.3kg 0.4 ± 0.3kg 0.6 ± 0.4kg 0.8 ± 0.5kg
Incremental costs  
(per 1 kg weight loss)
€76.85 €94.31 €103.06 €137.08
HbA1c change (%)
Liraglutide + insulin − 0.8 ± 0.1% NA − 0.9 ± 0.1% − 0.7 ± 0.1%
Standard (insulin) treatment 0.0 ± 0.1% NA − 0.1 ± 0.1% 0.0 ± 0.1%
Incremental costs  
(per 1% decrease in HbA1c)
€307.41 NA €579.73 €998.71
A change in HbA1c of 1% corresponds to 11 mmol/mol. NA, not available (HbA1c levels were measured every 
8 weeks)
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Treatment costs for the best cost-controlling treatment strategy
Application of ≥3% weight loss or ≥60% reduction in insulin dose at 8 weeks as early 
response criteria, with discontinuation of liraglutide in those not meeting one of these 
targets, would decrease additional treatments costs for the whole group of 47 patients 
from €32,858 to €22,888 for a period of 26 weeks, saving €9,970, or €453 per non-responding 
patient. As  costs for the 8-week trial period amount €246 per non-responder, total costs 
per effectively treated patient would decrease from €1429 to €1079 for the first 26 weeks 
with this strategy. After 26 weeks, the additional costs for liraglutide treatment are €957 for 
6 months, assuming that insulin dose will not change. 
Discussion
The present analysis of the ELEGANT trial shows that the addition of liraglutide to insulin 
treatment is associated with an additional cost of ~€700 for 26 weeks, or ~€140 per 1 kg 
weight loss, but that the total costs per effectively treated patient would decrease by €350 
for the first 26 weeks when liraglutide is discontinued after an 8-week trial period in 
patients not showing an early response. Early response, defined by either ≥3 percent 
weight loss or ≥60 percent decrease in insulin dose, had high positive and negative 
predictive values for treatment response after 26 weeks. The costs of this 8-week trial 
period are ~€250 for one patient. The analysis in this study may help in cost-controlling 
clinical decision making by selecting those patients who are most likely to benefit from 
addition of a GLP-1 receptor agonist to insulin therapy.
Reimbursement for treatment with GLP-1 receptor agonists is limited because it is 
considered expensive [7,13]. On the other hand, GLP-1 receptor agonist treatment may 
also yield indirect cost-savings: less hypoglycaemia, a decreased need for glucose 
monitoring, and cost-savings associated with improved glycaemic control, weight loss, 
simplification of diabetes treatment and potentially less cardiovascular complications 
[12,14]. The present analysis only calculated direct costs associated with a relatively short 
treatment period of adding liraglutide to insulin. A complete cost-benefit analysis is 
complex and contains many undetermined factors, including a possible increase in costs 
on the longer term due to additional life years gained. 
Earlier studies have assessed the cost-effectiveness of GLP-1 receptor agonists in general 
and of liraglutide in particular, but mainly in comparison with other glucose lowering 
therapies [15,16]. The evidence review group from NICE reported an estimated cost-effec-
tiveness of £15,130 per Quality Adjusted Life Year (QALY) for liraglutide 1.8 mg compared 
with insulin glargine [17]. The investigators conducted additional sensitivity analyses and 
concluded that the factors that carried most weight in the comparison with glargine, were 
Figure 2   Change in body weight (A), HbA1c (B) and insulin dose (C) for responders 
(white squares) versus non-responders (black circles) at various time-points 
Treatment response was determined on the basis of meeting at least two of the following treatment 
targets at 26 weeks: ≥4% weight loss, and/or HbA1c ≤7% (53 mmol/mol), and/or discontinuation of 
insulin therapy. Horizontal bars represent optimal cut-off points for identifying early treatment 
response; including as much responders as possible whilst little non-responders are included.
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the direct utility effects of body mass index (BMI) changes and systolic blood pressure, 
underlining the significance of body weight. One other study assessed the cost-effective-
ness of adding a GLP-1 receptor agonists to insulin and showed that the addition of 
lixisenatide to basal insulin treatment was associated with increased quality-adjusted life 
years (QALYs) and reduced lifetime healthcare costs as compared with the addition of 
bolus insulin [18]. These results support our previous reported findings of improved 
quality of life with liraglutide [11]. Because liraglutide is more effective in weight loss and 
lowering HbA1c than lixisenatide [19,20], its potential benefits are higher. Nevertheless, 
outcomes of cost-efficiency calculations are largely dependent on assumptions regarding 
long-term benefits [21]. While our treatment strategy yields less direct costs, our data can 
neither determine potential gain in QALY’s nor their costs.
In this study, we have used a number of rather arbitrary cut-off points. A 4% weight loss 
was chosen because this was the average weight gain in patients starting on insulin 
treatment [2]. In a recent study among patients with type 2 diabetes, a gain in body 
weight of ≥5% was associated with a 14% increase in medical costs, when glycaemic 
control was suboptimal (HbA1c ≥7% [53 mmol/mol]) [22]. Some may consider the clinical 
impact of 4% weight loss limited, but a minimal weight reduction of 3-5% in obese 
participants is already associated with a clinically relevant improvement in cardiometabol-
ic health [3,23,24]. Moreover, weight loss is considered very important by patients and is 
associated with higher treatment satisfaction, better treatment adherence and a healthier 
lifestyle [25-27]. 
In the present analysis we have used quite strict criteria in defining treatment success. 
Current guidelines advise to aim for less strict treatment targets, especially concerning 
HbA1c in elderly people [5]. NICE-guidelines define a beneficial response to GLP-1 receptor 
agonists as an HbA1c-reduction of at least 1% (11 mmol/mol) or a weight loss of at least 3% 
after 26 weeks of treatment [8]. Although one of the four ‘non-responders’ at 8 weeks in 
our trial stopped treatment because of adverse events, the three remaining subjects all 
had clinical responses at week 26 that many clinicians would view as clinically relevant. 
One 64-year old patient showed 6.5% weight loss with a stable HbA1c of 7.5%, another 
patient showed 2.2% weight loss in combination with 0.8% decrease in HbA1c and the 
third patient lost 3.9% of body weight and had an HbA1c decrease of 1.3%. Surely, less 
strict targets could be applied, but such would result in more people being eligible for 
treatment, thereby increasing overall treatment costs.
Our findings extend those of a previous study on the predictive value of short-term 
weight loss with a GLP-1 receptor agonist to a more generic good response in the longer 
term and an earlier decision time-point. Subgroup-analyses of the SCALE diabetes trial, in 
which overweight or obese patients with diabetes were treated with liraglutide 3.0 mg, 
showed that early (within 16 weeks) loss of >5% of initial body weight with liraglutide was 
a good predictor of clinically meaningful weight loss after one year of treatment [28,29]. In 
the present analysis, we show that the weight response after eight weeks of such 
treatment may suffice and not only predicts a good weight but also a good glycaemic 
effect (either reduction of HbA1c or cessation of insulin therapy). This time-point may aid 
the clinician in making treatment decisions with respect to continuation or discontinua-
tion of GLP-1 receptor agonists. As current guidelines, e.g. the NICE-guidelines, mostly 
advocate a trial period for GLP-1 receptor agonists of 26 weeks [8], our approach would 
lead to a substantial decrease in costs. 
The strength of the present analysis is that we were able to calculate additional treatment 
costs in a real-life situation, which might be helpful in clinical decision making. Our 
strategy to select patients with prominent treatment responses that are likely to translate 
into long-term clinical benefit was associated with ~€1100 per successfully treated patient 
for the first half year and ~€1900 for each treatment year thereafter. The present analysis 
also has limitations. Our model includes several assumptions that may affect outcomes. 
For example, the current assumption of needing four test strips per week probably 
underestimated actual use of strips, particularly in patients assigned to continuing 
standard insulin therapy on premixed or basal-bolus insulin regimens. None of these 
patients could simplify insulin treatment, which contrasts with three patients in the 
liraglutide group who simplified from basal-bolus to basal insulin alone. We also did not 
consider the drop in costs associated with the cessation of oral glucose-lowering agents 
in five patients on liraglutide versus none in the standard insulin group. Neither did we 
model the costs associated with adverse gastrointestinal events. Although these were 
mild to moderate and of relatively short duration, we cannot fully exclude loss of labor 
productivity and missing of work. These side effects should be balanced with the reduced 
risk of hypoglycaemia with GLP-1 receptor agonist treatment, which is also associated 
with substantial direct and indirect medical costs [30]. Only one severe adverse event 
(myocardial infarction) occurred, which was deemed unrelated to the study drug. We 
were not able to identify lifelong costs, which may change as cardiovascular outcome 
improves [12,14], and as the effects of liraglutide on body weight and decrease in HbA1c 
tend to diminish over time. Finally, the analysis was based on selected patients who may 
not necessarily be representative for the entire diabetes population.
In conclusion, an 8-week trial period of adding liraglutide to insulin in patients with 
pronounced insulin-associated weight gain is a good strategy to control costs, when 
patients not showing ≥3 percent weight loss or ≥60 percent decrease in insulin dose 
discontinue such treatment. With prolonged treatment, costs are likely to decrease further 
due to a decrease in long-term diabetes complications mediated by weight loss and 
better glycaemic control. 
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Abstract
Aim: The size of the placebo response in type 2 diabetes (T2DM) treatment and its relation 
to the route of drug-administration have not been systematically reviewed. We aimed to 
determine weight loss, change in HbA1c and incidence of adverse events after treatment 
with injectable placebo GLP-1 receptor agonist (GLP-1ra), compared with oral placebo 
DPP-4 inhibitor (DPP-4i) and placebo SGLT-2 inhibitor (SGLT-2i). 
Methods: PubMed, EMBASE, and Central were searched up to September 2014 for 
randomized placebo-controlled trials investigating GLP-1ra, DPP-4i or SGLT2-i. Data on placebo 
groups were extracted and pooled using a generic inverse variance random effects model. 
Results: Sixty-seven trials were included, involving 2522, 5290, and 2028 patients randomized 
to placebo GLP-1ra, placebo DPP-4i, and placebo SGLT-2i, respectively. Body weight 
decreased by -0.67 kg (95%CI -1.03, -0.31) after treatment with placebo GLP-1ra (-0.76 kg 
[-1.10, -0.43] with placebo short-acting GLP-1ra and -0.32 kg [-1.75, 1.10] with placebo 
long-acting GLP-1ra) and by -0.31 kg (-0.64, 0.01) with placebo DPP-4i (P=0.06 for difference 
with placebo short-acting GLP-1ra). Placebo SGLT-2i resulted in an intermediate -0.48kg 
(-0.81, -0.15) weight loss. Weight loss with placebo showed a strong correlation with the 
active comparator drug (r2 = 0.40-0.78). HbA1c changed little with placebo treatment 
(-0.23%, 0.10%, and -0.13% for placebo GLP-1ra, DPP-4i, and SGLT-2i). Adverse events 
occurred frequently with placebo, were often similar to the active comparator drug, and 
led to drop-out in 2.0-2.7% of cases.    
Conclusions: The response to placebo treatment was related to its active comparator, 
with injectable placebo GLP-1ra showing a relevant response on weight, whereas oral 
placebo DPP4i showed no significant response. These findings may suggest that subjective 
expectations influence T2DM treatment efficacy, which can possibly be employed thera-
peutically.
What is already known about this subject
• The magnitude of the placebo response depends on many factors, including patients’ 
expectations, and the route of drug administration. 
• Placebo responses are generally larger on subjective than objective endpoints.
• The placebo response has been studied in several conditions, especially pain syndromes, 
but was never systematically reviewed in type 2 diabetes treatment.
What this study adds
• Placebo injections, particularly in trials with short-acting GLP-1ra, show a significant response 
on weight and HbA1c as compared to oral DPP-4i, with oral SGLT-2i acting in between. 
• The placebo response is related to the efficacy of the active comparator.  
• Subjective expectations may influence type 2 diabetes treatment efficacy.
Introduction
Many medical treatments harbour a placebo effect, which can be both beneficial and 
undesirable [1]. Placebo effects are generally larger on subjective than objective endpoints 
[2-8], although a study in hypertensive patients showed that placebo treatment reduced 
blood pressure as compared with no treatment [9]. Placebo effects are, at least partly, 
based on expectations regarding the medication, which in turn are based on objective 
medical information from caregivers, but also on information received from other sources 
such as (social) media, experiences from other patients and anticipations from friends and 
relatives [4,5,10-12]. The placebo effect is modulated by the colour, size and shape of orally 
administered drugs and by the route of administration, with injections having a stronger 
effect than pills [6,11,13]. In migraine treatment, for example, sham acupuncture or sham 
surgery resulted in higher responder ratios than oral placebos [6]. Also price has an 
influence: expensive drugs work better than cheap ones [14,15]. The ‘true’ placebo effect 
must be distinguished from the placebo response, which represents the change within 
the placebo group from pretreatment to post-treatment. Placebo responses may be due 
to an effect of placebo, but also to other factors, such as the natural course of the disease 
or trial effects [3,6].
In the past decade, a number of new type 2 diabetes (T2DM) treatments have been 
introduced. The oral dipeptidyl peptidase-4 inhibitors (DPP-4i)  have no effect on weight 
[16], while the injectable glucagon-like peptide 1 receptor agonists (GLP-1ra) are associated 
with weight loss, but also with gastrointestinal side effects [17]. The new class of the oral 
sodium-glucose co-transporter 2 inhibitors (SGLT-2i) is also reported to decrease body 
weight [18]. Neither the size of the placebo response in T2DM treatments nor its relation 
with the route of drug-administration has ever been systematically reviewed. As appetite 
and satiety are relatively subjective endpoints, we reasoned that, by changing these 
subjective feelings, treatment with an injectable placebo GLP-1ra may show a significant 
response on weight and (consequently) on glycaemic control, but also on perceived side 
effects. This hypothesis was tested in a systematic review, in which we directly compared 
the placebo response of GLP-1ra and DPP-4i on weight, glycaemic control and adverse 
events, including hypoglycaemia. We included SGLT-2i as a class in this review and 
expected placebo SGLT-2i tablets to have an intermediate response.
Methods
This systematic review with meta-analyses is reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [19,20], 
and registered at PROSPERO (CRD42014014134).
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Data sources and searches
A literature search was conducted in PubMed, EMBASE and the Cochrane Central Register 
of Controlled Trials (Central), without restrictions to language or date of publication, 
at August 31 2014. Search terms were used for the substance names of GLP-1ra, DPP-4i and 
SGLT-2i, randomized controlled trial (RCT) using the sensitivity maximizing version of the 
Cochrane Handbook [21]; diabetes; and placebo or double-blind method (Methods S1).
Study selection 
Studies were considered eligible for inclusion if they were placebo-controlled RCTs, reporting 
data after 24 to 30 weeks of placebo treatment and conducted in adult T2DM patients. 
Eligible trial participants did not receive any background diabetes medication or were treated 
with metformin, and/or sulphonylurea, and/or thiazolidinediones. They were randomized 
between either a GLP-1ra (exenatide [twice daily or once weekly], liraglutide, lixisenatide, 
dulaglutide, albiglutide, semaglutide, taspoglutide), a DPP-4i (sitagliptin, vildagliptin, linagliptin, 
saxagliptin, alogliptin, linagliptin), a SGLT-2i (dapagliflozin, canagliflozin, empagliflozin, 
ertugliflozin) or matching placebo. We included only published trials, that reported either 
(changes in) HbA1c or weight as primary endpoints, as the primary aim of this meta-analysis 
was to evaluate the  placebo response on weight and HbA1c, the cornerstones of diabetes 
treatment efficacy.  
Exclusion criteria were observational and retrospective study design, no data available on 
24 to 30 weeks of follow-up, studies in which placebo was started together with anti - 
diabetic drugs or interventions, such as lifestyle measures (because this would interfere 
with the placebo response), double-dummy design (i.e. simultaneous administration of 
both active drug and placebo, or multiple placebos to participants), studies in which one 
placebo was linked to multiple active comparator drugs and studies conducted in 
participants receiving insulin or background diabetes medication other than metformin, 
sulphonylurea or thiazolidinediones, such as glinides, amylin agonists or acarbose, as these 
drugs have not been widely adopted in clinical practice.  
Two researchers (MtG and HdW) screened all titles and abstracts identified in the initial 
search, excluding studies that violated inclusion criteria. Following the initial abstract 
screen, full texts of all identified studies were acquired and screened in duplicate, with 
differences resolved by discussion with a third researcher (CT). 
Data Extraction and Quality Assessment
After trial inclusion, data were extracted and reviewed independently by two authors 
(HdW and MtG), according to a pre-defined spreadsheet. Information was extracted from 
each included study on characteristics of the trial and its participants, trial interventions 
(including dose, duration of intervention and percentage drop-out) and pre-specified 
outcome measures for the groups receiving placebo or its active comparator (mean ± SE 
change in body weight and HbA1c, number of patients reporting adverse events and 
hypoglycaemia). In case of multiple interventions within one study, only active comparator 
groups with a matching placebo group were included in the analysis, and different doses 
of the same active drug or placebo were combined into one group [21]. In case of 
incomplete data, the corresponding author and/or funding organization were e-mailed, 
with a maximum of two attempts. If more than one publication was available, outcome 
data from the original study were extracted.  
Methodological quality within included trials was evaluated by two independent 
reviewers (HdW and MtG) using the Cochrane Collaboration’s risk of bias tool [21]. Selection 
bias (random sequence generation and allocation concealment), performance bias 
(blinding of participants and investigators), detection bias (blinding of evaluators), attrition 
bias (incomplete outcome data) and reporting bias (selective outcome reporting) were 
judged to be of either low, unclear or high risk. 
Data synthesis and analysis
The primary endpoint was the change in body weight after treatment with placebo GLP-1ra 
and placebo DPP-4i for 24-30 weeks, and the difference between these two treatments. 
The response of placebo SGLT-2i on body weight was evaluated as an intermediate. Secondary 
endpoints were the change in HbA1c, the incidence of adverse events including hypogly -
caemia and the percentage of drop-outs due to adverse events from baseline to 24-30 weeks 
for placebo GLP-1ra and placebo DPP-4i, again with placebo SGLT-2i as an intermediate. 
To account for heterogeneity between trials, we calculated pooled estimates of mean 
differences in body weight and HbA1c with standard errors (SE) before and after placebo 
treatment using a generic inverse variance random effects model. When SEs were not 
reported, they were calculated from the SD and the sample size or 95% Confidence 
Interval (95%CI) [21]. For each trial, weight-change and change in HbA1c with placebo and 
its active comparator were displayed in a scatter plot. Adverse events and withdrawal 
rates were analyzed as dichotomous variables and risk differences between treatment 
with placebo and its active comparator were calculated using an inverse variance random 
effects model, because heterogeneity was moderate to high. 
Heterogeneity was characterized using the I2 statistic. Values of 50-75% and >75% were 
considered indicative of substantial and considerable heterogeneity, respectively [21]. 
Potential causes of heterogeneity were explored by looking at outliers and by performing 
sensitivity analyses, excluding reports with high overall risk of bias. For each trial, publication 
bias was assessed for the outcomes change in weight and HbA1c with placebo by 
constructing a funnel plot and with Egger’s test [22]. 
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Subgroup analyses were pre-specified based on different background medication, 
baseline weight, age, and ethnicity of the trial population and baseline HbA1c. Based on 
clinical reasoning, we planned to make a distinction between the placebo response of 
short-acting (once or twice daily: exenatide, liraglutide, lixisenatide) and long-acting (once 
weekly: exenatide QW, dulaglutide, albiglutide, taspoglutide, semaglutide) GLP-1ra using 
sensitivity analyses. All analyses were performed using RevMan 5.3 (Nordic Cochrane 
Centre, Copenhagen, Denmark) and scatterplots were created using Graphpad Prism 5.03 
(Graphpad Software Inc., San Diego, CA).
Results
In total, 2187 publications were identified through searching PubMed, EMBASE and the 
Cochrane Library (Figure 1). After excluding duplicates and screening references on the 
basis of title and abstract, 123 relevant references were identified and examined in full 
text. Sixty-seven of these publications fulfilled the inclusion criteria and were included in 
the analysis [23-89]. 
Characteristics of included studies
Of the 67 included RCTs, 18 investigated the efficacy of GLP-1ra (six examined exenatide 
[23-28], three liraglutide [29-31], five lixisenatide [32-36], one dulaglutide [37] and three 
taspoglutide [38-40]), 34 examined DPP-4i (eight sitagliptin [41-48], 10 vildagliptin [49-58], 
seven saxagliptin [59-65], four alogliptin [66-68], five linagliptin [70-74]) and 15 researched 
SGLT-2i (eight dapagliflozin [75-82], four canagliflozin [83-86], three empagliflozin [87-89]). 
All included trials were published in English. The included studies involved 29 685 
participants, with a mean number of 443 participants (range 165-1058). A total of 9840 
patients were randomized to placebo treatment in the included trials, 2522 in trials 
concerning GLP-1ra, 5290 in trials with DPP-4i and 2028 for SGLT-2i. Except for some 
[39,40,63,86], most RCTs did not provide details on the appearance and administration of 
placebo. The study duration was mostly 24 weeks, one study was 52 weeks but reported 
results on 26 weeks [37]. All trials were multicentre, most were multinational and 11 studies 
were conducted exclusively in Asian countries [28,31,35,47,55,58,62,63,81,82,86]. All trials 
reported HbA1c as a primary endpoint, except for one trial addressing the effect of the 
SGLT-2i dapagliflozin on weight [78]. In most studies, patients used (a combination of) 
metformin, sulphonylurea and thiazolidinediones as background therapy. Eighteen studies 
were conducted in ‘drug-naïve’ patients, but often after a wash-out of oral antidiabetic 
agents [26,28,38,41,46,49,52,60,63,64,66,71,75,79,81-83,86]. Patients had a mean baseline 
weight ranging from 65.8 to 102.5 kg, mean BMI from 24.9 to 36.7 kg m-2 and mean HbA1c 
from 7.2 to 9.2% (55-77 mmol mol-1). Mean weight and BMI were generally lower in trials 
conducted in Asian countries. Details on study characteristics, interventions and baseline 
characteristics of trial populations are represented in Table S1. 
Risk of bias assessment is displayed in Table S2. Half of all trials poorly reported allocation 
sequence generation and concealment, which was therefore considered unclear. None of 
the included trials described the success of blinding. Outcome data for HbA1c and weight 
were generally adequately reported, using a (modified) intention-to-treat analysis. None 
of the RCTs were unblinded prematurely, but in some studies attrition rates were high or 
disparate. There was no evidence of publication bias for the outcomes weight and HbA1c 
from the interpretation of the funnel plot (Figure S1) or Eggers test (P=0.56 and P=0.55, 
respectively).
Figure 1   Flow diagram of the study selection process 
OAD; oral antidiabetic agent, TZD; thiazolidinedione, SU; sulfonylurea, RCT; Randomized Controlled Trial.
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Placebo responses on weight
Data on body weight were reported in all included RCTs concerning GLP-1ra and SGLT-2i. 
Ten studies investigating DPP-4i did not provide sufficient data on weight change neither 
in the published article nor after seeking contact with the authors and/or funding 
organization [42,45,55-61,63], leaving 24 studies concerning DPP-4i for inclusion in the 
pooled analysis. One included RCT provided additional data that were not described in 
the published report [71].  Pooled effect estimates of weight change are represented in 
Figures 2A and 3A.
After treatment with placebo GLP-1ra body weight was significantly reduced by 0.67 kg 
(95%CI -1.03, -0.31; I2=87%). For placebo short-acting GLP-1ra, the pooled effect estimate of 
weight change was even -0.76 kg (95%CI -1.10, -0.43; I2=81%), for placebo long-acting GLP-1ra, 
this was -0.32 kg (95%CI -1.75,1.10; I2=95%). Placebo DPP-4i treatment did not show a 
significant response on weight (-0.31kg; 95%CI -0.64, 0.01; I2=91%). Exclusion of one trial 
conducted in elderly patients [46] in a subgroup analysis based on age of the trial population 
considerably affected the results and further reduced the weight response of placebo 
DPP-4i to -0.26 kg (95%CI -0.59, 0.07; I2=91%). As a result, there was a borderline significant 
difference between weight change after treatment with placebo short-acting GLP-1ra and 
placebo DPP-4i (P=0.06; P=0.04 after exclusion of the outlier study). With placebo SGLT-2i 
treatment body weight also decreased by -0.48 kg (95%CI -0.8, -0.15; I2=86%), but the effect 
size was less than with placebo GLP-1ra. Subgroup analyses showed more weight loss in 
trials conducted in drug-naïve patients or patients using only metformin (the use of thiazo-
lidinediones was associated with weight gain in all groups) and in Asian patients (Figure S2). 
BMI and baseline HbA1c did not affect weight change. Weight loss with placebo was related 
to weight loss with its active comparator drug for all placebo classes, GLP-1ra, SGLT-2i and 
DPP-4i (r2 0.40, 0.61 and 0.78, respectively, Figure 4A). In linear regression analyses, baseline 
body weight was not related to weight loss with the active drug, except for GLP-1ra treatment 
(Table S3). Sensitivity analyses showed that the results were quite robust (Figure S4).
Placebo responses on glycaemic control
All included trials reported change in HbA1c and were therefore included in the pooled 
analysis. Pooled effect estimates of change in HbA1c are represented in Figures 2B and 3B. 
After treatment with the placebo of GLP-1ra a small but significant HbA1c-reduction of 
-0.23% (2.5 mmol mol-1) (95%CI -0.34, -0.12%; I2=86%) was observed, which was similar for 
placebo short-acting GLP-1ra (-0.22% [2.4 mmol mol-1], 95%CI -0.35, -0.08; I2=87%) and 
placebo long-acting GLP-1 ra (-0.26% [2.8 mmol mol-1], 95%CI -0.47, -0.06; I2=87%). 
Placebo DPP-4i barely showed a response on glycaemic control of -0.09% (1.0 mmol mol-1) 
(95%CI -0.17, -0.01; I2=89%; P=0.05 for difference with placebo GLP-1ra). After treatment 
with placebo SGLT-2i, HbA1c was reduced by an intermediate -0.13% (1.4 mmol mol-1) 
(95%CI -0.21, -0.04; I2=83%). Subgroup analyses showed no effect of BMI, baseline HbA1c 
or age of the trial population (Figure S3). Asian patients and patients using thiazo-
lidinediones showed more improvement in glycaemic control, whereas in drug-naïve 
patients changes in HbA1c were almost negligible. The change in HbA1c with placebo 
was related to HbA1c change with its active comparator, although less so than change in 
body weight (r2=0.42, 0.50 and 0.07 for GLP-1ra, DPP-4i and SGLT-2i, respectively; Figure 4B). 
In linear regression analyses, baseline HbA1c was related to HbA1c change with the active 
drug, except for GLP-1ra treatment (Table S3).  Sensitivity analyses showed that the results 
were robust (Figure S4).
Figure 2   Pooled-effects summary of mean ± SEM change in body weight (A)  
and HbA1c (B) with placebo 
GLP-1ra, GLP-1 receptor agonist; DPP-4i, DPP-4 inhibitor; SGLT2-i, SGLT-2 inhibitor.
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Placebo responses on adverse events and hypoglycaemia
All included RCTs provided information on adverse events, but one publication could 
not be included in most analyses because it did not report the incidence of adverse 
events after 24-30 weeks of placebo treatment [64]. The reported proportion of patients 
experiencing adverse events ranged from 19-75% with placebo GLP-1ra, 18-72% with 
placebo DPP-4i and 40-73% with placebo SGLT-2i. The most commonly reported adverse 
events for all treatments and withdrawal rates are represented in Table 1. 
Placebo treatment was associated with comparable discontinuation rates as its active 
comparator drug (risk difference 0%, I2=76% for GLP-1ra; 3%, I2=52% for DPP-4i and 3%, 
I2=24% for SGLT-2i). Gastro-intestinal adverse events occurred far more often with placebo 
GLP-1ra than with placebo DPP-4i or placebo SGLT-2i, but incidence rates with placebo 
GLP-1ra were still lower than with active GLP-1ra (Table 1). The incidence of non-specific 
adverse events, such as headache, did generally not differ between groups. Strikingly, 
in trials concerning SGLT-2i, urinary tract infections also frequently occurred with placebo 
treatment, but this did not apply for genital infections. Hypoglycaemia was reported in 
65 trials, the incidence of which was generally lower in patients taking placebo, as 
compared with active treatment. In subgroup analyses, higher hypoglycaemia rates after 
placebo treatment were seen in trials with patients using sulphonylurea as background 
medication (Figure S5). Overall, cases of severe hypoglycaemia were rare. Only 4 trials 
regarding DPP-4i reported severe hypoglycaemia with placebo, all in patients taking 
concomitant sulphonylurea or thiazolidinedione [48,53,67,72].
Figure 4   Scatterplot representing the relationship between the response to placebo 
and its active comparator drug on body weight (A) and HbA1c (B)
GLP-1ra, GLP-1 receptor agonist; DPP-4i, DPP-4 inhibitor; SGLT2-i, SGLT-2 inhibitor.
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Discussion 
This meta-analysis shows that particularly short-acting GLP-1ra treatment is associated 
with a relevant placebo response regarding weight, as reflected by the weight difference 
in placebo groups of RCTs concerning this drug class. Weight loss with placebo DPP-4i 
was significantly less than with placebo GLP-1ra, whereas placebo SGLT-2i showed an 
intermediate response. For HbA1c this trend was similar, with a modest response of 
placebo on HbA1c but significant between-class differences. The placebo response was 
related to the efficacy of the active comparator drug. Adverse events and withdrawals 
occurred frequently in the placebo groups, mostly with GLP-1ra, and, interestingly, were 
often specific for the active comparator. Hypoglycaemia, however, was not related to the 
use of placebo. These findings suggest that effects of T2DM treatments on body weight, 
(indirectly on) glycaemic control, and on side effects may be partly dependent on 
subjective expectations and may also depend on the route of drug administration. 
Previous research has described placebo effects and responses in other conditions, such as 
pain syndromes including diabetic neuropathy, irritable bowel syndrome, and depression 
[4-6]. In these conditions with rather subjective endpoints, the placebo effect is substantial, 
dependent upon the way of drug-administration, and on the attitude of the caregiver [5,11]. 
We choose weight, and indirectly HbA1c as a focus of research, as appetite and satiety are also 
relatively subjective endpoints. For objective endpoints, contradictory results have been 
obtained, with some describing placebo as being powerless [1], whilst others showed 
significant placebo effects, for example in the treatment of hypertension [9], asthma [90,91], 
and glaucoma [92]. As suggestions made by caregivers, and patients’ expectations are very 
important for treatment outcome [5,11,12], suggestion towards treatment effects might 
explain the clear relationship between the response to placebo and its active comparator, a 
connection that has been described previously [8]. For weight, this relationship was strong, 
whereas for HbA1c the correlation was weaker and could possibly be partly explained by 
regression towards the mean, as baseline HbA1c scores were related to HbA1c change. 
Furthermore, the route of administration may be important, as patients may attribute larger 
effects to a placebo injection than to a tablet. Although it has not been investigated before, 
one may hypothesize that a more frequent placebo administration leads to stronger effects, 
explaining the greater response to placebo short-acting GLP-1ra. However, a more likely 
explanation for this observation is the small number of studies investigating long-acting 
GLP-1ra that could be included in the pooled analysis, leading to a high heterogeneity. All 
these hypotheses  must be viewed in the context of systematic differences in trial design and 
patient information regarding treatment effects and adverse effects that likely exist between 
RCTs investigating the three different placebos. While literature suggests that expensive 
treatments include a stronger placebo effect [14,15], it remains speculative whether the high 
price of GLP-1ra adds to the placebo response described in the present study.
Table 1  Adverse events in placebo-controlled RCTs
Adverse event Number 
of studies 
contributing 
data
Placebo
 (%)
Active 
comparator  
(%)
Risk Difference 
(95% CI)
GLP-1 receptor agonists
Withdrawal 18/18 15.5% 13.8% 0% (-3, 4)
Withdrawal due to AE’sa 18/18 2.7% 6.8% -4% (-5, -3)
  Nausea 17/18 8.3% 28.5% -20% (-24, -16)
  Diarrhoea 18/18 6.2% 9.7% -3% (-5, -2)
  Vomiting 17/18 2.5% 11.8% -9% (-12, -7)
  Headache 12/18 4.5% 6.9% -2% (-4, -1)
  Nasopharyngitis 7/18 7.8% 8.6% -1% (-3, 1)
Hypoglycaemia (any) 18/18 6.7% 14.0% -6% (-8, -4)
Hypoglycaemia (severe)b 18/18 0.0% 0.1% 0% (-0, 0)
DPP-4 inhibitors
Withdrawal 34/34 17.6% 14.8% 3% (2, 5)
Withdrawal due to AE’sa 33/34 2.0% 2.7% 0% (-1, 0)
  Nausea 14/34 1.8% 1.8% 0% (-1, 0)
  Vomiting 9/34 1.0% 0.9% 0% (-1, 1)
  Diarrhoea 22/34 3.3% 3.3% 0% (-1, 1)
  Nasopharyngitis 27/34 4.7% 5.4% 0% (-1, 1)
  Headache 22/34 3.7% 4.5% -1% (-1, 0)
Hypoglycaemia (any) 32/34 2.6% 4.5% 0% (-1, 0)
Hypoglycaemia (severe)b 28/34 0.1% 0.1% 0% (-0, 0)
SGLT-2 inhibitors
Withdrawal 15/15 13.4% 9.8% 3% (1, 5)
Withdrawal due to AE’sa 15/15 2.5% 2.7% -1% (-1, 0)
  Nasopharyngitis 12/15 5.3% 5.9% -1% (-2, 1)
  Urinary tract infectionc 15/15 6.0% 6.2% 0% (-2, 1)
  Genital infection‡ 13/15 1.6% 5.5% -4 (-5, -3)
  Headache 7/15 4.1% 3.7% 0% (-1, 1)
  Diarrhoea 8/15 3.4% 3.3% 0% (-1, 1)
Hypoglycaemia (any) 15/15 3.0% 4.3% -1% (-1, 0)
Hypoglycaemia (severe)b 12/15 0.0% 0.0% 0% (-0, 0)
For all treatments, the 5 most frequently reported adverse events are displayed. Rates indicate the number of 
patients reporting adverse events related to the total number of patients treated with the allocated treatment. 
aDiscontinuation rates include discontinuation due to changes in laboratory values. bMajor hypoglycaemic 
episodes require third-party assistance. cIncludes signs and symptoms of infection, without a definite diagnosis. 
AE, adverse event.
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It is unknown to which extent the ‘true’ placebo effect contributes to the placebo response 
as derived from RCTs. The ‘true’ placebo effect may be underestimated, because trial 
participants know that they have a 50% chance of being allocated to placebo. Specific 
adverse events (such as gastro-intestinal side effects in GLP-1ra treatment) could result in 
partial unblinding as patients and their caregivers might more easily suspect the allocated 
treatment. Unfortunately, none of the included RCTs reported the adequacy of blinding. 
Also, most trials did not provide details on the used placebo, making it unclear if the 
placebo was really identical to the active drug. Previous studies in which all patients 
received placebo showed even stronger effects [5], but conducting a trial in which the 
participant is not aware of the fact that he/she might receive a placebo harbours important 
ethical issues [3]. All these factors may ‘dilute’ the placebo effect, but responses observed 
in placebo groups of RCTs may also overestimate ‘real’ placebo effects. Placebo responses 
can result from the natural course of the disease or statistical effects, such as regression to 
the mean [3]. Another part of the placebo response is factors that are trial-specific, like 
background diabetes medication or lifestyle factors or the effect of trial-participation 
itself, the Hawthorne effect[6]. Although it is impossible to distinguish all these different 
effects, recent clinical research into placebo effects has provided compelling evidence 
that placebo effects are genuine and robust biopsychological phenomena that have 
therapeutic potential [93]. Accordingly, the observed trend that the response to different 
placebo T2DM treatments is related to its active treatment, which is consistent in subgroup 
analyses according to different background medication or BMI, is very clear and may have 
clinical implications. The realization that part of the weight-reducing response of new 
diabetes drug classes, particularly GLP-1ra (in which more than 40% of weight loss may be 
explained by placebo), may consist of a placebo effect does not reduce in anyway their 
therapeutic potential, as the overall effect determines treatment result and satisfaction for 
a patient and his caregiver. In fact, this may be exploited therapeutically as even simple 
explanation of expected effects in itself adds to the therapeutic efficacy. In other words, in 
real life, the placebo effect is included in the ‘total’ therapeutic effect of a pharmacological 
intervention. It also suggests that part of the ‘total’ therapy effect is lost by the placebo-arm 
of RCTs, and elimination of potential placebo effects in placebo-controlled RCTs could be 
considered less useful than trials comparing new interventions against current treatment 
strategies [94]. 
Our study has several strengths and some potential limitations. The fact that we only 
included published trials could be considered a limitation, but inclusion of unpublished 
trials may have enforced our conclusions, as they are more likely to have a smaller active 
treatment effect and possibly a stronger placebo effect [95], although funnel plot analyses 
did not show evidence for publication bias. We only included recently introduced T2DM 
treatments, as they are associated with weight loss and specific adverse events. Only trials 
with a duration of placebo administration of 24-30 weeks were included, which precludes 
any conclusions regarding the durability of the placebo response. In trials with an 
extension or long-term follow-up, however, the placebo response for both weight and 
HbA1c tended to decrease, along with the efficacy of the active drug [96-101]. We 
combined different doses into one active treatment arm, including possibly subclinical 
doses, which might have led to underestimation of treatment effects with active 
treatment. Furthermore, patients who received rescue medication were included in the 
intention-to-treat analysis for most trials, and may affect results, but again will lead to an 
underestimation of the placebo response. The main strengths of this systematic review 
are that we included the highest available evidence and were able to perform 
meta-analyses. Considerable heterogeneity across studies was present, but sensitivity 
analyses resulted in robust results. Furthermore, since the included trials consisted of a 
heterogeneous trial population, we think that our results are applicable to the overall 
T2DM population. 
Conclusion 
In conclusion, this meta-analysis of trials of new diabetes treatments identifies a relevant 
placebo response of GLP-1ra, particularly on weight and adverse effects, whereas oral 
placebo DPP4i showed no significant response, and SGLT-2i an intermediate response. 
This may suggest that subjective expectations influence T2DM treatment efficacy, which 
can possibly be employed therapeutically.
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PubMed search strategy 
1. Exenatide[nm] 
2. Exenatide*[tw] 
3. Liraglutide[nm] 
4. Liraglutide*[tw] 
5. Lixisenatide[nm] 
6. Lixisenatide*[tw]
7. Dulaglutide[nm] 
8. Dulaglutide*[tw]
9. Albiglutide[nm] 
10. Albiglutide*[tw] 
11. Taspoglutide[nm]
12. Taspoglutide*[tw]
13. Semaglutide*[tw]
14. Sitagliptin[nm] 
15. Sitagliptin*[tw] 
16. Vildagliptin[nm] 
17. Vildagliptin*[tw] 
18. Saxagliptin[nm] 
19. Saxagliptin*[tw] 
20. Alogliptin[nm] 
21. Alogliptin*[tw] 
22. Linagliptin[nm]
23. Linagliptin*[tw] 
24. Dutogliptin[nm] 
25. Dutogliptin*[tw]  
26. Dapagliflozin[nm] 
27. Dapagliflozin*[tw] 
28. Canagliflozin[nm] 
29. Canagliflozin*[tw] 
30. Empagliflozin[nm] 
31. Empagliflozin*[tw] 
32. Ertugliflozin*[tw] 
33. OR #1-32
34. randomized controlled trial[pt] 
35. controlled clinical trial[pt]
36. randomized[tiab] 
37. placebo[tiab] 
38. drug therapy[sh] 
39. randomly[tiab] 
40. trial[tiab] 
41. groups[tiab]
42. OR #34-41
43. animals[mh] NOT humans[mh]
44. #42 NOT #43
45. diabet*[tw] 
46. Diabetes Mellitus[mh]
47. #45 OR #46
48. Placebo*[tw]
49. Double-Blind Method [mh]
50. #48 OR #49
51. #33 AND #44 AND #47 AND #5
Methods S1   Search-term strategy
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EMBASE search strategy
1.  Exenatide.mp. or Exenatide*.ti,ab. or Liraglutide.mp. or Liraglutide*.ti,ab. or 
Lixisenatide.mp. or Lixisenatide*.ti,ab. or Dulaglutide.mp. or Dulaglutide*.ti,ab. or 
Albiglutide.mp. or Albiglutide*.ti,ab. or Taspoglutide.mp. or Taspoglutide*.ti,ab. or 
Semaglutide.mp. or Semaglutide*.ti,ab. or Sitagliptin.mp. or Sitagliptin*.ti,ab. or 
Vildagliptin.mp. or Vildagliptin*.ti,ab. or Saxagliptin.mp. or Saxagliptin*.ti,ab. or 
Alogliptin.mp. or Alogliptin*.ti,ab. or Linagliptin.mp. or Linagliptin*.ti,ab. or 
Dutogliptin.mp. or Dutogliptin*.ti,ab. or Dapagliflozin.mp. or Dapagliflozin*.ti,ab. or 
Canagliflozin.mp. or Canagliflozin*.ti,ab. or Empagliflozin.mp. or Empagliflozin*.ti,ab. 
or Ertugliflizon.mp. or Ertugliflozin*.ti,ab.
2. (random* or double-blind*).tw
3. Placebo.mp.
4. 2 or 3 [Wong 2006, best optimization of sensitivity and specificity for RCTs] 
5. Diabetes mellitus.sh.
6. Diabet*.tw.
7. 5 or 6
8. Placebo*.tw. 
9. Double-blind.mp
10. 8 or 9
11. 1 and 4 and 7 and 10
12. limit 11 to conference abstract
13. 11 not 12
Figure S1   Funnel plot for the change in body weight (A) and HbA1c (B) with placebo
A
B
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Insulin administered by needle-free jet 
injection corrects marked hyperglycaemia 
faster in overweight or obese patients  
with diabetes  
6
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Abstract
Aim: To test whether jet injection of insulin resulted in faster correction of marked hyper- 
glycaemia than when insulin is injected by a conventional pen in patients with diabetes. 
Methods: Adult, overweight or obese (BMI ≥25 and ≤40kg/m2) patients with type 1 
diabetes (n=10) or insulin-treated type 2 diabetes (n=10) were enrolled in a randomized, 
controlled, cross-over study. On two separate occasions, patients were instructed to 
reduce insulin dose(s) to achieve marked hyperglycaemia (18-23mmol/l). Subsequently, 
insulin aspart was administered either by jet injection or by conventional pen, in a dose 
based on estimated individual insulin sensitivity. Pharmacodynamic and pharmacokinetic 
profiles were derived from plasma glucose and insulin levels, measured for 6 hours after 
injection.
Results: After conventional injection, plasma glucose concentration dropped by ≥10mmol/l 
after 192.5 ± 13.6 minutes. The jet injector advanced this time to 147.9 ± 14.4 minutes 
(difference 44.6 [95% confidence interval 4.3, 84.8]; P=0.03), except in 3 patients who failed 
to reach this endpoint. The time advantage exceeded 1.5 hours in patients with a BMI 
above the median. Jet injection also reduced the hyperglycaemic burden during the first 
two hours (2042 ± 37.2 vs 2168 ± 26.1 mmol·min·l-1;P=0.01) and the time to peak insulin 
levels (40.5 ± 3.2 vs 76.8 ± 7.7 minutes, P<0.001), but did not increase the risk for 
hypoglycaemia. 
Conclusions: Administration of rapid-acting insulin by jet injection results in faster correction 
of marked hyperglycaemia in overweight or obese patients with insulin-requiring diabetes. 
Introduction
Hyperglycaemia frequently occurs in patients with diabetes and significantly affects 
overall glycaemic control, even when elevated glucose levels exist only for a short period 
of time [1]. When considerable, hyperglycaemia may cause symptoms, e.g. thirst, dizziness 
or headache, and predispose to severe metabolic disturbances when not corrected 
quickly. The correction of marked hyperglycaemia is often difficult, because glucose 
toxicity resulting from hyperglycaemia may induce insulin resistance, leading to a higher 
insulin dose requirement. Moreover, high insulin doses are probably more slowly absorbed 
than smaller doses [2], which may prolong the time spent in hyperglycaemia and tempt 
the individual to repeat the insulin injection, resulting in an increased risk of late hypo-
glycaemia.  
Insulin administration by jet injection is a needle-free alternative to conventional injections, 
which delivers insulin at high velocity (typically >100m/s) across the skin, dispensing it 
over a larger subcutaneous area than insulin injected with a needle [3]. This method of 
insulin administration, first developed in the 1950s [4], significantly accelerates insulin 
absorption from the subcutaneous tissue into the systemic circulation, resulting in a more 
direct onset and shorter duration of insulin action as compared with insulin injected with 
a needle [3-10]. We recently compared the efficacy of a contemporary jet injector (Insujet™; 
European Pharma Group, Schiphol-Rijk, The Netherlands) with that of a frequently used 
conventional insulin pen for the administration of a rapid-acting insulin analogue. Both in 
healthy participants without diabetes and in patients with type 1 or insulin-treated type 2 
diabetes, the jet injector considerably advanced insulin absorption and its subsequent 
glucose-lowering effect [11,12]. Furthermore, jet injection reduced the hyperglycaemic 
burden after a standardized meal [12]. 
The shorter time-action profile of insulin administered by jet injection may be especially 
advantageous for the correction of marked, potentially hazardous, hyperglycaemia. We 
therefore hypothesized that insulin administered by jet injection would result in more 
immediate and faster correction of marked hyperglycaemia than insulin administered by 
a conventional insulin pen. Because the rate of absorption of insulin injected by jet stream 
is much less affected by higher insulin doses and body weight than insulin injected 
conventionally [12,13], the aim of the present study was to test this hypothesis in patients 
with type 1 diabetes or insulin-treated type 2 diabetes who were either overweight or 
obese. We also aimed to compare the pharmacokinetics, safety, and ease of use of both 
modes of insulin administration. 
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Materials and methods
This randomized, controlled, crossover study was conducted at the Radboud university 
medical center between March and October 2014. The study was approved by the 
institutional review board of the Radboud university medical center and conducted 
according to Good Clinical Practice. All participants provided written informed consent 
and received a reimbursement. The trial was registered at ClinicalTrials.gov under the 
number: NCT01947556.
Participants
Potentially eligible subjects with type 1 or type 2 diabetes were selected from the 
Radboud university medical center outpatient diabetes clinic or recruited by social media. 
They were men or women aged 18-75 years, with a body-mass index (BMI) of ≥25 and 
≤40 kg/m2 and glycated haemoglobin concentration (HbA1c) of ≥6.5 and ≤10% (≥48 and 
≤86 mmol/mol), who were treated with basal-bolus insulin for at least 12 months, either 
by multiple daily injections with basal and prandial insulin or by subcutaneous insulin 
pump. Exclusion criteria were insulin requirement of <34 or >200 units per day (based on 
the minimum and maximum amount of insulin that could be injected by jet injection), use 
of oral antidiabetic agents or drugs known to interfere with glucose control other than 
metformin (a 4-week wash-out of thiazolidinediones, sulphonylurea, and dipeptidyl 
peptidase-4 inhibitors was allowed), known allergy to aspart insulin, symptomatic diabetic 
neuropathy, history of a major cardiovascular event in the previous 6 months, liver 
enzymes ≥3.0 times the upper limit of normal, plasma creatinine >150 μmol/l, anaemia 
(haemoglobin <7.5 or <8.3 mmol/l for females and males, respectively) and pregnancy.
Randomization and study procedures
The participants who were enrolled underwent two separate test days. Experiments 
started at 07:30 hours, with the patient in fasting condition, and having abstained from 
smoking, alcohol use, and caffeine-containing substances for 24 hours before the 
experiments. On the day before the experiments, patients were instructed to interrupt or 
reduce the use of long-acting insulin and short-acting prandial insulin in order to reach 
hyperglycaemia, targeting next-morning plasma glucose values of 15-18 mmol/l. Patients 
with insulin pumps were instructed to reduce the basal rate the evening and night before 
the experiment, and to stop the pump 2 hours before the experiment. Reductions in 
insulin dose were determined on an individual basis, and instructions were given to inject 
short-acting insulin according to an individualized schedule if glucose levels exceeded 
18-20 mmol/l up to 2 hours before arrival at the research unit. 
The experiments were performed with the patient in a supine position in a temperature- 
controlled room (22–24°C). First, a catheter was inserted in retrograde fashion in a dorsal 
hand vein for frequent blood sampling, whereby the hand was placed inside a heated box 
(~55°C) to arterialize venous blood [14]. Next, plasma glucose was measured to determine 
whether the glucose level was in the target range of 18-23 mmol/l. In case the glucose 
value was too low, we either (i) awaited the spontaneous rise in plasma glucose for a 
maximum of 3 hours; (ii) administered soda drink and subsequently waited for a minimum 
of 45 minutes until glucose levels had stabilized in the target range; or (iii) postponed the 
experiment if we expected that the glucose target was unattainable within 3 hours. 
After a stable plasma glucose level in the target range was obtained (as determined by 2-3 
glucose values measured within a 15 minute interval with a <2 mmol/l difference), the 
required insulin dose was calculated as the number of units required to reduce the plasma 
glucose value to 6 mmol/l, using the following formula:
 
Insulin dose = ([glucose - 6] ÷ [insulin sensitivity factor]) x 1.5, 
where glucose is the measured glucose value in mmol/l. The insulin sensitivity factor 
reflects the expected fall in plasma glucose after administration of 1 unit of insulin, and is 
calculated by dividing 100 by the total daily insulin dose [15]. We used a multiplicity factor 
of 1.5 to ensure that sufficient insulin was administered to overcome hyperglycaemia-in-
duced glucose toxicity and rounded the outcome up to the nearest round number or to 
a maximum of 40 units, as this was the maximum single dose the jet injector could inject. 
The calculated dose of aspart (Novorapid, Novo Nordisk, Bagsvaerd, Denmark) was 
administered subcutaneously in the abdomen either by jet injection (Insujet) or by 
conventional insulin pen (Flexpen®; Novo Nordisk). The InsujetTM jet injector delivers 
insulin across the skin with a short ‘click’ of 50-60 dB. The sequence by which the two 
devices were tested was randomized (1:1) by blocks of two according to diabetes type, 
using a computer-generated random number list. All participants were trained to use 
both devices. When possible (with the dominant hand free from cannulation), the 
injection was given by the participant under supervision of the research staff, as previously 
described [11]. 
After insulin administration, plasma glucose was measured on site using the glucose 
 enzymatic-amperometric method (Biosen C-line GP+; EKF-diagnostic GmbH, Barleben, 
Germany), at 5-minute intervals for the first 3 hours, and at 10-minute intervals for the 
subsequent 3 hours. Also, blood was drawn, processed, and serum was stored at -80°C 
for later determination of plasma insulin levels by radioimmunoassay every 10 minutes 
during the first hour, every 15 minutes during the second hour, and every 30 minutes 
thereafter [16]. 
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When glucose values dropped below 4.8 mmol/l, glucose 20% was infused intravenously 
through another catheter that was placed as needed, to prevent hypoglycaemia. Within 
30 minutes after insulin injection, a questionnaire was administered, asking participants 
to point out on a numeric rating scale from 0 to 10, the amount of discomfort or pain 
and the ease of use experienced with the tested administration method, and the device 
they would prefer for insulin injection should they have a choice. The experiments were 
terminated 6 hours after the insulin injection, and the patients were given a meal. The 
second experimental day was scheduled 2–4weeks later, following the same procedure 
and testing the other device.
Outcome measures
The primary endpoint was the time needed to achieve a drop in plasma glucose 
concentration of ≥10 mmol/l (T-BG≥10). Secondary pharmacodynamic endpoints included 
the time in minutes until plasma glucose values had dropped below 10 mmol/l (T-BG10) 
and 5 mmol/l (T-BG5); the slope of the glucose fall (Rfall), calculated from the time-glucose 
curve; and the hyperglycaemic burden for the first 2 hours (BG-AUC0-2h) and total 6 hours 
(BG-AUC0-6h) post-injection, reflected by the areas under the 2- and 6-hour time-glucose 
curves, respectively. Secondary pharmacokinetic endpoints were the time to maximal 
insulin concentration (T-INSmax); maximal insulin concentration (C-INSmax); the area under 
the baseline-corrected insulin-concentration curve (INSAUC), reflecting total insulin 
absorption; and the time until 50% of insulin absorption (T-INSAUC50%). Tolerability was 
tested by the amount of discomfort or pain and the ease of use experienced with the 
two administration methods using a numeric rating scale, and the proportion of subjects 
preferring the jet injector for insulin administration. Safety was tested by the number of 
patients requiring exogenous glucose infusion to prevent hypoglycaemia (blood glucose 
≤4.8 mmol/l) after insulin injection, the amount of exogenous glucose required, and the 
duration of glucose administration.
Statistical analysis
Since we previously found a 29.2 ± 42.1 minutes (~25%) reduction in time to achieve a 
similar glucose lowering effect over the first 2 hours after administration of a standard 
insulin dose by jet rather than conventional injection [11], we calculated that 17 participants 
would be required to detect a ~30-minute reduction in time to achieve the primary 
endpoint with 80% statistical power at a 5% level of significance. To correct for the 
relatively small number of subjects involved, a total of 20 subjects were enrolled, and 
additional participants were recruited in case of drop-out. To perform subgroup analyses, 
we enrolled an equal number of patients with type 1 and type 2 diabetes. All data are 
expressed as mean ± standard error (s.e.); differences are expressed as means with 95% 
confidence intervals (CIs), unless otherwise indicated. 
Paired t tests (or Wilcoxon signed-rank tests for nonparametric data) were performed to 
compare most study endpoints; in case of missing data for one of the pairs, e.g. when an 
endpoint was not reached, we performed unpaired t tests (or Mann-Whitney U tests). 
Glucose and insulin values for the two devices were analyzed with two-way repeated 
measures ANOVA. The chi-square test or Fisher’s exact test was used as appropriate for 
analysis of differences in categorical variables. Subgroup analyses were performed using 
a linear mixed model, with fixed effects for device-by-subgroup interaction. Data were 
entered in a validated data management system (MACRO; InferMed Ltd, London, UK), and 
analysed according to intention to treat, using SPSS 20.0 (IBM SPSS Statistics for Windows, 
Version 20.0, IBM Corp, Armonk, NY). P values <0.05 were considered to indicate statistical 
significance.
Results
A total of 26 patients with diabetes were screened, 23 of whom were included. Two were 
not eligible because they did not meet HbA1c criteria, and  was excluded because of 
anaemia.  After inclusion, three subjects were excluded and subsequently replaced: 
1 participant did not reach hyperglycaemia after interrupting insulin administration for 
72 hours, and 2 participants withdrew consent after the first experimental day was 
postponed, because of not reaching the hyperglycaemic target. The baseline characteristics 
of all subjects who underwent testing are shown in Table 1. 
In three cases, the experiment was rescheduled: in 1 patient, the insulin dose was 
erroneously calculated too low, and in two cases the jet injector produced a ‘wet injection’, 
i.e. insulin was released before the injector made proper contact with the skin. Two 
additional experiments were postponed because the first measured plasma glucose 
value was <10 mmol/l. In 13 experiments (7 with a jet injector and 6 with the conventional 
pen; 10 among 6 patients with type 2 diabetes and 3 among 2 patients with type 1 
diabetes), participants were given soda drink in order to reach the hyperglycaemic target. 
In half of the experiments, the patient operated the jet injector.   
Mean (± SD) glucose values before insulin injection were 20.6 ± 2.5 and 21.3 ± 2.8 mmol/l 
for patients with  type 1 and type 2 diabetes, respectively. These data were used to 
calculate the required insulin doses at 14.3 ± 5.9 and 29.1 ± 11.5 units. As the glucose 
values at baseline (at the moment of insulin injection) differed slightly, but significantly, 
between the jet injector and conventional pen (22.2 ± 0.6 vs 20.4 ± 0.5 mmol/l, P=0.004), 
we used the change in glucose levels rather than absolute values for analyses concerning 
the area under the glucose curve and time to reach glucose values below 10 and 5 mmol/l.
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Pharmacodynamic endpoints
The fall in plasma glucose values during the experiments is shown in Figure 1A, the slope 
of which was significantly steeper with the jet injector than with the conventional pen 
(Table 2). The time until plasma glucose concentration had dropped ≥10 mmol/l was 147.9 
± 14.4 minutes after insulin administration by jet injection, compared with 192.5 ± 13.6 
minutes after insulin administration with a conventional pen (difference 44.6 minutes 
[95%CI 4.3-84.8]; P=0.03). In 2 patients with type 1 and 1 patient with type 2 diabetes 
(mean BMI 32.6 ± 2.8 kg/m2), the primary endpoint was not reached on the jet injection 
day. The maximal falls in plasma glucose were 4.8, 8.6, and 9.6 mmol/l, with corresponding 
peak insulin levels of 63.1, 66.0 and 118.6 mU/l, respectively. Recalculation of the data 
(using a paired t test) after exclusion of these patients did not materially change the 
outcome (147.9 ± 14.4 vs 197.9 ± 15.0 minutes for jet injector and conventional pen, 
respectively, P=0.012). 
Table 1  Baseline characteristics 
Type 1 diabetes (n=10) Type 2 diabetes (n=10)
Sex, male:female 7:3 7:3 
Mean ± s.d. age, years 48 ± 12 59 ± 7
Mean ± s.d. diabetes duration, years 28.7 ± 11.9 17.8 ± 8.2 
Median (range) insulin treatment 
duration, years
28.9 (8.5 - 45.3) 10.9 (7.2 - 19.6)
Mean ± s.d. body weight, kg 93.8 ± 12.0 106.2 ± 15.8
Mean ± s.d. BMI, kg/m2 29.7 ± 3.7 34.7 ± 4.3 
Mean ± s.d. waist circumference, cm 99.7 ± 5.5 111.1 ± 17.1
Mean ± s.d. HbA1c, % (mmol/mol) 8.4 ± 1.1 (68 ± 12) 8.7 ± 1.1 (72 ± 12)
Median (range) insulin dose, Units/
day
57 (34-109) 136 (36-200)
Insulin regimen, n 
   Basal-bolus
   Pump therapy
4 
6
8
2
Oral glucose-lowering medication, n 
   Metformin only
   Metformin and DPP-4 inhibitor
   Thiazolidinedione
1
0
0
3
1
1
Current smoker, n 0 2
DPP-4, dipeptidyl peptidase-4; HbA1c, glycated haemoglobin; s.d., standard deviation.
Figure 1   Changes in plasma glucose and insulin levels during the experiments
Mean ± standard error changes in plasma glucose levels (A) and plasma insulin levels (B) during the 
experiments, from baseline (moment of insulin administration) to 6 hours after insulin administration 
by jet injection (black circles) and conventional insulin pen (white squares).
0 60 120 180 240 300 360
-15
-10
-5
0
Time (minutes)
Ch
an
ge
in
pl
as
m
a
gl
uc
os
e
(m
m
ol
/l)
0 60 120 180 240 300 360
0
50
100
150
Time (minutes)
Pl
as
m
a
in
su
lin
(m
U
/L
)
A
B
126 127
CHAPTER 6 INSULIN ADMINISTERED BY NEEDLE-FREE JET INJECTION TO CORRECT MARKED HYPERGLYCAEMIA
6
Similarly, when we calculated the time until all patients achieved the minimal measured 
fall in plasma glucose of 4.8 mmol/l, the jet injector still performed significantly faster than 
the conventional pen (80.8 ± 14.4 versus 92.5± 4.8 minutes, P=0.007). 
After 1 hour, glucose values had dropped by 4.4 ± 0.3 mmol/l after jet injection and by 3.0 
± 0.2 mmol/l after conventional injection (P=0.001). The hyperglycaemic burden, as 
reflected by the area under the glucose concentration curve was significantly less for the 
jet injector during the first 2 hours after insulin administration (P=0.01; Figure 1A and Table 
2), but did not differ for the remainder of the test. The times until plasma glucose values 
dropped below 10 and 5 mmol/l were also numerically shorter for the jet injector than for 
the conventional pen, but not statistically since these endpoints were achieved in a subset 
of patients (Table 2). 
In subgroup analyses, a higher BMI was independently associated with greater time 
benefit of jet injection with respect to the primary endpoint (97.2 ± 19.2 vs 3.1 ± 17.0 
minutes for BMI above and below the median of 31.2 kg/m2, respectively, P=0.007), but 
diabetes type was not (P=0.31). The use of soda drink prior to the experiments had no 
effect on this outcome (time benefit of jet injection 57.5 ± 31.9 minutes for soda-users 
compared with 43.3±19.5 minutes for non-users, P=0.703), or on any of the other outcomes.
Pharmacokinetic endpoints
Insulin values could be measured in all patients except for 1, in whom the presence of 
insulin antibodies resulted in cross-reactivity with the analysis. The changes from baseline 
in plasma insulin levels for both devices are shown in Figure 1B. Jet injection advanced the 
absorption of insulin compared with conventional injection, as reflected by a shorter time 
to peak insulin levels (40.5 ± 3.2 vs 76.8 ± 7.7 min, P<0.001; Table 2) and ~50% higher peak 
insulin levels (140.6 ± 24.4 vs 101.7 ± 14.7 mU/l, P=0.003). Jet injection significantly advanced 
the time in minutes until 50% of insulin absorption (by 32.6 minutes, P=0.003). Total insulin 
absorption, reflected by the area under the insulin-concentration curve, appeared to be 
greater after jet than after conventional injection (difference 1973 mU·min·l-1 [95%CI -229.2 
to 4175.2], P=0.06; Table 2), yet this was probably the consequence of the slightly greater 
insulin dose injected by jet stream. In 1 of the 3 patients who did not reach the primary 
pharmacodynamic endpoint, insulin levels remained relatively low (INSAUC 958.1 
mU·min·l-1; maximal drop in plasma glucose 4.8 mmol/l), suggesting insufficient insulin 
administration or absorption, whereas insulin levels were appropriately elevated in the 
other two cases (7049 and 8448 mU·min·l-1; maximal drop in plasma glucose 9.6 and 8.6 
mmol/l). 
Safety and ease of use
In seven experiments (18%), three with the jet injector and four with the conventional pen, 
all in patients with type 1 diabetes, exogenous glucose was administered to prevent 
hypoglycaemia. There were no differences between the two devices in the time to the 
start of glucose administration (208 ± 8 vs 218 ± 40 minutes; P=0.84), or the amount of 
exogenous glucose administered (14.3 ± 5.3 vs 17.7 ± 8.2 g; P=0.77). Adverse effects 
reported during the experiments were mostly mild to moderate in nature, and associated 
with hyperglycaemia (thirst, polyuria and nausea), which resolved quickly after glucose 
levels decreased. One patient requiring glucose infusion developed phlebitis, which 
resolved without treatment within four weeks. The amount of pain or discomfort 
experienced with the jet injector or conventional pen was rated 1.8 ± 0.4 and 1.2 ± 0.1 
(P=0.38), respectively;  the (un)ease of use was rated 2.7 ± 0.4 with jet and 1.6 ± 0.2 with 
conventional pen injection (P=0.49). Of the 20 patients included, 6 preferred the jet 
injector, 7 preferred the conventional pen, and 7 did not have a preference  (P=0.95). 
Table 2  Pharmacodynamic and pharmacokinetic endpoints
Endpoint Jet injector Conventional pen P
Pharmacodynamic endpoints
T-BG≥10, min 147.9 ± 14.4 (n=17) 192.5 ± 13.6 (n=20) 0.03
T-BG10, min 163.2 ± 17.3 (n=14) 214.1 ± 16.0 (n=17) 0.04
T-BG5, min 220.8 ± 21.5 (n=6) 270.0 ± 17.3 (n=3) 0.19
BG-AUC0-2h, mmol·min·l-1 2042 ± 37.2 2168 ± 26.1 0.01
BG-AUC0-6h, mmol·min·l-1 4226 ± 241.8 4539 ± 142.4 0.24
Rfall, mmol·l-1·min-1 0.080 ± 0.005 0.064 ± 0.004 0.03
Pharmacokinetic endpoints
C-INSmax, mU/l 140.6 ± 24.4 101.7 ± 14.7 0.003
T-INSmax, min 40.5 ± 3.2 76.8 ± 7.7 <0.001
INSAUC, mU·min·l-1 14363 ± 2498 12390 ± 1858 0.06
T-INSAUC50%, min 107.1 ± 9.4 139.7 ± 5.9 0.003
n represents the number of patients that reached the endpoint. T-BG≥10, time in minutes until plasma 
glucose concentration had dropped by ≥10 mmol/l; T-BG5 (10), time in minutes until plasma glucose values 
had dropped below 5 (10) mmol/l; BG-AUC0-2h (0-6h), area under the time-glucose curve, reflecting 
post-injection hyperglycaemic burden, from 0 to 2 (6) hours after insulin injection; Rfall, slope of the glucose 
fall, calculated from the time-glucose curve during the first 30-120 minutes of the test; C-INSmax, maximum 
insulin concentration; T-INSmax, time in minutes to maximum insulin concentration; INSAUC, area under the 
insulin concentration curve, reflecting total insulin absorption; T-INSAUC50%, time until 50% of insulin 
absorption.
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Discussion
The present study shows in overweight or obese patients with type 1 or type 2 diabetes 
that administration of a rapid-acting insulin analogue by jet injection resulted in faster 
correction of hyperglycaemia, by ~45 minutes, compared with administration with a 
conventional insulin pen. Insulin administration by jet injection also decreased the 
hyperglycaemic burden during the first 2 hours, without posing a greater risk of late 
hypoglycaemia. The two devices were rated equally, both with respect to discomfort as 
with respect to ease of use by the trial population, consisting of diabetes patients highly 
experienced with and unbiased towards contemporary insulin therapy. These findings 
suggest that insulin administration by jet injection provides an effective and user-friendly 
way to correct marked hyperglycaemia in patients with insulin-treated diabetes.
The advantage of insulin administration by jet over that by conventional injection with 
respect to normalizing plasma glucose levels, duration of hyperinsulinemia, and 
hyperglycaemic burden, is in line with our previous studies conducted both in healthy 
subjects and in subjects with diabetes [11-13], and with studies comparing jet injectors 
with needle syringes [3,5-9]. Indeed, in those studies, jet injection reduced both the time 
to peak insulin levels and to maximal insulin action as well as the duration of insulin action 
by ~30-45 minutes. Also in line with previous results is our observation that jet injection 
appeared most beneficial for patients with higher BMI, who consequently required more 
insulin, although the underlying mechanism remains to be explained [13]. 
Most guidelines recommend to measure plasma glucose 1 hour after administration of a 
corrective insulin dose for (marked) hyperglycaemia [17]. However, the initial drop in 
plasma glucose concentration after conventional pen injection in the present study was 
only 3 mmol/l (range, 1.1 - 4.6 mmol/l). A glycaemic response that is too small may tempt 
patients and health care-providers to repeat the insulin injection, which in turn increases 
the risk of late hypoglycaemia. Administration by the jet injector resulted in an almost 50% 
greater glucose fall. Other benefits of advanced correction of marked hyperglycaemia 
include less time spent in hyperglycaemia and the resultant potential to avert metabolic 
complications such as diabetic ketoacidosis and hyperosmolar hyperglycaemic state, 
potentially fatal conditions that often necessitate hospital admission [1,18]. Finally, apart 
from its use in an out-patient setting, the jet injector may also prove useful in the hospital, 
where hyperglycaemia is frequently encountered and difficult to manage [17]. 
In the present trial, we used an adjusted formula based on the individual insulin sensitivity 
factor to calculate insulin doses adjusted to individual patient needs. This contrasts with 
the more or less fixed sliding-scale algorithms used in daily practice and in most other 
trials conducted in patients with diabetes experiencing hyperglycaemia [14,19,20]. This 
easy-to-use calculation turned out to perform well, leading to adequate correction of 
marked hyperglycaemia in 93% of cases. 
The present study has strengths and weaknesses. A strength of our trial is that it reflects 
real-world practice, in that hyperglycaemia was reached without parenteral interventions, 
much the same as in daily life. A weakness of the study is inherent to its design, in that it 
allowed glucose values to differ slightly between the two test days. However, the 
difference in baseline glucose values was small (<10% from the mean value) and unlikely 
to have had a meaningful impact on any of the outcomes. To further represent real-world 
practice, the device was operated by the patient when feasible. Although the lack of a 
double-blind design may be criticized, it is hard to imagine how this would change the 
results, as the insulin-induced fall in glucose is difficult to manipulate. We made sure that 
all conditions were exactly the same on both testing days, so that any potential modulation 
by the participant or research staff was kept to an absolute minimum. Therefore, the 
absence of a placebo-injection might only have had minimal, if any, influence on the 
results. 
In 2 participants, insulin administration by the jet injector resulted in a ‘wet-injection’, for 
which we had to reschedule the test day. In another participant, even though we did not 
observe a wet injection, hyperglycaemia was inadequately corrected because of low 
plasma insulin levels, suggesting insufficient insulin absorption from the subcutaneous 
tissue. Such errors are obviously undesirable for a product that needs to be administrated 
on a daily basis [21], and underscore that handling this device may be cumbersome. 
Previous research showed that administration of an entire insulin dose by jet injection can 
be achieved in almost all circumstances, when sufficient training is provided [22]. 
Nevertheless, the inter-individual variability in insulin action observed in the present study 
appeared not different for conventional and jet injection. In line with our previous research, 
insulin administration by this jet injector was well tolerated and not dissimilar from 
conventional pens [12]. Finally, it should be acknowledged that the pharmacological 
profile of insulin injected by jet stream and the tolerability of the device are specific to 
the jet injector used in this study; our data cannot simply be extrapolated to other jet 
injectors [23].
In conclusion, aspart insulin administered by jet injection results in a more rapid and 
equally safe correction of marked incidental hyperglycaemia as compared with administration 
by a conventional insulin pen, especially in patients with a higher BMI. These effects may 
be clinically relevant for patients with diabetes treated with rapid-acting insulin. Further 
research is needed to elucidate the applicability of jet injection in daily practice.
130 131
CHAPTER 6 INSULIN ADMINISTERED BY NEEDLE-FREE JET INJECTION TO CORRECT MARKED HYPERGLYCAEMIA
6
Acknowledgements
We wish to thank the study subjects for their participation in the trial. We also thank Anja 
Rasing, Karin Saini, Mariëlle Verstegen, Simone Hins, and Adrianne Hofboer, research 
nurses (Clinical Research Center, Radboudumc) for their assistance during the experiments.
This is an investigator-initiated trial that was funded with an unrestricted grant from 
European Pharma Group B.V. (EPG), Schiphol Rijk, the Netherlands. The European Pharma 
Group was not involved in the design and conduct of the study, the collection, 
management, analysis,and interpretation of the data, nor in the writing of the manuscript 
and the decision to submit for publication.
References
1. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the 
overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes 
Care 2003; 26: 881-885.
2. Mader JK, Birngruber T, Korsatko S, et al. Enhanced absorption of insulin aspart as the result of a dispersed 
injection strategy tested in a randomized trial in type 1 diabetic patients. Diabetes Care 2013; 36: 780-785.
3. Malone JI, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet stream and disposable 
insulin syringe. Diabetes Care 1986; 9: 637-640.
4. Weller C, Linder M. Jet injection of insulin vs the syringe-and-needle method. JAMA 1966; 195: 844-847.
5. Halle JP, Lambert J, Lindmayer I, et al. Twice-daily mixed regular and NPH insulin injections with new jet 
injector versus conventional syringes: pharmacokinetics of insulin absorption. Diabetes Care 1986; 9: 279-282.
6. Kerum G, Profozic V, Granic M, Skrabalo Z. Blood glucose and free insulin levels after the administration of insulin 
by conventional syringe or jet injector in insulin treated type 2 diabetics. Horm Metab Res 1987; 19: 422-425.
7. Lucas A, Ribas L, Salinas I, et al. Insulin levels after injection by jet stream and disposable syringe. Diabetes Care 
1988; 11: 298-299.
8. Pehling GB, Gerich JE. Comparison of plasma insulin profiles after subcutaneous administration of insulin by 
jet spray and conventional needle injection in patients with insulin-dependent diabetes mellitus. Mayo Clin 
Proc 1984; 59: 751-754.
9. Taylor R, Home PD, Alberti KG. Plasma free insulin profiles after administration of insulin by jet and conventional 
syringe injection. Diabetes Care 1981; 4: 377-379.
10. Houtzagers CM, Berntzen PA, van der Stap H, Heine RJ, van der Veen EA. Absorption kinetics of short- and 
intermediate- acting insulins after jet injection with Medi-Jector II. Diabetes Care 1988; 11: 739-742.
11. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of 
rapid-acting insulin using needle-free jet injection technology. Diabetes Care 2011; 34: 1804-1808.
12. Engwerda EE, Tack CJ, de Galan BE. Needle-free jet injection of rapid-acting insulin improves early postprandial 
glucose control in patients with diabetes. Diabetes Care 2013; 36: 3436-3441.
13. de Galan BE, Engwerda EE, Abbink EJ, Tack CJ. Body mass index and the efficacy of needle-free jet injection for 
the administration of rapid-acting insulin analogs, a post hoc analysis. Diabetes Obes Metab 2013; 15: 84-86.
14. Guerci B, Meyer L, Salle A, et al. Comparison of metabolic deterioration between insulin analog and regular 
insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. 
J Clin Endocrinol Metab 1999; 84: 2673-2678.
15. Shashaj B, Busetto E, Sulli N. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal 
flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 2008; 25: 
1036-1042.
16. Abbink EJ, Walker AJ, van der Sluijs HA, Tack CJ, Smits P. No role of calcium- and ATP-dependent potassium 
channels in insulin-induced vasodilation in humans in vivo. Diabetes Metab Res Rev 2002; 18: 143-148.
17. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006; 355: 
1903-1911.
18. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes 
Care 2009; 32: 1335-1343.
19. Gredal C, Rosenfalck AM, Dejgaard A, Hilsted J. Targeting postprandial hyperglycaemia in patients with 
recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart. Scand J Clin Lab Invest 
2008; 68: 739-744.
20. Holleman F, van den Brand JJ, Hoven RA, et al. Comparison of LysB28, ProB29-human insulin analog and 
regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 1996; 19: 1426-1429.
21. Schramm J, Mitragotri S. Transdermal drug delivery by jet injectors: energetics of jet formation and penetration. 
Pharm Res 2002; 19: 1673-1679.
22. Bremseth DL, Pass F. Delivery of insulin by jet injection: recent observations. Diabetes Technol Ther 2001; 3: 
225-232.
23. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006; 
5: 543-548.
Correction of marked hyperglycaemia 
in people with insulin-requiring diabetes  
7
Helena M. de Wit,*  Elsemiek E.C. Engwerda,*  Cees J. Tack, Bastiaan E. de Galan
*Both authors contributed equally 
Submitted
134 135
CHAPTER 7 CORRECTION OF MARKED HYPERGLYCAEMIA IN PEOPLE WITH INSULIN-REQUIRING DIABETES
7
Abstract 
Aim: It is usually recommended to check plasma glucose one hour after insulin injection 
for the correction of incidental marked hyperglycaemia in people with insulin-requiring 
diabetes, even when standard sliding scale regimens unadjusted to individual needs are 
used. We evaluated the clinical relevance of this recommendation when the correctional 
dose of insulin was individualized. 
Methods: We analyzed data from a randomized, controlled, cross-over trial on the correction 
of a plasma glucose value of 20.4±0.5 mmol/l with a widely-used commercial insulin pen 
in people with insulin-treated diabetes. Aspart insulin was injected subcutaneously in a 
dose determined by the following calculation: ([measured glucose value in mmol/l–6 
[=target glucose value]÷[100÷total daily insulin dose])•1.5). Plasma glucose levels were 
measured for 6 hours thereafter. 
Results: 10 people with type 1 diabetes and 10 with type 2 diabetes were enrolled. 
Glucose values dropped 14.2±0.6 mmol/l to a nadir of 6.4±0.4 mmol/l after injection of 
20.3±2.4 insulin units. Glucose values fell by only 3.2±0.5mmol/l one hour after injection 
and by 7.3±0.7mmol/l after two hours. In 60% of patients, plasma glucose values fell 
<3 mmol/l in the first hour. The formula led to optimal correction on 17 occasions (85%), 
but overestimated insulin needs (requiring exogenous glucose to prevent hypoglycaemia) 
on 3 (15.0%) occasions.  
Conclusions: Despite high individualized insulin doses, which were sufficient to optimally 
correct marked hyperglycaemia in most participants, the initial glucose-lowering response 
was modest. The clinical significance of checking glucose values one hour after insulin 
injection is limited, even when ‘rapid-acting’ insulin is used.
Introduction
In non-critically ill in-patients with diabetes, the American Diabetes Association (ADA) 
recommends that glucose values should be below 10 mmol/l, and that treatment should 
be initiated once this level is exceeded [1]. Despite these recommendations, glucose levels 
far exceeding this threshold are frequently encountered in daily practice [2]. In these 
patients, hyperglycaemia is associated with increased risks of cardiac, neurologic and 
infectious complications, higher mortality and increased length of hospital stay [3-5]. 
The hospital setting creates a particularly high risk of the development of marked hyper-
glycaemia due to co-existing illness, use of drugs that increase blood glucose levels 
(e.g. glucocorticoids), the need to stop glucose-lowering drugs (e.g. metformin), or the use 
of tube or parenteral feeding or diets otherwise rich in carbohydrates. 
Although basal-bolus insulin regimens are preferred to optimize glucose control in 
hospitalized patients with diabetes [1], standard sliding scale regimens are still widely 
applied for the correction of marked hyperglycaemia. These regimens are usually not or 
only barely adjusted to individual needs [6] and tend to underestimate the required 
correctional insulin dose. In our experience, many in-patient protocols recommend to 
repeat a glucose measurement 1 hour after insulin injection, even though it takes at least 
90 minutes for the maximal glucose lowering effect to set in, even with rapid-acting 
insulin analogues [7]. Re-applying the sliding scale regimen may then result in injecting 
the same insulin dose, which increases the risk for late hypoglycaemia and considerable 
glucose fluctuations [8,9]. 
Recently, we compared two insulin injection pens for the correction of marked hyper-
glycaemia in overweight people with type 1 or insulin-treated type 2 diabetes. In this 
study, we calculated the correctional dose of rapid-acting insulin for each individual on 
the basis of the insulin sensitivity factor, multiplied by 1.5 to compensate for hyperglycaemia -
induced glucose-toxicity [10]. In this paper, we evaluated the data on the rate of the 
decline in plasma glucose when this easy-to-use algorithm was applied to correct marked 
hyperglycaemia with a widely-used commercially available insulin pen. The data were 
used to assess the significance of retesting glucose measurements 1 hour after insulin 
administration and the overall performance of the algorithm.
Materials and methods
This was an analysis of data from a randomized, controlled, cross-over study that was 
originally developed to compare the pharmacokinetic and -dynamic properties of a jet 
injector insulin pen (InsujetTM; European Pharma Group bv, Schiphol-Rijk, the Netherlands) 
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and a conventional pen (FlexPen®, Novo Nordisk, Bagsværd, Denmark) for the correction 
of marked hyperglycaemia. For the present analysis, we only used data from the Flexpen. 
The study was approved by the institutional review board of the Radboud university 
medical center and all participants provided written informed consent. The procedures 
followed were in accordance with the Declaration of Helsinki.
The details of enrollment criteria and study procedures have been published elsewhere 
[10]. Briefly, the study enrolled adults with type 1 or type 2 diabetes, aged 18-75 years, with 
a BMI of 25-40 kg/m2. All participants were on a basal-bolus insulin regimen (i.e. with 
multiple injections at least four times daily, or with a subcutaneous insulin pump) with a 
total daily insulin dose (TDID) of at least 34 and no more than 200 units. Participants were 
tested in fasting condition. They were instructed to reduce their insulin doses one day 
before the experiments, in order to reach hyperglycaemia. On the experimental day, 
a catheter was inserted in retrograde fashion in a dorsal hand vein for blood sampling and 
frequent glucose measurements (Biosen C-line GP+, EKF-diagnostic GmbH, Barleben, 
Germany). After having obtained a plasma glucose level of 18-23 mmol/l, insulin aspart 
(NovoRapid®, Novo Nordisk, Bagsvaerd, Denmark) was administered by a conventional 
insulin pen (Flexpen®). Thereafter, plasma glucose levels were measured at 5-minute 
intervals during the first three hours, and at 10-minute intervals for the next three hours. 
If plasma glucose values dropped below 4.8 mmol/l, a second intravenous catheter 
was inserted in the opposite arm for the administration of glucose 20%. After six hours, 
the experiment was terminated, and the participant was given a meal. 
The administered insulin dose was calculated by the following formula:
1.5 x ([actual glucose]-[glucose target]) ÷ ISF, 
in which [actual glucose] is the glucose level at the start of the experiment; [glucose 
target]  the glucose objective, set at 6 mmol/l in our study; and ISF the insulin sensitivity 
factor [11], calculated by dividing 100 by the total daily insulin dose (TDID). The multi-
plication factor of 1.5 was used to compensate for possible hyperglycaemia-induced 
insulin resistance (glucose toxicity) [12,13], and to ensure that sufficient insulin was 
administered. Thus, for a participant with a TDID of 50 units and an initial plasma glucose 
level of 22 mmol/l, the number of units to be administered was calculated as: 1.5 x (22-6) 
÷ (100÷50) = 12. The calculated insulin dose was rounded up, to a maximum of 40 units.  
Statistical analyses
Endpoints were derived from the time-action glucose profiles. These included the 
accuracy of the formula, as determined by the proportion of experiments in which a 
plasma glucose value between 4.8-10 mmol/l was achieved,  the mean maximal drop in 
plasma glucose levels after insulin injection, the time in minutes until plasma glucose 
levels dropped below 10 mmol/l, and the amount of exogenous glucose needed to 
prevent hypoglycaemia. Subgroup analyses were performed according to diabetes type, 
sex, and the accuracy of predicting insulin needs by the formula. For the latter, we 
distinguished the subgroup in whom the formula performed optimal (defined as achieved 
plasma glucose between 4.8-10 mmol/l) from those in whom the formula overestimated 
insulin needs (achieved plasma glucose value <4.8 mmol/l, requiring exogenous glucose) 
or underestimated insulin needs (achieved plasma glucose level >10 mmol/l). Glucose 
values for subgroups were tested for normal distribution and compared with an unpaired 
T-test or Wilcoxon signed rank test. Correlation coefficients were calculated by using 
Pearson’s correlation test. Percentages were compared with a Chi-square test. Statistical 
analyses were performed by SPSS 20.0 (IBM SPSS Statistics for Windows, Version 20.0, IBM 
Corp, Armonk, NY USA). A P-value of <0.05 was considered significant.
Results 
Twenty participants, 10 with type 1 diabetes and 10 with type 2 diabetes, were enrolled. 
Baseline characteristics are presented in Table 1. The mean plasma glucose value before 
insulin injection was 20.4 ± 0.5 mmol/l, for which 20.3 ± 2.4 units of insulin were injected. 
In 1 case, the maximal insulin dose of 40 units was administered, which was slightly below 
the calculated dose (42 units). 
The first 5-10 minutes after insulin injection, plasma glucose levels slightly increased to 
20.6 ± 0.5 mmol/l. Subsequently, glucose levels dropped by 3.2 ± 0.5 mmol/l and 7.3 ± 0.7 
mmol/l during the first and second hour after insulin injection, respectively (Fig. 1). In 12 
patients (60%), plasma glucose values fell <3 mmol/l in the first hour. On average, plasma 
glucose levels fell below 10 mmol/l after 201.3 ± 13.9 minutes, whereas it took 323.5 ± 12.1 
minutes before the glucose nadir of 6.4 ± 0.4 mmol/l was reached (Fig. 1). On 17 (85%) 
occasions the formula well predicted insulin needs. On three (15%) occasions (all with type 
1 diabetes), the formula overestimated insulin needs, thus requiring administration of 
exogenous glucose (14.3 ± 5.3 g, range 4-22 g) after 207.7+/-7.9 minutes to avoid 
hypoglycaemia. Underestimation of insulin needs did not occur. 
One- and 2-hour plasma glucose values were significantly lower on occasions where the 
formula overestimated insulin needs, as compared with occasions in which the formula 
predicted well (1-hour: 15.2 ± 0.6 vs. 17.8 ± 0.5 mmol/l; 2-hour: 8.9 ± 2.1 vs. 14.1 ± 
0.6 mmol/l; both P<0.05, Fig. 2). The rate of initial glucose decline (as measured by 
the slope during the first 2 hours) and the glucose nadir were associated with estimated 
insulin sensitivity (R=0.55, P=0.013 and R=-0.46, P=0.048). The  algorithm tended to be 
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more accurate for patients with type 2 diabetes (P=0.060), but there was no significant 
difference in accuracy between males and females (P=0.89). 
Discussion
This analysis showed that the individualized dose we calculated to correct marked 
hyperglycaemia was relatively high, yet resulted in near-normalization of plasma glucose 
values in 85% of patients with diabetes. Surprisingly, despite the high insulin dose, the fall 
in plasma glucose one hour after insulin injection was fairly modest, even in patients in 
whom the algorithm overestimated insulin needs. Although it is common practice to 
evaluate glucose levels at this time point to guide further treatment decisions, our data 
suggest that it would be better to wait another hour.
Our data underscore the importance of patience. The duration of absorbing insulin from 
the subcutaneous compartment into the circulation and its subsequent glucose-lowering 
Table 1  Baseline characteristics
Type 1 diabetes Type 2 diabetes
Mean age, years 48.0 ± 12.3 58.7 ± 6.8
Sex, men:women 7 : 3 7 : 3
Duration of diabetes, years 28.7 ± 11.9 17.8 ± 8.2
Treatment regimen
Pump therapy 6 2
MDI 4 8
TDID, units/day, median (range) 57 (34-109) 136 (36-200)
HbA1c 
mmol/mol 68.0 ± 11.7 71.8 ±12.4
% 8.4 ± 1.1 8.7 ± 1.1
BMI, Kg/m2 29.7 ±3.7 34.7 ± 4.3
Initial plasma glucose, mmol/l 20.8 ± 2.7 21.8 ± 2.7
Insulin dose administered, units 14.3 ± 5.9 29.1 ± 11.5
Data are expressed as number, median (range) or mean ± SD. BMI denotes body mass index; TDID denotes 
total daily insulin dose; MDI denotes multiple daily injections.
Figure 1   Plasma glucose values after insulin injection for participants with type 1 
diabetes (black circles) or type 2 diabetes (white squares)
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Figure 2   Plasma glucose values at t=120 minutes (A) and t=180 minutes (B) after insulin 
injection, according to the accuracy of the algorithm for achieving target 
glucose values. 
Foptimal: optimal prediction of insulin needs; Foverestimation: overestimation of insulin needs. *P<0.05
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action has been estimated at 30-45 minutes [7,14]. Indeed, glucose values fell only 
modestly in the first hour and could even increase within the first 10 minutes. We therefore 
recommend to repeat glucose measurements not earlier than 120 minutes after insulin 
administration. Hypoglycaemia did not occur before this time point, although our data 
suggest that it would be wise to ingest some carbohydrates when glucose levels have 
fallen below 12 mmol/l at 120 minutes to prevent such an event (Fig. 2). We would also 
recommend to wait at least another hour before considering a repeated insulin injection 
because of insufficient glucose decline. While most of the fall in plasma glucose occurred 
in the second hour, the glucose levels achieved after two hours did not discriminate 
between participants who reached the glycaemic target range and those who did not 
(Fig. 2a). This only occurred after the third hour, when over 75% of insulin action was 
completed, although there was still substantial overlap between these two groups 
(Fig. 2b). It should be noted that the algorithm presented here cannot be used to calculate 
the amount of extra insulin necessary to achieve the glycaemic target when the first 
injection was insufficient. 
Marked elevations in plasma glucose levels are fairly common among people with insulin- 
treated diabetes. However, most guidelines provide very little assistance on how to 
manage marked hyperglycaemia or fail to mention the issue at all [15]. Sufficient insulin 
administration is not only important to limit the hyperglycaemic period, but also to 
dissuade patients from repeating insulin injection(s) when glucose levels fail to respond, 
which ultimately increases the risk for hypoglycaemia. Standard sliding scale regimens 
remain largely devoid of individualization, ignore glucose toxicity and are therefore prone 
to considerable underestimations of the required dose for adequate correction, particularly 
in type 2 diabetes. Indeed, we used an average insulin dose of more than 20 units, whereas 
guidelines advocate a maximal dose of 18 units of insulin only for severely insulin-resistant 
patients with a glucose level exceeding 22 mmol/l [16]. Published algorithms to correct 
hyperglycaemia in hospitalized patients are similarly restrictive [17]. Considering both the 
effect of glucose toxicity and individualized insulin requirements, we developed an 
algorithm resulting in correction insulin doses that were considerably higher than usually 
advocated. Yet we showed that doses up to 40 units were safe for achieving normo-
glycaemia in the vast majority of participants. 
Our study has limitations. First, the study population consisted of overweight participants 
with diabetes who were otherwise healthy. Extrapolation to a normal-weight diabetes 
population should be done with caution. Second, hyperglycaemia was induced by insulin 
depletion. We therefore cannot vouch for the accuracy of the algorithm in settings in 
which other factors, such as the use of prednisone, overeating, infections, and stress 
contribute to hyperglycaemia. Nevertheless, the algorithm is unlikely to overestimate 
insulin requirements in these conditions and may still provide guidance in determining 
the insulin dose needed to overcome hyperglycaemia. Third, we only tested the algorithm 
in participants with marked hyperglycaemia (arbitrarily set at a plasma glucose level of 
>18 mmol/l) that had not yet progressed to hyperosmolar disruption or ketoacidosis. 
Therefore we do not know whether the algorithm is also appropriate for higher or lower 
levels of hyperglycaemia. Fourth, the algorithm tended to overestimate insulin needs 
in insulin- sensitive patients with type 1 diabetes. Although exogenous glucose was not 
required in the first two hours,  it may be better to use a lower correction factor than 
1.5 or not use the factor at all in these patients. Finally, we did not compare the algorithm 
to that of routine care for hyperglycaemic excursions in the hospital, so that we cannot 
determine the exact differences between the two methods. 
In conclusion, our observations suggest that it takes long to correct marked hyperglycaemia, 
despite the relatively high dose of insulin used in this study. Thus, it would be advisable 
to wait two hours rather than one before repeating the glucose measurement and 
three hours before considering another insulin injection. Our algorithm, which can be 
easily applied in daily clinical practice, may provide some guidance in calculating insulin 
doses needed to correct marked hyperglycaemia in persons with insulin-treated diabetes. 
Further studies are needed to reveal the predictive value of this formula in different 
settings and in larger populations.
Acknowledgements
We are indebted to Karin Saini, Anja Rasing, Mariëlle Verstegen, Simone Hins, and Adrianne 
Hofboer, research nurses, for their assistance during the experiments, and to the 
participants for their contribution to this study. This is an investigator-initiated trial that 
was funded with an unrestricted grant from European Pharma Group B.V. (EPG), Schiphol 
Rijk, the Netherlands. EPG was not involved in the design and conduct of the study, the 
collection, management, analysis, and interpretation of the data, or in the writing of the 
manuscript and the decision to submit for publication.
142 143
CHAPTER 7 CORRECTION OF MARKED HYPERGLYCAEMIA IN PEOPLE WITH INSULIN-REQUIRING DIABETES
7
References
1. American Diabetes A. Standards of medical care in diabetes--2014. Diabetes Care 2014; 37 Suppl 1: S14-80.
2. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. 
Endocrinol Metab Clin North Am 2012; 41: 175-201.
3. Hawkins K, Donihi AC, Korytkowski MT. Glycemic management in medical and surgical patients in the non-ICU 
setting. Curr Diab Rep 2013; 13: 96-106.
4. Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced 
oxidative stress. World J Gastroenterol 2009; 15: 4137-4142.
5. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in 
patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87: 978-982.
6. Gerards MC, Tervaert EC, Hoekstra JB, Vriesendorp TM, Gerdes VE. Physician’s attitudes towards diagnosing 
and treating glucocorticoid induced hyperglycaemia: Sliding scale regimen is still widely used despite 
guidelines. Diabetes Res Clin Pract 2015; 109: 246-252.
7. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of 
rapid-acting insulin using needle-free jet injection technology. Diabetes Care 2011; 34: 1804-1808.
8. Umpierrez G, Maynard G. Glycemic chaos (not glycemic control) still the rule for inpatient care: how do we 
stop the insanity? J Hosp Med 2006; 1: 141-144.
9. Hirsch IB. Sliding scale insulin--time to stop sliding. JAMA 2009; 301: 213-214.
10. de Wit HM, Engwerda EE, Tack CJ, de Galan BE. Insulin administered by needle-free jet injection corrects 
marked hyperglycaemia faster in overweight or obese patients with diabetes. Diabetes Obes Metab 2015; 17: 
1093-1099.
11. Shashaj B, Busetto E, Sulli N. Benefits of a bolus calculator in pre- and postprandial glycaemic control and meal 
flexibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med 2008; 25: 
1036-1042.
12. Solomon TP, Knudsen SH, Karstoft K, et al. Examining the effects of hyperglycemia on pancreatic endocrine 
function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab 2012; 97: 4682-4691.
13. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H. Mechanisms of hyperglycemia-induced insulin resistance in 
whole body and skeletal muscle of type I diabetic patients. Diabetes 1992; 41: 571-580.
14. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharma -
cokinet 2001; 40: 641-659.
15. Mathioudakis N, Golden SH. A comparison of inpatient glucose management guidelines: implications for 
patient safety and quality. Curr Diab Rep 2015; 15: 13.
16. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in 
non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 
16-38.
17. Thomann R, Schutz P, Muller B, et al. Evaluation of an algorithm for intensive subcutaneous insulin therapy in 
noncritically ill hospitalised patients with hyperglycaemia in a randomised controlled trial. Swiss Med Wkly 
2013; 143: w13808.
Summary, discussion 
and future perspectives
8
147
SUMMARY, DISCUSSION AND FUTURE PERSPECTIVES
8
Summary and discussion
Insulin is the cornerstone in the treatment of type 2 diabetes, when lifestyle measurements 
and oral antidiabetic agents fail to achieve glycaemic targets. For patients with type 1 
diabetes, insulin is a lifesaving therapy. Insulin treatment has many benefits: it is highly 
efficacious in improving glycaemic control, reduces the risk of microvascular complications of 
diabetes, has an excellent long-term safety profile and is relatively affordable. Nevertheless, 
some patients with insulin-treated diabetes experience important side-effects of insulin 
therapy. Particularly insulin-induced weight gain and hypoglycaemia frequently occur, 
resulting in reluctance to initiate or continue insulin treatment especially for patients 
with type 2 diabetes. Another limitation of insulin therapy is that patients may frequently 
experience fluctuations in blood glucose levels, which is in part due to the relatively slow 
pharmacological profile of even rapid-acting insulin analogues. In this thesis we studied 
different novel strategies to optimize insulin treatment in patients with diabetes. Here, the 
results are summarized and discussed per topic.
Insulin-GLP-1 receptor agonist combination therapy 
Most patients with type 2 diabetes who commence insulin therapy experience weight 
gain, which can be quite pronounced. In the ’Effect of Liraglutide on insulin-associated 
wEight GAiN in patients with Type 2 diabetes’ (ELEGANT) trial, we studied the weight- 
reducing effect of GLP-1 receptor agonist treatment in patients with type 2 diabetes 
who showed pronounced weight gain shortly after the introduction of insulin therapy. 
The results are described in Chapter 2. We found that addition of the GLP-1 receptor 
agonist liraglutide for 26 weeks decreased body weight by ~5 percent, almost leading to 
complete reversal of the insulin-associated weight gain. While not primarily intended, 
HbA1c also improved, often beyond recommended targets. Insulin requirements more 
than halved and insulin could be discontinued completely in one out of five patients. 
In Chapter 3, the findings of the 26-week extension period of the ELEGANT trial are 
presented, showing that continuation of liraglutide up to 52 weeks led to sustained effects 
on body weight, HbA1c and insulin-dose requirements. Furthermore, addition of liraglutide 
within 22 months after initiating insulin therapy was as effective as addition within 16 months 
in reversing insulin-associated weight gain, with similar beneficial effects on glycaemic 
control and decrease in insulin dose. During the trial, liraglutide was well tolerated. 
 Gastro-intestinal adverse events were common, but mostly mild-to-moderate in severity 
and typically resolved after the first 4-8 weeks. Only 4 (of 47 liraglutide-treated) patients 
discontinued the treatment due to adverse events. These results suggest that addition of 
liraglutide within 22 months provides a valuable pharmacological treatment strategy for 
patients with type 2 diabetes and pronounced insulin-associated weight gain.
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Since GLP-1 receptor agonist treatment is considered expensive, we aimed to explore the 
costs associated with a short-term trial period of adding liraglutide to insulin therapy and 
to identify early predictors of response to liraglutide therapy. As reported in Chapter 4, 
the addition of liraglutide to insulin for 26 weeks resulted in an additional cost per patient 
of approximately 700 euro, or 140 euro per one kg of body weight loss. We then defined 
treatment success when at least two of the following three targets were achieved: ≥4% 
weight loss, HbA1c ≤7% [53 mmol/mol], or the ability to stop insulin. The combination of 
more than 3 percent body weight loss or 60 percent decrease in insulin dose after a 
treatment period of 8 weeks was highly predictive for such a successful treatment 
response at 26 weeks of insulin-GLP-1 receptor agonist combination treatment, whereas 
change in HbA1c did not distinguish between responders and non-responders. The costs 
of such an 8-week trial period would be approximately 250 euro per patient. Altogether, 
these results suggest that a short-term trial period of GLP-1 receptor agonist treatment 
added to insulin therapy in patients with type 2 diabetes and pronounced insulin-associated 
weight gain would be a cost-controlling treatment strategy, when identifying early response 
by applying a combined weight loss and decrease in insulin dose criterion. 
Alternative approaches to combine insulin and GLP-1 receptor agonist treatment could 
also be deployed. Currently, several insulin-GLP-1 receptor agonist combination treatment 
strategies have been investigated prospectively. These strategies include (1) adding a 
GLP-1 receptor agonist to existing insulin treatment [1-11]; (2) adding insulin to existing 
GLP-1 receptor agonist treatment [12-14]; and (3) starting GLP-1 receptor agonist and 
insulin treatment simultaneously (e.g. in a fixed combination) [15-22]. In the ELEGANT-trial, 
we followed the first approach and showed the ability of GLP-1 receptor agonist treatment 
to almost reverse pronounced insulin-associated weight gain. Adding a GLP-1 receptor 
agonist to existing insulin treatment decreases HbA1c by 0.6-1.7% (7-19 mmol/mol), and 
weight by 0.4-5.3 kg after 24-30 weeks [2-8,10,11]. The second approach prevents most of 
the insulin-associated weight gain, resulting in a stable body weight (weight change -0.16 
kg [12] and -0.05 kg [13]) in 2 studies, and 2 kg weight gain in another [14]. The third 
approach, starting GLP-1 and insulin treatment simultaneously, has been extensively 
researched over the past few years following the development of two fixed-dose 
combinations of a GLP-1 receptor agonist and basal insulin: insulin degludec with 
liraglutide (IDegLira [15-18,22]), and insulin glargine with lixisenatide (IGlarLixi [19-21]). 
Initiation of GLP-1 receptor agonist - insulin combination therapy in a fixed dose resulted 
in a decrease of body weight of 0.3-1.4 kg after 24-30 weeks [15-21] and of 0.4 kg after 52 
weeks [22], whereas HbA1c fell by 1.1-1.7% (12-19 mmol/mol) in patients with poor 
glycaemic control with or without insulin [15-18]. Thus, the simultaneous start of insulin 
and GLP-1 receptor agonist treatment in a fixed combination prevented the gain in body 
weight that usually follows insulin-induced improvement in glucose control. This effect 
may in part be due to an insulin-sparing effect by 37 percent at 52 weeks of combination 
therapy, as compared with basal insulin alone [22]. Besides advantages, such as ease of 
use, compliance and efficacy, fixed dose combinations are also associated with 
disadvantages. The dose of the individual components cannot be changed, and it may be 
challenging to determine the next step after the combination fails to achieve glycaemic 
control and additional insulin is needed. 
Recently, two large cardiovascular outcome trials on GLP-1 receptor agonist therapy in 
patients with type 2 diabetes and high cardiovascular risk have been published [23,24]. 
These studies have shown that both semaglutide and liraglutide, against a background of 
various glucose-lowering treatment including insulin, reduced the primary outcome 
(a composite outcome of first occurrence of death from cardiovascular causes, nonfatal 
myocardial infarction or nonfatal stroke) as compared with placebo treatment [23,24]. 
This decrease in macrovascular complications may reduce treatment-related costs, and 
improve the cost-efficiency of insulin-GLP-1 receptor agonist therapy. This information 
is important, as the reimbursement of (supposedly expensive) GLP-1 receptor agonist 
therapy in combination with insulin is often restricted. To reduce costs, both from the 
patient and healthcare payer’s perspective, selecting patients who will benefit most from 
insulin-GLP-1 receptor agonist combination therapy is essential, and requires a personalized 
approach [25]. Discontinuing an (expensive) drug when individualized treatment targets 
are not met within a trial period fits within such an approach, and benefits cost-efficacy.
Placebo effects and responses in diabetes treatment
Injectable treatment is generally associated with stronger placebo effects than treatment 
with pills. Furthermore, suggestion of anticipated treatment effects and side-effects are 
determinants of the placebo effect. We thus wondered if injectable GLP-1 receptor agonist 
treatment, which may have strong effects on appetite and hence weight but likewise lead 
to substantial side effects, would also result in a strong placebo response. To answer this 
question, we performed a meta-analysis to compare the response to injectable placebo 
GLP-1 receptor agonists with the response to oral placebo DPP-4 inhibitors and SGLT-2 
inhibitors in randomized, placebo-controlled trials. The results, described in Chapter 5, 
showed that injectable placebo GLP-1 receptor agonists had a stronger response 
regarding weight reduction than oral placebo treatment. The same was true, albeit to a 
lesser extent, for the decrease in HbA1c and the reporting of side effects. In addition, we 
found a strong correlation between the effect of placebo and the effect of the active 
comparator, implying that the suggestion of treatment effect might play an important 
role in the real treatment effect. These findings support the concept that an injectable 
placebo treatment might harbour stronger effects than oral placebo, especially when 
accompanied by suggestion, a concept that could be explored therapeutically in diabetes 
treatment.
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Diabetes mellitus might offer an interesting model for investigating placebo effects or 
responses, since its management comprises both injectable and oral agents as well as 
non-medical interventions, and effects on body weight and some adverse effects are 
subject to suggestion. Apart from its role in painful diabetic neuropathy [26], the placebo 
effect in diabetes treatment has never been studied before. Our meta-analysis on placebo 
responses related to medication for type 2 diabetes may be viewed as a starting point for 
new research in this field. The placebo effect observed in a placebo-controlled randomized 
controlled trial is potentially underestimated, because trial participants know that they 
have a 50% chance of being allocated to placebo treatment. A better method to study the 
placebo effect would be by performing a prospective trial, which ideally investigates 
subjects who are not aware of placebo treatment. Conducting such a trial may be 
challenging because of ethical issues [27]. A prospective trial, in which patients are not 
aware of placebo treatment, permits unbiased examination of the effect of suggestion on 
the reduction of body weight and HbA1c and the experience of adverse effects. Also, 
placebo effects in insulin treatment, the most practised injectable therapy in diabetes 
treatment could be investigated. As weight loss with GLP-1 receptor agonists is subject to 
suggestion and placebo effects, this might also apply for the weight gain induced by 
insulin treatment. Interestingly, open-label placebo was effective and superior to no 
treatment in a trial involving patients with episodic migraine [28]. Recently, placebo effects 
have received more attention, and are regarded real psychobiological phenomena, which 
should not be underestimated [29,30]. The placebo effect of a therapy might thus be an 
important target for treatment, which could be considered when treating patients with 
diabetes. 
Insulin administration by jet-injection 
In the final part of the thesis, we focused on managing acute, rather than chronic, 
hyperglycaemia. Acute hyperglycaemia poses a recurrent therapeutic challenge for many 
patients with diabetes treated with insulin, since correction is often slow because of the 
relatively delayed onset of action of rapid-acting insulin. We investigated whether 
correction of marked hyperglycaemia in patients with insulin-treated diabetes can be 
accelerated when the correctional dose of insulin is administered by jet injection 
technology. Indeed, as described in Chapter 6, marked hyperglycaemia could be 
successfully corrected by administration of short-acting insulin by a jet injector. Compared 
to a conventional insulin pen, jet injection resulted in more rapid correction of acute, 
marked hyperglycaemia and less time spent in hyperglycaemia, without increasing the 
risk for hypoglycaemia. Patients rated the jet injector equally as the conventional insulin 
pen, both with respect to discomfort as with respect to ease of use by the trial population. 
In this study, the administered insulin dose was calculated by a formula based on an 
individual’s insulin sensitivity, instead of a standard sliding scale regimen which is more 
often applied in clinical practice. In Chapter 7, we describe in more detail the effect of this 
calculated insulin dose on the course of plasma glucose values and how well the formula 
worked for the eventual correction of hyperglycaemia. Although the calculated dose was 
much higher than usually applied in clinical practice, the fall in plasma glucose over the 
first hour after insulin injection was still very modest. A plasma glucose measurement at 
this time-point, as is commonly recommended, could erroneously tempt the individual to 
repeat the administration of insulin, consequently creating a risk for late hypoglycaemia. 
Therefore, measuring a plasma glucose value after a correctional insulin dose has been 
administered for marked hyperglycaemia can better be done after 2 hours instead of one 
hour. In fact, since it takes approximately three hours before most of the insulin effect has 
set in, administration of an additional correctional dose can better be delayed another 
hour to prevent late hypoglycaemia. 
In this thesis, we aimed to advance the onset and shorten the duration of insulin action by 
administrating currently available insulin with a jet injector. Another option for improving 
the time-action profile of injected insulin concerns the development of so-called ultrafast 
insulin analogues. Currently, two ultrafast insulins are in development: faster-acting insulin 
aspart and BioChaperone lispro insulin [31-37]. Faster aspart is insulin aspart in a new 
formulation that contains niacinamide, which is responsible for faster initial absorption 
after subcutaneous administration. In (elderly) subjects with type 1 diabetes mellitus, 
faster aspart had a twice-as-fast (3-5 minutes) onset of appearance, and a two-fold higher 
exposure and >50% greater glucose-lowering effect than regular insulin aspart within the 
first 30 minutes after subcutaneous administration [31-34]. This led to a small improvement 
in HbA1c by 0.15% (1.6 mmol/mol) in patients with type 1 diabetes treated with multiple 
daily injections [38]. BioChaperone Lispro has been developed as an ultra-rapid formulation 
of insulin lispro, both alone [35-37] and in a fixed combination with glargine [37]. With 
Biochaperone Lispro, the performance of insulin is enhanced and its degradation is 
blocked by forming a complex with ‘chaperoned’ proteins. This insulin is reported to have 
a 30 percent earlier onset of action and a 69 percent stronger metabolic effect in the first 
two hours after administration as compared with regular insulin lispro, but total and 
maximum metabolic effects are comparable [36]. Apart from possible therapeutic 
advantages in the prandial insulin treatment of type 1 and type 2 diabetes, ultra-fast 
insulins are particularly considered for use in insulin pumps as part of closed-loop systems. 
In our trial, we found that the time to maximum insulin concentration was halved after 
insulin administration by jet injection, whereas this time advantage was only approximately 
ten percent with faster aspart [34] and 35 percent with BioChaperone Lispro [36]. Also, 
total insulin concentration after jet injection was 40 percent higher in our trial, whereas 
with faster aspart this was at most ten percent in elderly subjects [32]. Possibly, both 
technologies may be very effective when used in combination, as the absorption of 
ultra-fast insulins could be even further enhanced when administered by jet injection, 
thereby further approaching the time-action profile of endogenous insulin. Another way 
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to more closely mimic endogenous insulin, is by using ‘smart’ or glucose-responding 
insulin, the concept of which is promising but its development is still at an early stage [39].
Conclusions and future perspectives
In conclusion, different pharmacologic strategies are available when conventional insulin 
therapy is limited by side effects. Our studies include the addition of a GLP-1 receptor 
agonist to insulin treatment, using the therapeutic potential of placebo effects, or applying 
jet injection technology for the administration of (particularly rapid-acting) insulin. These 
approaches could be followed when the standard approach to initiate insulin treatment 
that is often formulated in guidelines does not lead to desired effects. Implementation of 
such treatment strategies would, instead of a one-size-fits-all approach, allow a focus on 
personalized patient care. Balancing the benefits of glycaemic control with its potential 
risks, taking into account the adverse effects of glucose-lowering drugs, and formulate 
individualized treatment targets is a continuous challenge for health care providers and 
patients. 
Ideally, a health care provider would like to select the most optimal treatment strategy for 
a given individual patient, but so far the information needed to make such a selection is 
lacking. If it would be possible to predict which patient will experience side effects of 
glucose-lowering therapy and which patient will show a strong treatment response, true 
patient-centred diabetes care (yielding the highest benefit and the lowest harm, both 
from the patient perspective and in terms of costs) would be feasible. We made a proposal 
for selecting patients with pronounced insulin-associated weight gain who would benefit 
most from adding a GLP-1 receptor agonist. In the future, genetic profiling might play a 
role in predicting response to treatment. Another future direction that might be addressed 
based on the investigations in this thesis, is to investigate the placebo effect in diabetes 
treatment prospectively. In such a trial, in which participants are not aware of placebo 
treatment, the effect of suggestion in diabetes treatment efficacy as well as the role of the 
way of drug administration can be studied. Also, the effect of open label placebo may be 
investigated prospectively, which, when presented in a positive context, might have a 
great therapeutic potential. As recent evidence suggests that genetic variations may also 
modify placebo effects [40], it might be possible in a future trial to identify placebo 
responders by their ‘placebome’, a finding which would greatly improve therapeutic care. 
Finally, jet injection technology may be used in combination with ultra-fast insulin 
analogues that are currently under development, in order to further approach the 
time-action profile of endogenous insulin. For patients with diabetes requiring prandial 
insulin replacement, this may help to improve glycaemic stability and to reduce the risks 
of hyper- and hypoglycaemia. 
In this thesis, we describe treatment strategies that may help to optimize insulin treatment 
in patients with diabetes. Such strategies may aid clinicians and patients in shared clinical 
decision making. The results of our studies can contribute towards the ultimate goal of 
tailoring diabetes management, i.e. the most effective and affordable glucose-lowering 
treatment with the fewest side effects for any given individual with diabetes.
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Nederlandse samenvatting
Diabetes mellitus is een heterogene ziekte, die wordt gekenmerkt door verhoogde gluco-
sespiegels door een absoluut of relatief tekort aan insuline. Er zijn 2 belangrijke typen 
diabetes: type 1 diabetes en type 2 diabetes. Type 1 diabetes ontstaat meestal op de 
kinder- of jongvolwassen leeftijd en is het gevolg van een auto-immuunproces gericht 
tegen de insulineproducerende bètacellen in de alvleesklier, waardoor een ernstig 
insulinetekort ontstaat. Hierdoor wordt behandeling met insuline noodzakelijk. Type 2 
diabetes ontstaat meestal op oudere leeftijd en is gerelateerd aan overgewicht en 
lichamelijke inactiviteit. Deze vorm van diabetes wordt in eerste instantie gekenmerkt 
door een verminderde insulinegevoeligheid en een relatief tekort aan insuline, maar in 
een latere fase kan een absoluut insulinetekort ontstaan door progressieve achteruitgang 
van de bètacelfunctie van de alvleesklier. Type 2 diabetes kan aanvankelijk meestal 
worden behandeld met dieet, leefstijladviezen en orale medicatie gericht op stimulering 
van insuline-afgifte of verbetering van insulinegevoeligheid. Op den duur is voor veel 
patiënten (aanvullende) behandeling met insuline echter noodzakelijk.
Steeds meer mensen krijgen diabetes; dit geldt vooral voor type 2 diabetes, wat samen- 
hangt met het vaker voorkomen van obesitas en een westerse leefstijl. Volgens de 
Internationale Diabetes Federatie (IDF) hebben in 2015 naar schatting 60 miljoen 
volwassenen in Europa diabetes en 415 miljoen wereldwijd, men verwacht dat deze cijfers 
zullen stijgen tot respectievelijk 71 en 642 miljoen in 2040. Deze stijging gaat gepaard 
met een grote stijging in kosten gerelateerd aan de behandeling van diabetes en de door 
diabetes veroorzaakte complicaties. Verhoogde glucosespiegels zijn een onafhankelijke 
risicofactor voor het ontstaan van microvasculaire complicaties, zich uitend in schade aan 
de ogen, nieren en zenuwen. Meer dan 60 procent van alle personen met type 2 diabetes 
zal hart- en vaatziekten ontwikkelen. Diabetes vormt dus een belangrijk gezondheids-
probleem. Effectieve behandelstrategieën, die zorgen voor lagere glucosespiegels, zijn van 
essentieel belang om de complicaties van diabetes tegen te gaan.  
Behandeling met insuline is nu sinds bijna een eeuw voorhanden. Het is relatief betaalbaar, 
veilig en effectief in het verlagen van glucosespiegels. Ook vermindert insulinetherapie 
het voorkomen en de ernst van micro- en macrovasculaire complicaties van diabetes. 
 Insulinetherapie is voor personen met type 1 diabetes levensreddend en het vormt voor 
patiënten met langer bestaande type 2 diabetes de hoeksteen van de behandeling. 
Ondanks de bewezen effectiviteit zijn er ook belangrijke bijwerkingen en risico’s van 
insuline therapie. De belangrijkste nadelen aan insuline zijn toename van het lichaams-
gewicht, verlaagde glucosespiegels (hypoglykemieën of hypo’s) en wisselingen in glucose-
spiegels. 
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Gewichtstoename geassocieerd met insuline ontstaat meestal in de eerste 9-12 maanden 
na het starten van de behandeling. Deze gewichtstoename wisselt per persoon, maar in 
een deel van de insuline-behandelde patiënten is dit aanzienlijk en kan meer dan 5% 
van het initiële lichaamsgewicht bedragen. Deze gewichtstoename is niet alleen erg 
onwenselijk gezien het vaak al bestaande overgewicht, maar kan ook leiden tot een 
toename van de insulineresistentie. Er is dan een hogere insulinedosis nodig, met als 
gevolg een verdere toename van het lichaamsgewicht leidend tot een ongunstiger 
cardiometabool risicoprofiel en het tenietdoen van de gunstige effecten van insuline. 
Daarnaast lopen patiënten die met insuline worden behandeld een belangrijk risico op 
hypoglykemieën. Naar schatting hebben personen met type 1 diabetes tenminste wekelijks 
en personen met type 2 diabetes tenminste maandelijks last van een hypoglykemie. 
Meestal kunnen zij dit zelf oplossen door iets te eten. Soms moet door een buitenstaander 
worden ingegrepen. We spreken dan van een ernstige hypoglykemie. Dit komt veel minder 
frequent voor, maar is geassocieerd met een verhoogde mortaliteit. Hypoglykemieën en 
de angst daarvoor beperken de kwaliteit van leven en vormen een belangrijke barrière 
voor het bereiken van optimale glucoseregulatie, deels omdat een hypoglykemie nogal 
eens resulteert in verhoogde glucosespiegels (hyperglykemie). 
Omdat hypo- en hyperglykemieën elkaars gevolg kunnen zijn, kan insulinetherapie resulteren 
in sterk wisselende glucosespiegels. De relatief trage werking van insuline is daar debet 
aan. Zelfs de zogenaamde ‘snelwerkende’ insulineanalogen, die worden gebruikt bij de 
maaltijd of om verhoogde glucosewaarden snel te behandelen werken nog relatief traag. 
Zo wordt het maximaal glucoseverlagende effect na toediening pas na ruim 90 minuten 
bereikt en houdt het effect vaak meer dan 3 uur aan. Het corrigeren van verhoogde 
glucose spiegels duurt daardoor vaak lang, zeker als de glucosespiegels sterk verhoogd 
zijn, omdat een aanzienlijke hyperglykemie kan resulteren in een tijdelijk verhoogde 
insuline resistentie. Een te trage daling van glucosespiegels kan er bovendien toe leiden 
dat te snel een extra (hogere) insulinedosis wordt toegediend, waardoor alsnog een 
hypoglykemie kan ontstaan. 
In dit proefschrift hebben we alternatieve behandelstrategieën onderzocht, om de 
genoemde bijwerkingen van insulinetherapie tegen te gaan.
Allereerst hebben we ons gericht op personen met type 2 diabetes die tenminste 4% in 
lichaamsgewicht zijn aangekomen kort na de start van insulinetherapie. Bij deze patiënten 
hebben we het effect van aanvullende behandeling met de glucagon-like peptide 1 
(GLP-1) receptor agonist liraglutide onderzocht, in de zogenaamde ELEGANT (Effect of 
Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes) studie. 
GLP-1 receptor agonisten stimuleren de afgifte van insuline, remmen de afgifte van 
glucagon en verminderen voedselinname door vertraging van de maagontlediging en 
stimulering van het verzadigingsgevoel. Deze middelen verbeteren daarom de glucose-
regulatie, maar leiden ook tot gewichtsverlies, zonder dat het risico op hypoglykemie 
wordt vergroot. Wel is het gebruik van GLP-1 receptor agonisten zoals liraglutide 
geassocieerd met gastro-intestinale bijwerkingen, zoals misselijkheid, diarree en braken. 
In hoofdstuk 2 beschrijven we de resultaten van de eerste 26 weken van de ELEGANT-
studie, waarin de helft van de deelnemers aanvullend werd behandeld met liraglutide en 
de andere helft doorging met de standaard insulinetherapie, die zo nodig werd aangepast 
om adequate glucosewaarden te behalen. Het onderzoek toonde aan dat deze aanvullende 
behandeling met liraglutide het lichaamsgewicht met ongeveer 5% verminderde, waardoor 
vrijwel de complete insuline-geassocieerde gewichtstoename teniet werd gedaan. Ook 
verbeterde de glucoseregulatie, vaak zelfs in grotere mate dan beoogd volgens algemeen 
aanbevolen behandeldoelen. De insulinebehoefte werd gemiddeld meer dan gehalveerd 
en insuline kon geheel worden gestopt bij één op de vijf patiënten. In hoofdstuk 3 wordt 
de tweede helft (26 tot 52 weken) van het onderzoek beschreven, waarin alle deelnemers 
aanvullend werden behandeld met liraglutide. In deze fase van het onderzoek zagen 
we dat de positieve effecten van liraglutide op lichaamsgewicht, glucoseregulatie en 
insulinedosis aanhielden tot en met een behandelduur van 52 weken. Ook bleek het 
toevoegen van liraglutide 6 maanden later even effectief als een vroegere start voor het 
herstellen van insuline-geassocieerde gewichtstoename, met vergelijkbare gunstige effecten 
op glucoseregulatie en daling in insulinedosering. Gastro-intestinale bijwerkingen door 
liraglutide kwamen bij vrijwel alle patiënten voor, maar waren over het algemeen mild 
tot matig van aard en verdwenen vaak na de eerste 4 tot 8 weken van de behandeling. 
Slechts 4 van de 47 personen die met liraglutide werden behandeld moesten de 
behandeling staken door bijwerkingen. Deze gegevens suggereren dat het toevoegen 
van liraglutide een waardevolle behandelstrategie vormt voor personen met type 2 
diabetes en aanzienlijke insuline-geassocieerde gewichtstoename.
Omdat liraglutide wordt beschouwd als een duur geneesmiddel, is het erg belangrijk om 
de kosten te beheersen en het middel te reserveren voor patiënten die goed op de 
behandeling reageren. In hoofdstuk 4 berekenden we de (additionele) kosten die de 
behandeling met liraglutide, toegevoegd aan insulinetherapie, met zich meebrengt. 
Ook onderzochten we vroege voorspellers van een positieve reactie op liraglutide na 
26 weken, met betrekking tot gewichtsverlies, daling in HbA1c en reductie in insulinedosis. 
We vonden dat de toevoeging van liraglutide gedurende 26 weken resulteerde in aanvullende 
kosten van ongeveer 700 euro per patiënt, of 140 euro per kilogram daling in lichaams-
gewicht. Vervolgens definieerden we een succesvolle behandeling als het behalen van 
tenminste twee van de volgende drie behandeldoelen na 26 weken: ≥4% gewichtsverlies, 
HbA1c ≤7% (53 mmol/mol), of het vermogen om de insulinetherapie te kunnen stoppen. 
Zowel een daling van meer dan 3% in lichaamsgewicht als een daling van meer dan 60% 
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in insulinedosis na een behandelperiode van 8 weken bleken goede voorspellers te zijn 
van zo’n succesvolle behandeling na 26 weken, terwijl daling in HbA1c niet bleek te 
verschillen tussen personen met of zonder succesvolle behandeling. De kosten van zo’n 
proefperiode van 8 weken zouden ongeveer 250 euro per patiënt bedragen. Deze 
resultaten suggereren dat een korte proefbehandeling met liraglutide voor patiënten met 
type 2 diabetes en aanzienlijke insuline-geassocieerde gewichtstoename de kosten 
beheerst, mits de behandeling na 8 weken wordt gestopt als er onvoldoende gewichts-
verlies of daling in insulinedosis optreedt. 
Elke medische behandeling bevat een placebo-effect en behandeling met injecties is 
geassocieerd met grotere placebo-effecten dan behandeling met tabletten. Veel andere 
factoren hebben invloed op placebo-effecten, zoals de verwachtingen van een patiënt, 
de houding van de arts, de prijs van de behandeling en de ontvangen informatie met 
betrekking tot de (bij)werking van een behandeling. Placebo-effecten zijn meestal groter 
voor subjectieve dan voor objectieve eindpunten. Omdat eetlust en verzadiging en het 
opvolgen van leefstijladviezen als subjectief kunnen worden beschouwd, zouden zelfs 
‘objectieve’ eindpunten zoals lichaamsgewicht en (indirect) HbA1c kunnen profiteren van 
placebo-effecten. Omdat GLP-1 receptor agonisten moeten worden geïnjecteerd en 
omdat de behandeling is geassocieerd met gewichtsverlies, een verminderde eetlust en 
gastro-intestinale bijwerkingen, vroegen we ons af of deze behandeling ook zou kunnen 
leiden tot sterke placebo-effecten. Overigens moet het placebo-effect worden onder -
scheiden van de placeborespons; het laatste representeert de verandering in een 
placebogroep in een gerandomiseerd klinisch onderzoek voor en na de behandeling. 
Placeboresponsen kunnen worden verklaard door een placebo-effect, maar ook door 
andere factoren, zoals het natuurlijke beloop van een ziekte en onderzoekseffecten. 
Het placebo-effect of de placeborespons is nooit onderzocht in type 2 diabetes en kan 
dus mogelijk een grote bijdrage leveren aan de behandeling. In hoofdstuk 5 worden 
de resultaten beschreven van een meta-analyse waarin we de respons op geïnjecteerde 
placebo in gerandomiseerde placebogecontroleerde onderzoeken naar GLP-1 receptor 
agonisten vergeleken met de respons op placebotabletten in onderzoeken met DPP-4 
remmers en SGLT-2 remmers. Deze twee soorten tabletten zijn relatief nieuwe genees-
middelen voor de behandeling van type 2 diabetes die zorgen voor glucoseverlaging en 
gewichtsneutraal zijn of leiden tot gering gewichtsverlies, in het algemeen ten koste van 
weinig bijwerkingen. We onderzochten placeboresponsen met betrekking tot lichaams-
gewicht, glucoseregulatie en bijwerkingen. De resultaten van de meta-analyse laten zien 
dat geïnjecteerde placebo GLP-1 receptor agonisten leiden tot een grotere respons met 
betrekking tot gewichtsverlies dan orale placebo behandeling. Hetzelfde gold, maar in 
mindere mate, voor de daling in HbA1c en het optreden van bijwerkingen (nocebo-effect). 
Daarnaast vonden we ook een sterk verband tussen het effect van de placebo en het 
effect van het actieve geneesmiddel. Dit laatste impliceert dat de suggestie van een 
behandeleffect een belangrijke rol kan spelen in het echte behandeleffect. Deze 
bevindingen geven steun aan het concept dat geïnjecteerde placebo sterkere effecten 
heeft dan orale placebo, vooral als dit gepaard gaat met suggestie. Dit concept kan 
worden gebruikt in de behandeling van diabetes, aangezien zelfs een simpele uitleg van 
verwachte behandeleffecten kan leiden tot een grotere effectiviteit van de behandeling. 
Tot slot hebben we naast de aandacht voor behandeling van chronische hyperglykemie 
ons ook gericht op acute hyperglykemie. Acute hyperglykemie vormt een therapeutische 
uitdaging voor veel diabetespatiënten die met insuline worden behandeld, omdat de 
correctie vaak traag is door de relatief vertraagde start van zelfs snelwerkende insuline. 
We onderzochten of correctie van aanzienlijke hyperglykemie bij patiënten met insuline- 
behandelde diabetes versneld kan worden als de correctiedosis wordt toegediend met 
een jet injector. Een jet injector is een naaldloze insulinepen, die insuline onder hoge druk 
(meestal >100 m/s) toedient onder de huid. Omdat deze toedieningsvorm de insuline 
over een groter subcutaan oppervlak verdeelt dan insulinetoediening met een naald, 
wordt de insuline sneller opgenomen, wat resulteert in een snellere en kortere werking. 
Een ander voordeel van jet injectie is dat een hogere insulinedosis en zwaarder lichaams-
gewicht minder invloed hebben op de opname van insuline in vergelijking met normale 
insulinetoediening. Door het gunstigere farmacologische profiel van insuline, zou jet 
injectie erg nuttig kunnen zijn voor de correctie van acute, aanzienlijke hyperglykemie 
met snelwerkende insulineanalogen en daarmee de wisselingen in glucosewaarden 
kunnen verminderen. 
In hoofdstuk 6 onderzochten we het effect van het snelwerkende insulineanaloog aspart, 
toegediend met een jet injector, in vergelijking met toediening met een conventionele 
insulinepen voor de correctie van aanzienlijke hyperglykemie (glucose 18-23 mmol/l). 
We onderzochten dit in een gerandomiseerde, gecontroleerde cross-over studie waaraan 
personen met type 1 en type 2 diabetes deelnamen, die overgewicht of obesitas hadden en 
werden behandeld met intensieve insulinetherapie. In vergelijking met een conventionele 
insulinepen, zorgde jet injectie voor snellere correctie van acute, aanzienlijke hyperglykemie 
en een kortere tijdsduur van de hyperglykemie, zonder dat het risico op hypoglykemie 
toenam. Patiënten beoordeelden de jet injector en de conventionele insulinepen gelijk, 
zowel met betrekking tot ervaren ongemak als het gebruiksgemak. 
Omdat standaard bijspuitschema’s, die in de klinische praktijk worden gebruikt om aanzienlijke 
hyperglykemie te corrigeren, de correctiedosis meestal onderschatten gebruikten we in 
dit onderzoek een formule die was gebaseerd op de individuele insulinegevoeligheid 
voor het berekenen van de correctiedosis. In hoofdstuk 7 beschrijven we het effect 
van deze berekende insulinedosis op het beloop van de glucosewaarden en laten we zien 
hoe goed de formule werkte voor de uiteindelijke correctie van de hyperglykemie. 
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Ondanks het feit dat de berekende dosis veel hoger was dan meestal toegepast in de 
klinische praktijk, was de daling in plasma glucose het eerste uur na de insulinetoediening 
erg beperkt. Een glucosemeting op dit moment, zoals vaak wordt aanbevolen, zou een 
persoon dus foutief kunnen verleiden om de insuline injectie te herhalen, wat weer een 
risico geeft op late hypoglykemie. Op basis van onze gegevens adviseren we daarom om 
de plasma glucose na toediening van insuline voor de correctie van een aanzienlijke 
hyperglykemie te meten na twee, in plaats van na één uur. Aangezien het bijna drie uur 
bleek te duren voor het insuline-effect grotendeels voorbij was, adviseren we daarnaast 
om een eventuele herhaalde correctiedosis pas na drie uur toe te dienen om het risico op 
late hypoglykemie te verminderen. 
Diabetes mellitus en de daarmee geassocieerde hart- en vaatziekten vormen een groot 
gezondheidsprobleem. Insulinetherapie heeft een belangrijke plaats in de behandeling 
van diabetes, maar kan leiden tot bijwerkingen. Dit proefschrift biedt verschillende farmaco-
logische strategieën die gebruikt kunnen worden als conventionele insulinetherapie 
wordt beperkt door bijwerkingen. Onze onderzoeken omvatten de toevoeging van een 
GLP-1 receptor agonist aan insuline, het gebruiken van het therapeutische potentieel van 
placebo-effecten en het toepassen van jet injectie voor de toediening van (snelwerkende) 
insuline. Verder hebben we ook een voorstel gedaan voor de selectie van patiënten met 
aanzienlijke insuline-geassocieerde gewichtstoename die het meest zouden kunnen profiteren 
van GLP-1 receptor agonist behandeling. Toepassing van deze behandel strategieën kunnen 
onderdeel vormen van zogenaamde gepersonaliseerde diabeteszorg en patiënten en 
hun artsen helpen in het samen maken van een rationele behandelkeuze. 
Meer werk is nodig om te bepalen wat de rol kan zijn van genetische profielen van 
patiënten in het voorspellen van de reactie op een behandeling. Ook zou het placebo- 
effect in de diabetesbehandeling prospectief kunnen worden onderzocht. Idealiter zijn 
de deelnemers zich dan niet bewust van de (mogelijke) behandeling met placebo. 
Ook in de reactie op placebo zouden genetische profielen een rol kunnen spelen. 
Jet injectie zou mogelijk kunnen worden toegepast in combinatie met ultrakort werkende 
insulineanalogen die tegenwoordig in ontwikkeling zijn, om zo het profiel van lichaams -
eigen insuline nog meer te benaderen. 
De resultaten van onze onderzoeken kunnen bijdragen aan het ultieme doel van diabetes-
behandeling op maat, namelijk het vinden van de meest effectieve en betaalbare glucose-
verlagende behandeling met de minste bijwerkingen voor elke individuele patiënt met 
diabetes. 
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Dankwoord
Ik heb vele metaforen voorbij zien komen 
voor het promotietraject. Misschien moet ik 
het niet vergelijken met het lopen van de 
Nijmeegse vierdaagse, die liep ik namelijk niet 
uit, maar gelukkig is deze promotie ondanks 
de gebruikelijke obstakels redelijk soepel ver- 
lopen. Ook heb ik een aantal unieke ervaringen 
en vaardigheden opgedaan, zoals congres- 
bezoek in diverse landen, het geven van een 
interview in de krant om proefpersonen te kunnen bereiken, het prikken van infusen, het 
centrifugeren en afdraaien van bloed en het injecteren van insuline met diverse devices. 
Dit boekje was niet tot stand gekomen zonder de steun van een aantal personen. Of, zoals 
een Burkinees spreekwoord zegt: ‘Un seul bras ne fait pas le tour d’un baobab’ (met één 
enkele arm kun je niet een baobab omhelzen). Graag wil ik deze personen hier bedanken.
Allereerst de proefpersonen die hebben bijgedragen aan de onderzoeken die staan 
beschreven in dit proefschrift. Jullie enthousiasme maakten het doen van klinisch onder- 
zoek voor mij tot een voorrecht en bovenal een erg leerzame ervaring om te kunnen zien 
en mede-ervaren hoe de theorie in de praktijk uitpakte. Het was niet altijd weinig wat 
ik van jullie vroeg, maar de observaties die we hebben kunnen doen zijn van onschatbare 
waarde.
Mijn promotor. Beste Cees, toen ik in 2011 voor de allereerste keer bij je aanklopte adviseerde 
je me om vooral verder te zoeken naar andere mogelijkheden voor het doen van onderzoek. 
Gelukkig wist je me later snel te vinden toen duidelijk werd dat Henry niet zelf de ELEGANT 
studie ten uitvoer ging brengen. Ondanks dat je misschien niet erg enthousiast was toen 
ik later de overstap wilde maken naar het AMC, heb je me hiervoor wel alle ruimte gegeven 
en de juiste stappen ondernomen om dit mogelijk te maken. Hiervoor ben ik je zeer 
erkentelijk. Aan je vermogen om dingen goed en punctueel te verwoorden heb ik veel 
gehad, ik vond het altijd prettig om samen met je te schrijven. Jouw (of eigenlijk William 
Strunks) adagium ‘omit needless words’ zal ik niet meer vergeten!
Mijn co-promotoren, dr. Bastiaan de Galan en dr. Gerald Vervoort. Bastiaan, ik ken weinig 
personen die zo snel reageren en energiek zijn als jij. Ik vond je begeleiding ontzettend 
waardevol, met jouw snelle en doortastende reacties kon ik altijd snel weer verder. Ook 
van jouw schrijfstijl heb ik veel geleerd, jij hebt wat minder moeite om iets kort te 
omschrijven en om woorden te schrappen dan ik. Ik vond het bijzonder om een middag 
met jou door San Francisco te lopen, al had ik soms moeite om je bij te houden. Dank ook 
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voor je felheid en doortastendheid om Testmedium er als placebo door te krijgen bij de 
ethische commissie, helaas heeft het niet mogen baten. 
Gerald, je enthousiasme tijdens de ELEGANT studie was aanstekelijk. Ik kon bij je terecht 
voor alle klinische vragen, ook gingen we samen ‘de boer op’ toen het met de inclusie niet 
zo wilde vlotten. Mede daardoor hebben we toch voldoende proefpersonen kunnen 
vinden.
Mijn voorganger Henry Jansen, en mijn mede-onderzoeker aan de Insujet studies, Elsemiek 
Engwerda. Henry, dankzij alle moeite die jij in de opzet van de ELEGANT studie hebt gestopt, 
kwam ik in een gespreid bedje terecht. Fijn ook dat we zoveel personen in Den Bosch 
hebben kunnen includeren. Elsemiek, ook jouw voorwerk in de eerdere Insujet studies 
maakten de opzet van de studie erg gemakkelijk, ontzettend fijn dat jij alle analyses hebt 
kunnen doen, anders had ik het nooit binnen dit tijdsbestek af kunnen krijgen. Dank 
daarvoor.
Het combineren van promotieonderzoek en de opleiding tot internist(-endocrinoloog) 
was soms wat passen en meten, maar had nooit gekund zonder flexibiliteit van de 
opleiders. Hier wil ik met name noemen de opleiders in het Radboudumc, Jacqueline de 
Graaf en Jan Smit. Eric Fliers en Peter Bisschop, mijn overstap naar het AMC voelde als een 
warm bad, hartelijk dank voor de ruimte en werktijd die jullie me hebben gegeven om 
mijn promotieonderzoek te kunnen afronden. 
Aart Mudde en Foeke de Vries, misschien voor jullie onbewust, maar de opmerkingen dat 
het echt zonde zou zijn als ik géén onderzoek zou gaan doen waren voor mij de stimulans 
om de stappen te ondernemen tot het doen van dit promotieonderzoek. Bedankt voor 
het duwtje in de rug. 
Een prettige werksfeer wordt gemaakt door collega’s. Janna, ik vond je een hele prettige 
en fijne kamergenoot, naast alle gezelligheid vond en vind ik bij jou altijd een luisterend oor. 
Pleun, helaas kon ik niet bij jouw promotie zijn, ik vond het erg fijn om de beslommeringen 
van het promotietraject, de opleiding en ook de leuke momenten buiten het werk te 
kunnen delen. Pieter, Hanne, Rinke, Duby, Anneleen, dank voor alle uren die we samen 
hebben doorgebracht in de buitenhoek en op congressen.
Sanne, Onno, Annegreet, Antoon, Sarah, Marlous, Lars, Matthijs, Tamira, waarde mede- 
fellows, dank voor de prettige werksfeer in het AMC. 
Beste diabetesverpleegkundigen in het Radboudumc (Petra, Sandra, Sandra en Lisa) en 
het Jeroen Bosch ziekenhuis (Anette en Joke), zonder jullie ondersteuning had de ELEGANT 
studie er niet kunnen komen. Dank voor jullie hulp bij de inclusie en het doen van de 
metingen.
Beste Evertine, Anja, Karin, Mariëlle en Simone, hartelijk dank voor jullie ondersteuning op 
het CRCN tijdens de Insujet metingen. 
Maarten, bedankt voor je praktische hulp bij de meta-analyse. Erg prettig dat we met zijn 
tweeën de klus van het beoordelen van de ruim duizend artikelen voor inclusie hebben 
kunnen klaren. Maroeska, bedankt voor je uitleg tijdens het opstarten van de meta-analyse.
Wim de Grauw, er bleek soms een kloof te bestaan tussen de eerste en derde lijn, bedankt 
voor je hulp in het overbruggen daarvan. 
De mensen van Novo Nordisk en EPG. Raoul, Jonathan, Barbara en Michiel, bedankt voor 
het prettige contact en het bieden van de mogelijkheid om mijn resultaten te kunnen 
presenteren in Kopenhagen.
Erik, bedankt voor het monitoren van de Insujet studie. 
Lieve vriendinnen en vrienden, bedankt voor jullie steun en de mooie momenten die ik 
met jullie heb mogen meemaken. Ik moest soms tijd vrijmaken om dit boekje te kunnen 
afmaken, maar ik hoop dat er nu weer tijd komt om samen leuke dingen te ondernemen. 
Ik voel me gezegend met jullie vriendschap!
Beste paranimfen, lieve Patty en Charlotte, met jullie aan mijn zijde moet het helemaal 
goedkomen. Bedankt dat jullie mij willen ondersteunen op deze bijzondere dag!
Lieve ouders, nu kunnen jullie eindelijk zien waar ik al die tijd zo druk mee ben geweest. 
Maria, het schrijftalent heb ik echt van jou geërfd en daar heb ik erg veel plezier en 
voordeel van. Leo, de opdracht op de eerste pagina’s heb jij ooit voor mij in een boek 
geschreven, dat had je goed gezien! Ook al zijn jullie soms verbaasd over het opleidings-
niveau dat wij hebben behaald, dit was nooit mogelijk geweest zonder jullie steun en 
stimulering. Overigens ben ik ervan overtuigd dat jullie hetzelfde hadden gekund onder 
andere omstandigheden.
Joost, grote broer, fijn om zowel dichtbij als veraf onze levens te kunnen delen. Ik hoop dat 
dit altijd zo zal blijven. 
Beste schoonfamilie, bedankt voor jullie interesse en de fijne momenten samen. Guus, 
leuk om te kunnen spuien over de perikelen die het doen van onderzoek met zich mee 
kan brengen.
Lieve Stijn, ik kan mij herinneren dat jij in het begin wat argwanend was toen ik met een 
bewegingsarmband om ging slapen om te ervaren hoe het voor proefpersonen zou zijn 
om zo’n ding dag en nacht te dragen. Ik hoop niet dat je nu ook de druk voelt om te 
promoveren, want voor mij is het wel even genoeg. Mensen zeggen soms dat ik zo rustig 
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blijf onder stressvolle omstandigheden, jij weet wel beter. Bedankt voor je steun en 
begrip, jij gaf me raad als ik het even niet zag zitten en niet te vergeten ‘the mind’s eye.’ 
Ook praktisch heb je me enorm geholpen met het maken van mooie plaatjes. Ik houd 
ontzettend veel van jou!
Lieve Jan, misschien vind je ooit dit boekje met je naam erin. Je zult het niet meer weten, 
toch ben jij een belangrijke plaats gehad in de laatste fase van dit proefschrift. Je gaf op 
menige tekst commentaar terwijl je op mijn schoot achter de laptop zat. Ik vind het een 
voorrecht om jouw moeder te mogen zijn en geniet elke dag weer met volle teugen van 
je blije gezicht! 
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